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Neuromuscular diseases manifest by a handful of known phenotypes affecting 
the peripheral nerves, skeletal muscle fibers, and neuromuscular junction. Common 
signs of these diseases include demyelination, myasthenia, atrophy, and aberrant 
muscle activity—all of which may be tracked over time using one or more 
electrophysiological markers. Mice, which are the predominant mammalian model for 
most human diseases, have been used to study congenital neuromuscular diseases for 
decades. However, our understanding of the mechanisms underlying these pathologies 
is still incomplete. This is in part due to the lack of instrumentation available to easily 
collect longitudinal, in vivo electrophysiological activity from mice. There remains a need 
for a fully wireless, batteryless, and implantable recording system that can be adapted 
for a variety of electrophysiological measurements and also enable long-term, 
continuous data collection in very small animals.  
To meet this need a miniature, chronically implantable device has been 
developed that is capable of wirelessly coupling energy from electromagnetic fields 




events and may be chronically implanted in rodents as small as mice. This grants 
investigators the ability to continuously observe electrophysiological changes 
corresponding to disease progression in a single, freely behaving, untethered animal. 
The fully wireless closed-loop system is an adaptable solution for a range of long-term 
mechanistic and diagnostic studies in rodent disease models. Its high level of 
functionality, adjustable parameters, accessible building blocks, reprogrammable 
firmware, and modular electrode interface offer flexibility that is distinctive among fully 
implantable recording or stimulating devices. 
The key significance of this work is that it has generated novel instrumentation in 
the form of a fully implantable bioelectric recording device having a much higher level of 
functionality than any other fully wireless system available for mouse work. This has 
incidentally led to contributions in the areas of wireless power transfer and neural 
interfaces for upper-limb prosthesis control. Herein the solution space for wireless 
power transfer is examined including a close inspection of far-field power transfer to 
implanted bioelectric sensors. Methods of design and characterization for the iterative 
development of the device are detailed. Furthermore, its performance and utility in 
remote bioelectric sensing applications is demonstrated with humans, rats, healthy mice, 









CHAPTER 1. INTRODUCTION 
1.1 Neuromuscular Diseases 
Inherited pathologies of the muscles, peripheral nerves, or neuromuscular 
junctions fall under the broad classification of neuromuscular diseases. Some prominent 
examples include inherited peripheral neuropathies (IPNs), muscular dystrophies, 
myasthenic syndromes, and myasthenia gravis. It is estimated that one in 3,500 people 
worldwide suffers from one of these diseases [1]. In some cases the disease symptoms 
are barely noticeable and patients live normal, unimpaired lives [2]. For others, though, 
these diseases lead to muscle weakness and atrophy; numbness or pain in extremities, 
scoliosis, wheelchair reliance, and cardiovascular or pulmonary complications [3-5]. The 
ability to improve the compromised quality of life for these individuals hinges on a 
thorough understanding of neuromuscular disease mechanisms, from which effective 
therapies can be developed.  
IPNs represent a large subset of neuromuscular diseases which will be used 
throughout this work as an illustrative example, allowing for more specific discussions 
on the study of disease pathologies and mechanisms. IPNs can lead to premature 
muscle weakness, dysfunction, and atrophy. They are distinguished from other 





like muscular dystrophy (MD) by the fact that their primary pathophysiology occurs in 
the peripheral axons rather than the motor neuron cell body, neuromuscular junction, 
or within the muscle fibers themselves. Changes in muscle behavior, strength, and mass 
in patients afflicted with an IPN are attributed to the impairment of efferent nerves. 
However, hereditary neuropathies can also affect afferent and autonomic nerves, 
causing sensory deficits [6] or impairment of the sympathetic and parasympathetic 
nervous systems [5]. 
IPNs affect millions of people worldwide with symptoms often manifesting early 
in life—typically adolescence or early adulthood [7]. This can lead to functional deficits, 
diminished quality of life, and decreased mobility in patients with severe afflictions of 
the disease [8]. The most common IPN is demyelinating Charcot-Marie-Tooth (CMT) 
Type 1 disease [9]. CMT is referred to as a Mendelian disease, meaning it is linked to 
(and defined by) the mutation of a single gene [10, 11]. CMT types are broadly classified 
by their primary pathophysiological phenotype: either demyelinating (CMT1 and its 
subclass, CMT4), axonal (CMT2), or both (DI-CMT and CMTX) [5]. 
Age of onset and symptom severity vary greatly among patients diagnosed with 
CMT, even within a particular classification [12]. This is likely due, in part, to 
environmental factors that either exacerbate or moderate the effects of the main gene 
mutation. Another possible explanation is the influence of modifier genes on the 
presentation of main gene mutation phenotypes. Previous work examining a variety of 
degenerative disease such as retinal dystrophy [13], Parkinson’s disease [14], and CMT 





presentation of a particular gene mutation depends on the expression of genes from 
modifier loci occurring within the genetic background. In this way the effects of multiple 
mutations can synergize to alter disease presentation and progression. This can, in turn, 
blur the boundaries between disease subclasses and make precise diagnoses difficult 
[12]. 
One of the ways in which our understanding of these often complex disease 
mechanisms can be improved is by creating more advanced tools that allow new or 
higher quality data to be collected from animal disease models. Sections 1.1.1 and 1.1.2 
identify a range of metrics used to characterize neuromuscular disease mechanisms and 
the experimental protocols used to collect those metrics. These protocols are most 
often carried out in mice, which serve as the premier mammalian model for most 
inherited human diseases. In vivo electrophysiology is often utilized for direct 
observation and quantification of disease markers over time. Section 1.2 offers an 
overview of established methods for long-term electrophysiology in mice. This overview 
exposes a gap in available instrumentation for untethered, freely behaving mice. Finally, 
the common need for improved bioelectric sensors in both the study of animal 
neuromuscular disease models and human clinical applications is addressed in Section 
1.3. 
 
1.1.1 Metrics of Neuromuscular Disease Progression 
Many difference methods and metrics are used to characterize neuromuscular 





histopathological and electrophysiological means of discerning disease origins and 
progression. Amongst these are nerve biopsies, imaging techniques such as magnetic 
resonance neurography, nerve conduction velocity (NCV), electromyography (EMG), and 
nerve action potentials (NAPs) [17, 18]. In some instances spontaneous, aberrant 
activity may also be measured. For example, uncontrolled fasciculation and fibrillations 
are well-documented in human patients having ALS [19, 20] and MD.  
Some metrics such as NCV and compound motor action potential (CMAP) are 
triggered by applied stimuli. While useful, stimulus evoked potentials only reveal a 
subset of the functional characteristics of the peripheral nervous system. In some 
situations, particularly those involving the analysis of disease states, it may be necessary 
to also observe voluntary evoked potentials in the nerves or muscles. 
Animal models—particularly transgenic and knockout mice—play a crucial role in 
understanding the genetic and molecular factors that contribute to neuromuscular 
diseases like IPNs [21, 22]. Information can be extracted from these animal models and 
used to improve understanding disease mechanism, evaluate new therapies, and 
improve the quality of genetic counseling. This work will focus on the 
electrophysiological metrics that can be measured in mouse disease models over time 
to create signatures for disease progression. What follows is a discussion of the different 
experimental methods that may be used to record bioelectric data from the affected 






1.1.2 Experimental Design 
The first decision that must be made in a long-term electrophysiological 
examination of a disease model is which signal or metric is going to be obtained This will 
depend on the study hypothesis and what is already known about the model’s 
phenotypes. Once the experimental objective is set, it must be decided whether the 
data are to be collected from ex vivo preparations or in vivo. The study of the 
neuromuscular system and its associated disorders requires functional readouts of 
muscle and nerve function that can be—and often are—obtained in reduced 
preparations at fixed time points. Such preparations limit mechanistic interpretations 
and in vivo relevance as well as the ability to track disease progression. 
If in vivo data collection is part of the experimental protocol, then the benefits of 
using a single animal over time should be weighed against the use of acute animal 
cohorts at fixed time points. The benefits of using a single animal over time include 
expending fewer animals, enabling higher temporal resolution in measured parameters, 
and allowing data to be normalized internally to each animal for ease of comparison. 
The relative benefit of using animal cohorts is that it avoids repeated surgical 
procedures in the same animal and ensuing post-operative care. It is possible for 
longitudinal single animal studies to enjoy the same benefits as acute animal group 
studies by using tethered or wireless headstages, which only require a single surgical 
procedure. These solutions are examined in more detail within the discussion on 





Finally, the decision should be made whether or not the target signal can and 
should be measured under anesthesia. Stimulus evoked behaviors will likely be easier to 
measure if the animal is subdued. However, voluntary evoked and spontaneous 
aberrant bioelectric activities are suppressed under anesthesia, and will need to be 
recorded from awake and freely behaving animals. 
 
1.2 Instrumentation for Longitudinal Electrophysiology in Mice 
Voluntary evoked nerve and muscle activity carry important information about 
neuromuscular disease mechanisms. The various instrumentation options for collecting 
these bioelectric signals in mice over time are covered in this section. The use of 
tethered apparatuses for longitudinal stimulation and recording of neuromuscular 
activity in mice is observed only a handful of times within the literature [23, 24]. 
Tethered setups involve the connection of an animal subject to a data processor 
through a cable that connects to a headstage, which is typically fixed on top of the 
animal’s head or on the back of the neck. This practice is far more prevalent in 
experiments that use larger rodent models such as rats: an observation that points to 
the technical difficulty of installing and anchoring bulky hardware in animals as small as 
mice. Tethered systems do offer some advantages such as large bandwidth and DC 
power supplies. However, they can be impractical for collecting longitudinal 
neuromuscular information. Headstage unseating and lead wire breakage are common 
culprits in premature termination of animal experiments. Moreover, the physical 





on the animal’s testing environment. For example, a tethered animal cannot be placed 
in water or made to move in and around obstacles. In fact, most tethering apparatuses 
offer very little leeway and confine the animal to a small testing space. This raises 
additional concerns about the potential for behavioral constructs resulting from the 
unnatural influence confining and burdening the animal. 
Wireless headstages serve as an alternative to tethered headstages, but tend to 
be bulky and cumbersome. This can cause them be dislodged or damaged during 
behavioral tests or normal animal activity. Moreover, wireless headstages are typically 
intended and configured for neural recording in the cortex. In order to measure signals 
from the peripheral nerves and muscles, these devices would have to be fitted with 
longer leads that can be routed to remote targets. 
Table 1.1 compiles the performance specifications for a series of fully wireless and 
commercially available devices that may be used for chronic biopotential measurements 
in mice. Four crucial observations should be made about the information in Table 1.1. 
First, there is no fully wireless recording device which enables both biopotential 
acquisition and stimulation, which would be an incredibly powerful tool for closed-loop 
control of bioelectric systems. Some fully wireless standalone stimulators have been 
developed for mice [25-27], but they do not have biopotential recording capabilities. 
Second, none of these sensors gives the user the ability to adapt the functional protocol 
for different experimental needs, making them one-size-fits-all solutions. Third, the 
bandwidths and associated sampling rates of these fully wireless systems are, in almost 





have frequency content up to a few kHz. Lastly, almost all of these systems rely on 
batteries and therefore have finite lifespans (typically one to two months). It should be 
noted that the recording device from Triangle BioSystems, which does offer a large 
enough bandwidth for EMG and NAP is a battery powered headstage with a battery 
lifespan of up to 4.2 hours [28]. 
 
Table 1.1 Summary of available fully wireless bioelectric sensors for mice. Devices that 






























No No No 1.4 19 1 0.1-200 




No No No 1.9 20 2 1-50 
        
EPOCH-MSE-SYS 
(BIOPAC Systems, Inc. 
[30]) 
No No No 0.76 10 2 0.1-100 
        
MT10B  
(Millar [31]) 
Yes No No 1.4 22 1 2-440 






No No No 4.54 -- 5 0.8-7,000 
1Adaptable programming refers to the ability to change the sensor’s functional protocol 
in firmware. 
2This product is a battery powered headstage and is not fully implantable. 
 
1.2.1 Battery Powered Implants 
Battery powered devices have the advantage of storing energy chemically, which 





solution [32]. An onboard battery is an appealing powering solution for fully wireless 
recording device. The best evidence for this might be the ubiquitous use of batteries in 
commercial hardware as shown in Table 1.1. Batteries are highly portable and 
proximate energy reservoirs that evade the losses from free space energy dissipation 
and tissue attenuation, which are significant concerns in wireless power coupling [33-
35]. However, the energy storage capacity of a battery is directly related to battery 
volume, which has implications for the implant size. The most significant disadvantage 
of single-charge (primary) batteries is the repeated, invasive surgery required to replace 
them. It is worth noting that in some cases a hybrid system consisting of a rechargeable 
(secondary) battery or capacitor in combination with remote powering for cyclical 
charging and discharging can be an effective powering strategy [36, 37]. However, 
continuous data collection at high sampling rates precludes the use of any battery 
power source for long-term, fully implantable solutions. 
 
1.2.2 Potential for Energy Harvesting Implants 
Energy harvesting or scavenging is a broad term for the collection, storage, and 
use of energy (thermal, mechanical, metabolic, photonic, etc.) from a system’s 
environment [32]. Energy harvesting might be used to collect trace amounts of energy 
from proximate sources, convert it to electrical energy, then use that energy to power 
an integrated circuit (IC) that can measure or modulate some biological activity. Since 
the sources of energy come from the environment it may be thought of as “free” energy 






or tethered connection to a power source. However, many harvesting strategies either 
exhibit low conversion efficiencies or face significant practical limitations that limit their 
usefulness in active implantable devices. The efficiency of a mechanical piezoelectric 
system, which depends on its material and resonance of the mechanical stimulation, is 
in one case reported to be 0.46%. When one considers that the existing energy in this 
source is already extremely low, it seems this strategy may only be sufficient for 
extremely low power systems. The lack of solar energy available within the body 
prevents the use of more efficient photovoltaic cells and inadequate temperature 
gradients make effective thermal energy conversion within the body difficult [38]. 
 
1.2.3 Wireless Power Transfer Strategies for Implants 
Wireless power transfer (WPT) is a method of converting incident 
electromagnetic fields generated in the radio frequency (RF) band into an electrical 
current [39]. This current can then be used to power an IC that can perform the desired 
tasks of recording, filtering, transmitting, and stimulating biological signals. This idea of 
remote powering is an extremely powerful one for implantable systems as it offers a 
continuous supply of energy constrained only by the efficiency of the wireless link and 
the limits for exposure of tissue to RF electromagnetic fields—a concern which will be 
explored thoroughly in Section 2.2. 
Remote powering has been employed in a variety of implantable device 
applications because it circumvents many of the previously discussed detriments of 






information. Different WPT strategies can be categorized by the type of link between 
the source of the electromagnetic field and the receiving structure. These links may be 
inductive, radiative, or a combination of inductive and radiative. Inductive links couple 
energy in the near-field region whereas radiative links collect energy from the far-field 
region of an electromagnetic field source. The transition from near-field to far-field is 
gradual, but a typical heuristic used to define the upper bound of the near-field is 
    ⁄  where D is the largest dimension of the radiating body and λ is the wavelength of 
the RF source [40]. 
Near field (inductive) coupling is the most prevalent form of WPT used for 
implantable devices. This is, in part, a result of over a century of work devoted to 
characterizing and optimizing the behavior of inductive links [41]. Inductive energy 
coupling is the same phenomenon used in a transformer; a current applied to a primary 
conductive coil generates a magnetic field which induces current in a separate 
(secondary) conductive coil. Crucially, the amount of energy transferred in this 
arrangement is strongly affected by the alignment, proximity, and matching of both coils’ 
physical properties [39, 42]. This knowledge dates back to the work of Nikola Tesla, who 
revealed the significance of coil turning and resonance to energy coupling efficiency, 
which he used to wirelessly illuminate vacuum tubes [43]. The other reason that 
inductive power coupling is frequently used for WPT to implants is the fact that 
biological tissue has an extremely low magnetic susceptibility, making it is essentially 






One of the early successes for inductive power coupling in active biomedical 
implants was its use to charge a cardiac pacemaker battery in 1960 [45]. Today, this 
form of WPT is used for a variety of biomedical applications such as cochlear implants 
[46, 47], blood pressure monitors [37], electrocardiogram (EKG) sensors [48], EEG 
electrodes [49], and human EMG acquisition [50]. The broad application of near-field 
inductive power coupling for biomedical and other commercial applications stems from 
many years of experimentation with different parameters (coil diameter, number of 
turns per coil, coil alignment, operating frequency, etc.) to improve PTE [51-53]. It is well 
known that the PTE of an inductive link is strongly affected by the mutual inductance of 
the primary and secondary coils. This mutual inductance is derived from the physical 
properties and spatial relationship of the primary and secondary coils and can decrease 
rapidly as a result of increased separation or angular misalignment of the two coils 
relative to one another [34, 39, 42, 54]. A study conducted by William Heetderks in 1988 
evaluated five inductive coil arrangements for powering relatively small implants within 
various parts of the body. The results of this study indicate that there are inherent 
inefficiencies in inductive systems when there is a large discrepancy between powering 
and receiving coil size [51], which would invariably be the case for a miniature system 
suitable for implantation within a mouse.  
The relationship between PTE and coil size in inductive links is one that is 
disadvantageous to WPT in very small animals. Solenoid coils are bulky and, with an 
increasing number of turns, comes additional mass and volume--both of which are at a 






Printed spiral coils are one implementation of the pancake coil and are fabricated by 
printing the desired coil shape with a conductive material on an insulating substrate. 
This may be done using a strategy like photolithography or milling from a copper-clad 
sheet. Uei-Ming and Ghovanloo demonstrated a PTE between pancake coils as high as 
86% at a separation distance of 1 cm in free space [54]. These sorts of flat coils have the 
potential to be integrated with clothing on account of their thin profiles and flexibility 
when fabricated on very thin substrates. This could be useful for powering implantable 
systems for collecting neural information for directing a prosthesis or monitoring 
physiological parameters [55]. Sections 3.3.3 and 4.2.2 detail the fabrication of printed 
spiral coils designed specifically for implantation in small animal monitoring. When 
paired with a purely inductive power coupling scheme, however, these pancake coils 
present the same limitation as solenoid coils. That is, mutual inductance (and thereby, 
PTE) can vary drastically—and unpredictably in the case of a freely behaving animal—as 
a result of even minor misalignments and separations of more than a few centimeters 
between the primary and secondary coils [34, 53]. For these reasons a purely inductive 
WPT link is deemed unsuitable for an implantable system in freely behaving animals. 
Far-field RF powering distinguishes itself from near-field RF powering in that it 
extracts energy from the radiating region of an electromagnetic field rather than the 
nearby inductive region. Traditional applications of far-field wireless links include radar, 
wireless communication, and radio frequency identification (RFID) tags [41].The 
transmission and collection of far-field power transfer took off in the 1960s when it was 






isotropically. This vastly improved the transmission efficiency of far-field links, making it 
a more attractive solution for those interested in coupling energy from radiating fields 
[56, 57]. 
The improvements in far-field efficiency that came with the development of 
waveguide transmission were accompanied by improvements to RF rectifiers, which can 
be used to generate stable DC currents from oscillating electromagnetic fields. This 
progress was aided greatly by advances in semiconductor diodes [58]. There have since 
been a number of efforts in the way of increasing RF rectifier efficiency [59, 60]. Soon 
after the development of the RF rectifier came the conception of the rectenna: a 
rectifier circuit plus a receiving antenna in one portable assembly. One of the first 
applications of the rectenna was a remotely powered helicopter, which was an effort 
headed by William Brown in the 1960s. Brown pointed out that the changing orientation 
of the target device (in this case a helicopter) necessitated a powering strategy with 
some immunity to the constantly shifting physical arrangement of the receiver relative 
to the source [61]. This idea carries over into the field of chronically implanted sensors 
as there is, likewise, a good deal of inherent unpredictability in defining the spatial 
relationship between the device within the animal and the external powering unit. 
One prevalent and related use for far-field powering and telemetry is RFID tags. 
The rapid growth of the technology came as a result of miniaturization and expanded 
capabilities of complementary metal-oxide semiconductor (CMOS) technology. RFID 
tags are used for applications such as highway tolling and merchandise tracking. 






power source. Each tag has an integrated transponder or IC that allows it to emit either 
a fixed identification or recorded signal of interest when interrogated [60, 62]. 
The ubiquitous nature of far-field links in today’s world and the robustness of 
these links to changes in receive antenna orientation might lead one to expect that far-
field power transfer for implantable sensors is common practice. However, application 
of far-field WPT in implantable devices is limited. This might be partially attributed to 
the added complexity of antenna design when its functional properties can be altered 
by the properties of proximate dielectric mediums such as biological tissue [63, 64]. The 
more likely impediment, though, is the fact that operating frequency and signal 
attenuation of radiative electromagnetic fields in lossy dielectric mediums such as 
biological tissue are positively correlated [33, 35]. Additionally, smaller antennas (which 
are needed for very small implants) resonate at higher frequencies. The resonant 
frequency of the receiving antenna has a bearing on the antenna gain, so energy loss 
occurs when the incident electromagnetic field frequency does not match the resonant 
frequency of the antenna. Thus, it is prudent to assign antenna dimensions based on the 
intended operating frequency. There is the additional point that far-field RF links have 
traditionally operated at higher frequencies to take advantage of increased bandwidth 
and reduced interference with other wireless transmissions [65]. Combining this 
information results in the following crucial point: the interplay between antenna size, 
electromagnetic field (operating) frequency, and energy attenuation in tissue must be 
well understood in order to create an effective WPT link and may render far-field WPT 






This might serve to illustrate why far-field WPT has been largely dismissed as a 
viable solution for continuous power transfer to microelectronics implanted in a body. 
Some exceptions include the work of Le et al [59] and Radiom et al.[66]. Their results 
suggest that perhaps in the right environment, with a carefully configured 
electromagnetic field source, and an implantable device with appropriately low power 
consumption, far-field power coupling may be sufficient for continuous device operation 
within a freely behaving animal. Chapter 2 explores the feasibility of a far-field RF power 
coupling strategy for this application. It also contains a detailed analysis of the complete 
power link budget for a far-field RF link, a summary of findings from a model using finite 
element method (FEM) analysis, and a discussion of the broader implications of those 
findings for the utility of far-field WPT for implantable sensors. 
The final wireless powering strategy that will be considered here is magnetic 
resonance coupling (MRC), which uses series resonators to optimally impedance match 
both the primary and secondary coils. This is a way of tuning the system and thereby 
increasing the quality factor, Q, for a particular set of non-optimal conditions for 
inductive links (poor angular alignment, large coil-to-coil separation, etc.). The quality 
factor is a numerical representation of the strength of coil coupling which depends on 
the previously discussed mutual inductance, operating frequency, and series resistance 
of the coils [67]. In this way MRC has the potential to greatly exceed the PTE observed in 
inductive links under conditions in which the primary and secondary coils are poorly 
coupled [68, 69]. Since this was the key impediment to using purely inductive power 






alternative that ultimately proves to be the most efficacious wireless powering solution 
for this application.  
The development of an implantable, single-channel recording device that is 
compatible with MRC power transfer between two poorly coupled inductive coils is the 
subject of Chapter 3. Recently, the same theory governing MRC between two 
conductive coils was used to create a resonant cavity structure which offers the largest 
available WPT environment for freely behaving animals [70, 71]. The subject of Chapter 
4 is the design and implementation of a multifunctional device capable of functioning 
while implanted in freely behaving animals housed within the resonant cavity. 
 
1.3 Wirelessly Powered Sensors for Upper-Limb Prosthesis Control 
In addition to the multitude of potential animal research applications, fully 
wireless bioelectric sensors also have utility in the human clinical sphere. An exciting 
frontier in rehabilitation of upper-limb amputees is how myoelectric control systems can 
be made to work synergistically with chronic intramuscular electromyography (imEMG) 
to improve the performance of sophisticated electric-powered prostheses [50, 72]. 
For many upper-limb amputees the devastation of limb loss is often coupled with 
disappointment in the performance of commercially available prostheses. When a 
replacement limb falls short of a patient’s expectations—that is, the control is 
unintuitive, the response to a mental command is excessively delayed, or the prosthetic 
itself is heavy and uncomfortable—the frustration can lead the patient to abandon the 






dexterous and complex system, which makes it difficult to replicate and command. 
There is a need to address these frustrations, which are so common amongst upper-limb 
amputees. There is an especially critical need for improved neural interfaces for 
transhumeral, shoulder disarticulation, and bilaterial amputees. These individuals have 
lost significant ability, may be highly dependent on others, and present unique 
challenges to prosthetic design and control. 
It comes as a surprise to some that the main adversity to meeting the 
expectations of upper-limb amputees is not a lack of sufficiently advanced prostheses. 
In fact, a robotic (powered) upper-limb prosthesis capable of over twenty degrees of 
freedom has been developed [76]. Additionally, there is a well-developed solution space 
for prosthesis control algorithms that work with various neural interfaces [77-83]. 
However, the use of sophisticated prostheses and control algorithms are both limited by 
the lack of sufficient motor control information. In both cases there is a need for a 
greater number of independent channels of neural information in order to decipher and 
manage the dynamics of so many degrees of freedom simultaneously [73, 84]. 
Most upper-limb amputees who are fit with an electric-powered prosthesis use 
surface electromyography (sEMG) to control their artificial limb [85]. The selection of 
recording locations on the residual limb depends on the level of amputation (transradial, 
transhumeral, shoulder disarticulation, etc.), whether or not the patient is willing to 
undergo additional surgery such as targeted muscle reinnervation (TMR) [84], and 
whether conventional amplitude-based [77] or pattern recognition control methods [84, 






Regardless of electrode location, sEMG is often limited in its use by signal cross-
talk as well as variability in electrode impedance and position from sweating, shifting of 
the socket, and donning/doffing of the prosthetic; all of which can necessitate 
recalibration of the system [78] or reduce the functional performance of the control 
system [72, 80]. While more invasive, imEMG offers significant advantages when it 
comes to signal reliability and specificity, which could enable the use of more advanced 
and efficacious control algorithms not just in the controlled environments of labs and 
clinics, but in-home as patients take on diverse daily tasks. 
The last five years have seen some advances in chronic, wirelessly powered 
intramuscular recording systems for upper-limb amputees [87-89], including the first 
human trials [50]. However, due to the purely inductive method of power coupling 
employed by these systems, the efficacy of their WPT links can vary drastically as a 
result of minor misalignments or separations of the primary and secondary coils [53, 
90].These systems of are useful in applications where all target muscles are relatively 
close together and/or positioning of the on-board coil(s) are fixed relative (and in close 
proximity) to the external coil. Their use may be limited in other configurations where 
the external coil is prone to shifting or when an external coil cannot be wrapped around 
all target muscles. A compelling example of this might be an array of devices embedded 
in muscles within the chest and shoulder of an amputee following TMR surgery, which 
has been established as a pragmatic method for enhancing the performance of 






The surgical procedure for TMR in upper-limb amputees was pioneered by Dr. 
Todd A. Kuiken and Dr. Greg Dumanian. The surgery itself involves rerouting various 
branches of the residual brachial plexus nerve bundle to denervated muscles in the 
shoulder or chest of an amputee. Over the course of three to six months these muscles 
become reinnervated by the nerves that used to be responsible for directing 
movements in the hand and arm. So these reinnervated muscles will contract in unique 
ways in response to motor commands intended for the missing limb. The ultimate 
advantage of this procedure is that is provides easier access to electrical activity that can 
be correlated with the intent of the patient, enabling intuitive control mechanisms in 
which the patient does not have to re-train their motor cortex. All of the learning is 
done by a processor equipped with a control algorithm. 
TMR surgery takes advantage of a process called hyper-reinnervation, which 
refers to the regrowth of axons when a nerve containing a greater number of fibers is 
affixed to a smaller, previously incised nerve containing fewer fibers. The smaller nerve 
is distal to the larger nerve and usually innervates either a single muscle or a small group 
of muscles. Hyper-reinnervation increases the odds that a fiber in the smaller nerve will 
form a connection with a fiber in the larger nerve and eventually lead to muscular 
reinnervation [92]. The process of muscular reinnervation takes place as a result of 
axonal regrowth guided by residual Schwann cells from old nerve sheaths. This process 
reestablishes the link from the brain’s motor cortex to a muscle’s neuromuscular 
junctions so that muscle contracts are once again evoked as a result of motor 






hyper-reinnervation, some of which have proven to be highly advantageous to the 
rehabilitation of transhumeral and shoulder disarticulation amputees [94, 95]. 
Hyper-reinnervated muscle exhibits some unique characteristics compared to self-
reinnervated muscle (resulting from re-appending the two ends of the same nerve 
following an incision) or native muscle. First, hyper-reinnervated muscle recovers more 
mass and strength due to the increased probability of any give muscle fiber being 
reinnervated and the increased chance for polyneuronally innervated fibers. The most 
important artifact of hyper-reinnervation, though, is the spatial segmentation of motor 
units. Hyper-reinnervated muscles tend to have smaller motor units that cluster 
together instead of being distributed homogenously among other motor units, which is 
the case in native muscle [92, 96]. This behavior would improve signal selectivity of an 
implanted bioelectric sensor by granting the ability to place that sensor within clustered 
muscle fibers belonging to the same motor unit. Since a single motor unit encodes 
information about a very specific motor command, this would address the previously 
declared need for a greater number of independent channels of neural information in 
order to realize the full potential of sophisticated robotic prostheses and control 
algorithms. 
Furthermore, muscle has been demonstrated to be a viable environment for 
chronic implants. Long-term acceptance of an implanted device by proximate muscle 
can be expected provided the implant packaging is biocompatible and hermetically 
sealed [97]. Following implantation the encapsulation and anchoring of implants has 






potentials. However, the tissue environment surrounding the implant will eventually 
stabilize, leading to output signals which have consistent qualities over time [98, 99]. 
In summary, the TMR procedure offers a number of advantages that could work 
synergistically with fully wireless and implantable imEMG sensors to greatly improve 
upper-limb prosthesis control for upper-limb amputees [79, 100]. However, due to the 
abnormal arrangement of motor units at reinnervated muscle sites [101], a viable 
companion system for chronic imEMG acquisition would need to be able to 
accommodate variable and scattered device positions. Even upper-limb amputees using 
EMG from native muscle to control their prosthesis would benefit from a more versatile 
wireless powering strategy that can accommodate imperfect or non-stationary 
alignment inherent in real-world use. The desired level of flexibility in orienting remote 
sensors to an electromagnetic field source for this application presents a similar 
challenge to the one faced in freely behaving animal monitoring. In short, they both 
require a flexible, robust WPT strategy and an implantable recording device that is 
compatible with that WPT strategy, so it is possible that both instrumentation needs 
might be addressed at the same time. Chapter 3 includes a demonstration and 
discussion of how the wireless recording devices developed in this work might 
contribute to the clinical field of upper-limb prosthesis control. 
 
1.4 Conclusion 
The ongoing study of neuromuscular disease pathogenesis could be aided by tools 






tethering or anesthesia. There is no fully wireless system either on the market or within 
the literature that can both record from and stimulate excitable tissues in awake, freely 
behaving mice. Existing wireless systems for biopotential acquisition are limited by at 
least one of the following points: finite lifespan from battery power supply, low quality 
of data resulting from low (200 Hz or less) bandwidth, limited information output from 
by a single recording channel, and unsuitability for implantation owing to large 
dimensions.  
This leads to the principle objective of this work, which is to create novel 
instrumentation that will augment the study of neuromuscular disease mechanisms by 
significantly improving the ability track relevant electrophysiological metrics in a single 
mouse over time. A fully wireless and implantable device with the ability to both 
measure and evoke bioelectric activity would, in many ways, represent a significant 
improvement over current devices intended for electrophysiology in untethered, freely 
behaving mice (see Table 1.1). This implant would also be uniquely advantageous for 
studying certain other diseases. For example, cortical activity in rodent epilepsy models 
could be measured continuously to predict and then possibly curtail spontaneous 
seizure events through stimulation. The breadth of potential uses for an implantable 
closed-loop device are exciting but outside the scope of this work. However, hereditary 
motoneuron diseases like ALS manifest through phenotypes which are often similar to 
those observed in neuromuscular diseases and will be considered herein. 
The challenge of making an active, fully implantable sensor that is suitable for long-






of key system characteristics such size, performance, adaptability, reusability, and 
biocompatibility. This engineering design problem tenders the following criteria for 
success: 1) the device must be small enough to be fully implanted in a mouse; 2) the 
device must have sufficient functionality to be useful for a variety of electrophysiological 
experiments; 3) once implanted, the device must be able to function longitudinally in 
the living environment; 4) the device as well as its paired environment for WPTmust 








CHAPTER 2. FEASABILITY OF FAR-FIELD WIRELESS POWER TRANSFER FOR 
IMPLANTABLE ELECTRONICS 
2.1 Introduction 
The material presented in this Chapter incorporates content from the journal 
article “Far Field RF Powering of Implantable Devices: Safety Considerations” by R. 
Bercich, D. Duffy, and P.P. Irazoqui, which is published in IEEE Transactions on 
Biomedical Engineering [35]. © 2013 IEEE. 
Wireless energy coupling offers clear advantages over wired, battery powered, 
and energy scavenging strategies for chronically implanted sensors and stimulators (see 
Sections 1.2 and 1.3 for discussion on these strategies). Wireless powering negates the 
need for recurrent surgeries to replace batteries and sidesteps the issues with lead 
wires that risk infection by breaching the skin barrier and are prone to break or dislodge 
as a result of fatigue and micromotion. 
It is useful here to reexamine the criteria for success for this work, which are 
summarized in Section 1.4. Briefly, a miniature, multifunctional device that supports 
continuous WPT while enabling long-term data acquisition is needed for chronic animal 
and clinical applications. It is important to note early on in the design process that these 
objectives are interdependent and oftentimes destructive to one another. For example, 






of neural information may be collected. However, this would add complexity to the 
device’s functional protocol, increase power consumption, and likely add volume to the 
implant. This could result in a finished product that is too large to be implanted or one 
which requires more power than can be reliably and continuously coupled from the 
source. 
Much of the work that goes into developing WPT solutions seeks to improve some 
form of power transfer efficiency (PTE). In the case of WPT to an implanted device, PTE 
is defined as the percentage of energy from a source that is received by the target 
device and may be expended for some useful purpose such as lighting an LED for 
optogenetics [102, 103] or driving an IC that samples and transmits bioelectric data. It is 
crucial that the range of a wireless link’s PTE is well characterized when devising a 
strategy for WPT to a device having an unpredictable location and orientation—as 
would be the case within a freely behaving animal. This is important because the 
minimum PTE must be sufficient to meet the power requirements of the device and the 
maximum (peak) PTE must not be so large that damage might be done to the circuit 
components, which have voltage and power dissipation limits. The limitations of a 
purely inductive WPT strategy have been detailed in Section 1.3.2.  
Far-field RF powering is an attractive solution to the challenge of coupling energy 
to non-stationary remote devices because its PTE is less dependent on proximity of the 
electromagnetic field source and the receiving device than that of near-field RF 
powering. This is due to the fact that the energy density in the radiative field decreases 






inductive field in which energy density decreases with 1/r3 where r is the distance 
between the field source and the receiver in free space [104, 105]. However, far-field 
powering in the application of implantable devices introduces the obstacle of power 
density attenuation as the electromagnetic waves pass through tissue and tissue 
boundaries. Absorption and reflection of radiated energy in addition to the free space 
path loss all diminish the power return at the receiving antenna and decrease the PTE of 
the WPT link. 
The obvious solution to high energy losses from energy spreading and attenuation 
in tissue might be to increase the power output at the source. However, there are 
exposure limits set by the Federal Communications Commission (FCC) that restrict how 
much power may be incident on the surface or absorbed in a given volume of tissue 
[106] as excitation from oscillating electromagnetic fields can have adverse effects on 
tissue by way of both thermal and non-thermal mechanisms [107-110]. Thus, a careful 
consideration of the safety thresholds is necessary and will set the constraints for an 
analysis of the power link budget. Understanding the receive power capabilities of a far-
field WPT link will be assistive in determining the value of this solution compared to 
other wireless powering strategies.  
The viability of safely coupling energy from the far-field of a radiating body to 
power an implantable recording device is explored in Sections 2.2 through 2.4. It will 
also be important to demonstrate that local temperature spikes resulting from thermal 
discharge of the implanted microelectronics will not cause damage to proximate 






surrounding the device does not increase by more than a few degrees as various studies 
have shown that temperature increases greater than 2 °C can have adverse effects on 
living cells [111-114]. An experiment that tests the thermal safety of active implantable 
is the focus of Section 2.5. 
 
2.2 Safety Constraints for Far-Field RF Power Transfer 
The first point that should be noted in building a power transfer link in tissue is 
that the PTE will be affected significantly by the chosen operating frequency, f. This is 
because the efficiency of the receiving structure—an antenna in this case—is strongly 
impacted by the wavelength, λ, of the incident electromagnetic field which is related to 
f by the relationship f = c/λ where c is the speed of light. In order to maximize the 
efficiency of energy transfer, the receiving antenna should be tuned by precise selection 
of its dimensions for the chosen operating frequency. For example, dipole antennas are 
often used as receivers of far-field RF waves and will resonate with the oscillating field 
when their length is λ/2 or λ/4. Resonant conditions are desirable as they minimize 
losses and improve overall PTE, however the antenna length needed to achieve 
resonance is inversely proportional to the operating frequency. Resultantly, there is a 
lower limit for the RF field frequency when working with very small receiving devices 
(such as those that are suitable for implantation in mice) where the antenna length may 
be limited to a few centimeters. For this reason the proceeding far-field WPT analysis 






The extent of RF energy absorption in tissue will also be affected by f since the 
dielectric properties of tissues are frequency dependent [115]. Furthermore, it is known 
that RF attenuation is positively correlated with f [116]. This would encourage a lower 
operating frequency, which stands in opposition to the incentive to use higher 
frequencies for the sake of smaller receiving antennas. As a result f must be chosen such 
that antenna losses are balanced with losses from tissue attenuation. In practice, it is 
best to use an operating frequency which lies within an industrial, scientific, and medical 
(ISM) radio band since these are approved and reserved for purposes such as 
implantable devices. For this reason, the following ISM band frequencies will be 
considered in this analysis: 915 MHz, 2.4 GHz, and 5.8 GHz. 
The first safety consideration for the use of a radiating source is the time averaged 
surface exposure of tissue. The standards for maximum permissible exposure (MPE) are 
outlined in Table 1 of Section 1.131 in Title 47 of the Code of Federal Regulations, which 
outlines permissible use of telecommunication systems. The FCC standard for 
uncontrolled exposure to an intentional radiator depends on the operating frequency. 
The MPE limit for exposure to an electromagnetic field is given as an average over 30 
minutes and is 2 W/m2 in the range of 30—300 MHz; f/1.5e8 W/m2 in the range of 
300—1,500 MHz, where f is the operating frequency in Hz; and 10 W/m2 in the range of 
1,500—100,000 MHz. This translates into an average MPE limit of 6.1 W/m2 at 915 MHz 
and 10 W/m2 at 2.4 GHz and 5.8 GHz [106]. These particular limits will be used in the 






frequencies (915 MHz, 2.4 GHz, and 5.8 GHz) are considered suitable for the scale of the 
receive antenna needed for this work. 
The second safety standard established by the FCC for an antenna operating at RF 
frequencies is a set of restrictions for power absorption in tissue. This includes a whole-
body average specific absorption rate (SAR) limit, which is 0.8 W/kg, as well as a peak 
spatial SAR limit evaluated over any 1 g cube of tissue, which is 1.6 W/kg [106]. The 
surface exposure and the SAR experienced by any nearby human or animal tissue must 
remain below these established safety limits while power transfer is taking place to an 
implanted device. 
The efficiency of energy transfer between an electromagnetic field source in free 
space and a receive device embedded in tissue will depend on many factors. These 
include characteristics of the source such as output power, efficiency (which takes into 
account dielectric and parasitic losses), directivity, and operating frequency. It will also 
depend on free space dispersion, tissue attenuation, and reflections at boundaries 
between materials with different dielectric properties such as air, skin, adipose, muscle, 
bone, etc. After all of these losses have been accounted for there will be some power 
flux density incident on the receiving antenna which can be converted into usable 
energy. The conversion between this power flux density at the surface of the device and 
the power budget available to run the device’s embedded microelectronics will depend 
on the directivity and efficiency of the receiving antenna as well as the efficiency of the 
rectification circuit used to convert the incoming AC current to a stable DC supply 






wireless link is referred to as a link budget analysis. What follows is the complete link 
budget analysis for far-field RF power transfer between an external radiating source and 
a device implanted in mammalian tissue. 
 The amount of energy that exists at some distance from an electromagnetic field 
is often given per unit area in the form of power flux density. In free space the power 
flux density at some distance, x, from the radiating source can be found using the 
following relationship [40]: 
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where EIRP is the equivalent isotropically radiated power from the antenna (equal to 
the product of antenna input power, Pt; antenna gain, Gt; and the efficiency of the 
antenna’s matching network, emn). By setting S(x) equal to the MPE limit (for example, 
10 W/m2 at a frequency of 2.4 GHz), a relationship emerges between antenna-tissue 
separation and the transmitting antenna characteristics that must be satisfied in order 




       








For example, if the radiating antenna is isotropic (gain of 0 dB in all directions), has a 
matching network efficiency of 100%, and is given an average input power of 1 W (30 
dBm), then the minimum separation distance between that antenna and any part of the 
body must be 8.92 cm. This is one constraint to consider when constructing a model for 
the WPT link and in practice if this wireless powering strategy is used. 
 The second safety constraint established by the FCC pertains to energy absorbed 
in a volume of tissue. Assuming a one-dimensional power flux though a volume of tissue 
having a cubic form factor, the peak spatial SAR can be expressed as: 
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where S0 is the power flux density transverse to one face of the cube, Sa is the power 
flux density transverse to the opposite face of the cube, and a is the side length of the 
cube. Using the average density of human tissue, ρ = 1.04 g/cm3 [115], the side length, a, 
corresponding to a tissue mass of 1 g is calculated to be 9.87 mm. It is also known that 
the power flux density will decreases exponentially over the distance, a, in accordance 
with the following relationship: 
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where f is the powering frequency, μ0 is the permeability of free space (1.257e
-6 N/A2), 
and σ is the conductivity of the tissue at a given frequency. The term λd refers to the skin 
depth—the depth at which the amplitude of the electromagnetic field is reduced by a 
factor of e-1 [116]. So if the powering frequency is set to 2.4 GHz (at which point the 
conductivity of human tissue is 1.81 S/m [115]), the skin depth will be 7.64 mm. 
Substituting (2.4) into (2.3) yields an expression for the power absorbed by a cube of 
tissue depending on the power flux density at the surface of the cube: 
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Rearranging (2.6) gives an equation for the absolute maximum power flux 
density that may occur in tissue:  
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Using the known values of a and λd while substituting the peak spatial SAR limit (1.6 
W/kg) for Pabs in (2.7) yields an absolute power flux density limit of 17.76 W/m
2. This 






flux density averaged over 30 minutes cannot exceed 10 W/m2 because of the MPE limit 
and the average flux density cannot for any length of time exceed 17.76 W/m2 because 
of the local SAR limits. Equation (2.6) may be used to estimate the peak local SAR under 
the condition that the MPE limit has been reached by substituting  10 W/m2 for S0. This 
yields a peak local SAR of 0.90 W/kg. This number will serve as a point of comparison 
and validation for the FEM analysis described in Section 2.4. 
 The antenna-tissue separation needed to meet peak local SAR limits can be 
found using the peak power flux density and the relationship in (2.1). Given the same 
powering conditions as the previous example (isotropic antenna with 100% efficiency 
and 30 dBm input power), the calculated minimum separation is 6.69 cm. This is less 
than the antenna-body separation required to meet the MPE limits (8.92 cm), so it can 
be said that these powering conditions are within the safe limitations for RF 
electromagnetic field exposure so long as the antenna-body separation is >8.92 cm. This 
series of calculations can be performed on any set of powering conditions in order to 
establish the minimum antenna-body separation and corresponding maximum input 
power that will satisfy the FCC safety guidelines. For example, imagine that the desired 
antenna-body separation for a particular application is 1 cm. The average input power 
to an isotropic antenna would need to be reduced from 30 dBm to 11 dBm in order to 
satisfy the MPE limit and the free-space loss would, likewise, decrease by 19 dB. In the 
case of an isotropic source antenna this might be a good power saving strategy since the 
power flux density incident on the tissue surface remains at MPE limit yet the power 






antenna with directive gain is used, moving that antenna closer to the body may 
significantly restrict the space in which a device can receive adequate power. This would 
not be an optimal scenario in the case of a freely behaving animal which may be placed 
in a variety of environments for data collection. It would be necessary that the entire 
volume of the selected testing environment be within an area of the radiating 
electromagnetic field where the power flux density is larger enough to sustain the 
implant’s power budget. For this reason the radiation pattern, antenna-tissue 
separation, input power, and exposure limits must all be taken in to consideration when 
designing a practical far-field RF powering system for implantable devices. 
 
2.3 Power Link Budget for Far-Field RF Energy Coupling 
The power link budget is a calculation of the amount of power received from a 
wireless link once all losses and inefficiencies have been accounted for. The powering 
conditions calculated in Section 2.2 are used here to approximate the link budget for a 
far-field RF WPT link to a receive device embedded in tissue. This will be used to draw 
conclusions about the receivable power limits and, as a result, the feasibility of far-field 
power transfer for this particular application. 
The theoretical power link budget analysis begins with the assumption that all 
power incident on the tissue surface is absorbed. In this way a boundary condition for 
the power flux density may be imposed at the tissue surface and will be set to the MPE 
limit, which is a function of the electromagnetic field frequency. Equation (2.4) may then 






power flux density at the depth of the implant, Sd. The amount of useable power 
received by the device after voltage rectification, Pr, will depend on the incident power 
flux density, Sd, as well as the efficiency of the rectification circuit, erec; the efficiency of 
the matching network, emn; the receiving antenna power gain, Gr; and the field 
wavelength, λ, according to the following relationship [40]: 
 
 
     





 The power gain of the receive antenna (Gr) is the product of the antenna’s 
directivity (measured in dBi) and efficiency. Equation (2.8) illustrates how the level of 
power received by an implanted device can be influenced by the RF-to-DC conversion 
circuit efficiency as well as the gain of the receive antenna. It is worth noting that the 
efficiency of an RF-to-DC conversion circuit tends to increase as the amplitude of the 
input RF power increases. This behavior has been observed in previously developed 
rectenna assemblies designed to operate at 2.45 GHz, which have conversion 
efficiencies that range from 48% at -5 dBm [117] to 15.7% at -20 dBm [118]. Receive 
antenna gain can also vary significantly with the antenna’s size, geometry, and 
construction [117]. The size constraints imposed by small implantable devices –
specifically those appropriate for implantation in mice—make efficient antenna design 






necessitate larger antenna dimensions in order to achieve resonance and higher power 
gain.  
In one example constructed by Chow et al. [119], a quarter wavelength antenna 
is designed for implantation in the anterior chamber of the eye in order to measure 
intraocular pressure. The operating frequency in this example is 2.4 GHz, which means 
the implanted antenna is approximately 3.1 cm in length. The simulated gain of this 
antenna, which is looped into a semicircle, is -6 dBi. This antenna is intended for 
implantation in the eye of a rabbit or human and is too large for very small animal 
studies. A receive antenna that is suitably small for implantation in mice or for devices 
arrayed in a muscle for clinical applications such as prosthetic control would have to be 
much smaller than this and would likely fall into the range of what is described as 
electrically small antennas. An electrically small antenna is one in which the largest 
dimension (such as the length of a monopole antenna or the diameter of a loop antenna) 
is less than λ/10. This leads to a crucial point, which is that any antenna small enough to 
suit the application of chronic data acquisition in mice will likely be an electrically small 
antenna. This might be avoided by increasing the operating frequency to tens or 
hundreds of GHz (the wavelength being only 3 mm at 100 GHz). However, it is expected 
that power loss from tissue attenuation will be even more dramatic at these higher 
frequencies and will negate the benefits of using a half wavelength or quarter 
wavelength antenna. 
The narrowing of the antenna solution space to electrically small antennas is a 






expected antenna gain and matching network efficiency, which will be assistive in 
developing a realistic power link budget analysis and drawing conclusions about the 
suitability of this WPT strategy. The critical inefficiency of using an electrically small 
antenna is not the gain of the antenna itself. In fact, a standard half-wave dipole has a 
known gain of 2.15 dBi while a short dipole with a length of λ/10 can have a gain of 1.77 
dBi [120]. This gain assumes that the input impedance is well matched to the RF source 
impedance (typically 50 Ω). However, implementing this matching network in 
electrically small antennas comes at a price. What makes the electrically small antenna 
less efficient in practice is the high reactance component of its input impedance, which 
necessitates large-value reactive components (inductors and capacitors) in the matching 
network. These components—especially inductors—are accompanied by significant 
resistive losses, which can drastically decrease the efficiency of the matching network 
(emn) [120, 121]. An approximation of power loss through a matching network for 
electrically small antennas which accounts for practical and finite quality factors of 
inductors is derived in [120] with a result of around -20 dB. This number will serve as a 
sufficient approximation for emn in the link budget analysis. 
It is possible that the overall PTE through an electrically small antenna might be 
improved by designing it to have a higher directivity, which is a measure of the power 
density in the direction of strongest radiation. However this reduces the antenna’s 
effective area by focusing the emitted energy into a smaller range of space. Recall from 
Section 1.3.2 that the dependence on precise source and receiver alignment is one of 






power transfer to freely behaving animals. For the same reason it is not desirable to give 
the receiving antenna high directivity because changes in the animal’s posture and 
facing would dramatically change the PTE and lead to frequent shutdown of the 
implanted device. For the purposes of the link budget analysis, it is assumed that the 
receive antenna is isotropic; that is its gain is uniform and 0 dB in all directions. It should 
be noted that an isotropic antenna is a hypothetical antenna. It is modeled as a point 
source for electromagnetic waves and has no physical equivalent [116]. However, it can 
be used in this link budget analysis for a best case scenario calculation since a receive 
antenna with no directionality would be optimal for this application. 
The assumption that the receive antenna gain is equal to 0 dB and has a 
matching network loss of 20dB may be combined with (2.4) and (2.8) to calculate a 
realistic approximation of the power link budget for a device embedded in tissue. The 
result will depend on the type of tissue and depth at which the receive antenna is 
implanted. It is expected that the implant will be placed subcutaneously in rodents as 
their skin is loose, which can provide plenty of space that is also far from the vital organs. 
Even mice weighing 15 g can accommodate a device as long as 12 mm when placed 
subcutaneously [122]. For clinical applications it is possible that the device may be 
placed either subcutaneously or intramuscularly. For comparison a subcutaneous 
implantation is assumed, so the thickness of human versus rodent skin must be 
considered. The average skin thickness for humans is 2.58 ± 0.07 mm whereas the 
average thickness of rat skin (hairless) is 0.86 ± 0.06 mm and the average thickness of 






to calculate the skin depth used in (2.4), is acquired from [115]. In the absence of data 
for rodent skin conductance, the measured human skin conductance as a function of 
frequency is used for all calculations. The resulting power link budget for a device with a 
rectifier efficiency of 20%, 40%, and 60% is given in Figure 2.1. 
 
 
Figure 2.1 Calculated maximum power coupled through far-field RF link to a device 
implanted subcutaneously as a function of the electromagnetic field source frequency. 
Power budget given for human skin (thickness = 2.58 mm), rat skin (thickness = 0.86 
mm), and mouse skin (thickness = 0.41 mm) at rectifier efficiencies of 20% (green), 40% 
(blue), and 60% (orange). The frequency dependent maximum permissible exposure 
(MPE) limit is imposed on the skin surface boundary. Receive antenna is treated as an 
electrically small isotropic antenna with a matching network loss of 20 dB. 
 
Recall that the boundary condition used for this theoretical link budget analysis is 
the MPE limit at each operating frequency. This limit is calculated as an average over 30 
minutes, which means that the RF field exposure may exceed this limit for short periods 






increased unboundedly with shorter and shorter periods of exposure. There is still an 
absolute maximum power flux density limit as a result of the SAR safety threshold given 
by (2.7). Figure 2.2 shows the absolute maximum power flux density limit for skin 
resulting from the SAR safety threshold as a function of field frequency. 
 
 
Figure 2.2 Absolute maximum power flux density that may be present in mammalian 
skin tissue based on peak spatial SAR constraint for energy absorption from 
electromagnetic fields. Tissue mass is assumed to be 1.04 g/cm3 and the dielectric 
properties of the absorbing medium are based on data from human skin tissue. 
 
Figure 2.1 illustrates the severe power losses that may be sustained in the far-field 
link budget at higher and higher frequencies. Regardless of the species, receive power 
drops to below 0.25 mW at a frequency of 1 GHz through skin. The power budget is 
further reduced in all cases to below 0.1 mW at 2.4 GHz and below 0.01 mW at 5.8 GHz. 






electrically small antenna would be feasible in an implant suitable for mice. It is worth 
nothing that as the frequency continues to increase, resonant antenna design becomes 
more realistic and matching network losses might decrease. However, the exponential 
decrease in RF field power through tissue with the increasing frequency means that 
even a quarter-wavelength antenna at 5.8 GHz (which would have a length of 
approximately 13 mm) with no matching network losses would only yield a power 
budget of up to 1 mW. This estimate is calculated under the condition of subcutaneous 
implantation in a mouse and assumes a rectifier efficiency of 60%. 
 At this point it is reasonable to take the theoretically derived power link budget 
and compare it to the power demands of existing wireless biomedical sensors. Table 2.1 
offers a list of active devices that have been created for the purpose of wireless 
biopotential acquisition. These devices are designed for a variety of purposes and each 
has been developed under a unique set of constraints, which can make fair comparisons 
difficult. However, there are some fundamental building blocks of a bioelectric sensor, 
including an amplifier stage for signal conditioning, analog to digital converter (ADC), 
microprocessor or other digital logic circuit to mediate device tasks, and a transmitter 
for data telemetry. 
The type of bioelectric signal targeted by each system is listed along with the 
number of channels and sampling rate per channel that each solution offers. Total 
sampling rate (the product of the number of channels and the sampling rate per channel) 
is included since higher data rates increase the power consumption of RF transmitters, 






sensors. The list shown in Table 2.1 is not exhaustive, but it does give a sense for the 
range of power requirements needed to run electronics that can perform the essential 
tasks of conditioning, sampling, and transmitting bioelectric data. 
 
Table 2.1 Comparison of power consumption for active biomedical sensors configured 
for wireless data telemetry. Number of channels and sampling rate per channel are 
reported as these strongly affect the power consumption. 









Chow et al. [65] Neural (general) 32 30 8.8* 
Chestek et al. [124] Neural (general) 1 0.625 30 
Harrison et al. [125] EEG 1** 15 13.5 
Szuts et al. [126] EEG 64 20 645 
Fan et al. [127] EEG 16 30 27.8 
Zhang et al. [128] EEG 1† 0.1 >77.2 
Chang et al.[129] ECoG 16 12.5 27.6 
Charvet et al. [130] ECoG 32 1 100 
Parramon et al. [131] EMG 2 14.6 22.5 
Prabhav et al. [132] EMG 1 1 33 
Russell et al. [133] EKG 1 2 16 
Hsieh et al. [134] Bioelectric (general) 7 0.22†† 12 
*This system is solely a transmitter for biomedical sensors and does not include the additional power 
consumption contribution of signal amplifiers or ADC 
**Can select from one of an array of 100 electrodes 
† This device also includes three stimulating channels. Reported power consumption reflects transceiver 
and microcontroller contributions only. 
††Average sampling rate per channel is given, however each channel’s sampling rate is configured for a 
different signal. 
 
An evaluation of the range of reported power requirements for existing wireless 
bioelectric sensors shown in Table 2.1 suggests that these would not be compatible with 
a far-field WPT link. The theoretical link budget analysis summarized in Figure 2.1 






reducing the frequency to below 100 MHz. It seems possible based on the positive 
correlation between power consumption and number of recording channels that a 
system having only one recording channel would have a lower power consumption and 
might be amenable to WPT in the frequency range shown in Figure 2.1. However, the 
theoretical link budget is calculated under the assumption that the receive antenna is 
electrically small with a characteristic length of λ/10. Even at 434 MHz—the lowest ISM 
band considered—a λ/10 characteristic length equates to 7 cm. Considering that the 
body length (from nose to base of tail) of a normal, healthy mouse is 7.5—10 cm [135], 
this would still be too large for implantation. 
This analysis covers far-field power transfer to subcutaneous implants in rodents 
and humans. One can imagine that the low PTEs observed under these conditions will 
only get worse with deeper implantations, such as those envisioned for the clinical 
application for upper-limb amputees discussed in Section 1.3. In order to quantify the 
expected far-field RF power transfer through multiple tissue layers, a more complex 
model will need to be constructed. The evaluation of energy absorption and reflection 
between disparate tissues can rapidly become a computationally intensive endeavor, so 
a numerical solver is employed in proceeding section in order to model and simulate the 
electromagnetic fields in a more complex model—a human chest wall. The numerical 
results will also serve to validate the prior theoretical approximation and allow for a 
decision to be made as to whether or not far-field RF power transfer is a feasible WPT 






2.4 FEM Analysis of RF Electromagnetic Fields in Biological Tissue 
The link budget analysis performed in Section 2.3 is a good theoretical 
approximation but is limited in its application by some of the assumptions imposed. For 
instances of subcutaneous power transfer where the tissue boundary may be 
approximated by a single homogenous medium, the theoretical link budget is sufficient. 
However, the human clinical application of this wireless recording device, which is 
discussed in Section 1.3, is more complex owing to the variable depth of implantation 
and multiple tissue mediums through which the electromagnetic energy will pass. As a 
result the analysis of the WPT link for this application requires a more sophisticated 
model that accounts for the disparate dielectric properties of different types of tissues 
as well as the energy reflections which take place at the boundaries between the 
different tissues. A 3-dimensional tissue model for the human chest and an 
electromagnetic field source are simulated in this section using finite element method 
(FEM) software. The simulation is performed in ANSYS High Frequency Structure 
Simulator (HFSS®) 13.0 and will serve to corroborate the conclusions from the 
theoretical analysis and illustrate the power dispersion in a more complex tissue model.  
A field frequency of 2.4 GHz is used to illustrate one construction of the model and 
iteration of the simulation. The simulation environment is set up using a half-wave (6.25 
cm for an operating frequency of 2.4 GHz), center-fed dipole antenna placed parallel to 
the z-axis and a three-layered body model. The three layers of the model are skin, 
adipose, and muscle; each is assigned a thickness and dielectric properties based on 






model is placed one wavelength along the y-axis from the center of the antenna so that 
the model resided in the far-field region of the electromagnetic field. A cross-sectional 
view of the model in the simulation environment is shown in Figure 2.3. 
.The first simulation performed serves to check that the model has been set up 
correctly. In Section 2.3 the minimum antenna-tissue separation for an EIRP of 1 W 
(resulting from an input power of 1 W to an isotropic antenna with a matching network 
efficiency of 100%) is calculated using (2.2) to be 8.92 cm. Since the antenna-tissue 
separation in the 2.4 GHz field simulation is 12.5 cm, it is expected that the power flux 
density in the tissue model will fall below the MPE limit. In order to check that this is 
true, the 1 W EIRP powering condition will be replicated in the simulation environment 
and the resulting peak power flux density at the surface of the tissue model will be 








Figure 2.3 Simulation environment for a three-layer tissue model of the human chest in 
the far-field of a radiating antenna. Tissue model cross section is shown here from the 
perspective of the positive x-axis. Dipole-tissue separation is one wavelength, λ (12.5 cm 
at 2.4GHz). Skin layer thickness is 0.2 cm, adipose layer thickness is 0.84 cm, and muscle 
layer thickness is 2.16 cm. © 2013 IEEE. 
 
The antenna depicted in Figure 2.3 radiates uniformly in the xy-plane in free space. 
However, its radiation pattern changes when objects are introduced into its 
electromagnetic field. In order to ensure a 1 W EIRP in the direction of the tissue (along 
the y-axis), the radiation pattern of the antenna must be known. This is measured in 
HFSS® and is shown in Figure 2.4. The tissue model is constructed such that its length in 
the z- and x-directions are both twice the antenna-tissue separation. This places the 
tissue model between -45° and 45° on the antenna’s radiation plot. The peak gain in the 
direction of the tissue is -2.3029 dB and lies at ϕ = 90° and θ = 90° (in the direction of 






radiating antenna is 100%, the power input to the antenna can be set to 1.7 W to 
compensate for its less-than-unity gain, which leads to a peak EIRP of 1 W. 
 
 
Figure 2.4 Radiation pattern of a half-wave dipole in the HFSS® simulation environment 
with a 3-layer tissue model at 2.4 GHz when (a) φ = 90° and θ is swept from 0° to 180° 
and (b) θ = 90° and φ is swept from 0° to 180°. Due to its dimensions and separation 
from the antenna, the tissue lies within the region defined by 45° ≤ φ ≤ 135° and 45° ≤ θ 
≤ 135°. The local maximum gain within this angular region is -2.3029 dB. © 2013 IEEE. 
 
Oftentimes the resonance of an antenna will shift when objects are introduced to 
or moved within its electromagnetic field. For this reason the S11 reflection coefficient 
of the dipole antenna was measured in HFSS®, yielding a bandwidth of 2.06—2.48 GHz. 
This means the dipole antenna is still an effective radiator for a 2.4 GHz RF source in the 
simulation environment even with the effects of the tissue model in the 
electromagnetic field. 
The distribution of the power flux density incident on the tissue can be imaged by 






expected that the peak incident power flux density will be less than the FCC limit (10 
W/m2). The actual simulated maximum is 8.11 W/m2, which is (as expected) within the 
safe operating space for RF exposure. One of the benefits of using a high frequency field 
simulator is that is can easily and accurately model the reflection of energy at a 
boundary between two materials having unique dielectric properties. The power flux 
density at the air-tissue boundary in the skin (after reflection on the skin surface) is 




Figure 2.5 Poynting vector field (directional power flux density) in tissue at the air-tissue 
boundary with 1 W EIRP output from a half-wave dipole radiating at a frequency of 2.4 
GHz. The maximum power flux density is 6.56 W/m2, which occurs at the surface of the 
skin on the y-axis. This is expected since the maximum EIRP condition is imposed along 







Further validation of the virtual model may be done by examining the maximum 
power absorbed by 1 g of tissue and demonstrating that the SAR limits are not exceeded. 
This would corroborate the safe power guidelines established by the theoretical analysis. 
The maximum SAR evaluated over 1 g of tissue is evaluated using the HFSS® field 
calculator. This is done by first identifying the magnitude and coordinates of the peak 
local SAR. Unsurprising, this maximum is found to occur at the origin of the axes on the 
surface of the skin where the directional gain of the antenna is largest. The following 




        




where Pin is the total power entering a 1 g cube of tissue having mass, m, and Pout  is the 
total powering leaving the same cube. The net power through a single face of the cube, 
Pnet, can be found by taking the dot product of the Poynting vector, S, and the unit 
vector normal to the face and integrating over the area of the cube face, F: 
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A 1 g cube of tissue with a side length of a is defined in the simulation 
environment using six square plane. Each face of the cube is assigned a number as 
follows: face 1 (F1) lies on the xz-plane and transects the y-axis at the origin, face 2 (F2) 
transects the x-axis at x = a/2, face 3 (F3) transects the y-axis at y = a, face 4 (F4) 
transects the x-axis at x =  a/2, face 5 (F5) transects the z-axis at z = a/2, and face 6 (F6) 
transects the z-axis at z = -a/2. The total power absorbed by the tissue in this cube, Ptot, 
would then equate to the following: 
 
                                                      (2.11) 
 
The field calculator in HFSS® can be used to calculate each of the net power flux terms in 
(2.11). The total amount of power absorbed by this cube can then be determined by 
substituting the numerator of (2.9) with the sum of the net power flux terms, Ptot. This is 
evaluated in the simulation environment with a field frequency of 2.4 GHz, resulting in a 
peak absorbed power of 0.36 W/kg in 1 g of tissue. This is much less than the peak 
spatial SAR limit (1.6 W/kg over 1g of tissue), which further supports the compatibility of 
the tissue behavior in the simulated environment with expected theoretical results. 
However, the power flux density in skin at the air-tissue boundary necessary to reach 
the FCC’s peak spatial SAR limit in the simulated tissue model calculated is 29.14 W/m2, 
which is greater than the 17.76 W/m2 predicted by the theoretical analysis. This 






attributed to the observance of the reflection phenomenon as well as the different 
tissue dielectric properties in the HFSS® environment. 
A comparison can now be made between the power attenuation within the 
chest wall at different electromagnetic field frequencies using the validated tissue 
model in HFSS®. The model is adapted for operation at 915 MHz and, subsequently, 5.8 
GHz. The powering conditions for the simulation at each frequency are made uniform by 
equating the power flux density at the surface of the skin to the time-averaged MPE 
safety limit at each operating frequency. The simulated power flux density incident on 
the implanted device at various implant depths are shown in Table 2.2. Also contained 
in Table 2.2 are estimates of the receiving device’s power budget for each implant depth 
and field frequency. These estimates are calculated using (2.9) under the assumption 
that the receive antenna radiates isotropically and has a matching network loss of 20 dB. 
The results are given for three RF-to-DC conversion circuit (rectifier) efficiencies so that 







Table 2.2 Power flux density and estimated implant power budget at four implant 
depths within an HFSS® model of a human chest at three ISM bands: 915MHz, 2.4GHz, 
and 5.8GHz. In all cases the time-averaged MPE safety limit is imposed on the surface of 
the skin to create conditions for maximum allowable power transfer. Usable power is 
estimated under the assumptions that there are no losses from the receive antenna 









Average Usable Power (μW) 
Given erec = 
20% 40% 60% 
915 MHz 
Between skin and adipose 4.93 84.4 169 253 
Between adipose and muscle 4.64 79.4 159 238 
1 cm into muscle 2.37 40.6 81.2 123 
2 cm into muscle 1.21 20.7 41.4 62.1 
2.4 GHz 
Between skin and adipose 4.38 10.9 21.8 32.7 
Between adipose and muscle 3.16 7.86 15.7 23.6 
1 cm into muscle 1.57 3.90 7.80 11.70 
2 cm into muscle 0.561 1.40 2.80 4.20 
5.8 GHz 
Between skin and adipose 4.88 2.08 4.16 6.24 
Between adipose and muscle 2.20 0.936 1.872 2.81 
1 cm into muscle 0.129 0.0549 0.110 0.165 
2 cm into muscle 0.0150 6.38e-3 1.28e-2 1.91e-2 
 
The trend in power loss observed in Table 2.2 is closely correlated with the 
results of the theoretical analysis in Section 2.3. The relatively low quantities of power 
that may be expected from a far-field WPT link compared to the range of power 
requirements for wireless bioelectric sensors reported in Table 2.1 suggest that sourcing 
power solely from radiative electromagnetic fields would be insufficient to continuously 






power consumption than those given in Table 2.1 could be powered using a far-field RF 
WPT link. This might be achieved by implementing power cycling of the entire device or 
just the transmitter, which typically consumes the most power. For example, a single 
channel recording device with a desired sampling rate of 5 kHz could be turned on once 
every 200 μs to sample and transmit the desired signal and then turned off for the rest 
of the time. During the off-phase, energy could be accumulated and stored in a 
capacitor for use during the next on-phase. If the sampling and transmission of each 
data point could be achieved in less than 2μs, then the duty cycle of the on-phase could 
be reduced to 1%--conceivably reducing the average power consumption of the device 
by a factor of 100. Even more strategic solutions might be implemented such as utilizing 
a low power mode to sample and store multiple data points in a buffer and then 
transmitting them all at the same time. This would reduce the frequency of transmitter 
startup and shutdown, which comes with some power consumption overhead. The 
ability to utilize far-field WPT for a wireless implantable sensor would, resultantly, be 
contingent upon the design of a system that can implement sufficiently small duty cycles 
to reduce average power consumption into the range shown in Table 2.2 
 
2.5 Thermal Safety of Active Implantable Systems 
Active implantable devices dissipate heat into surrounding tissue. Sustained 
temperature increases can permanently damage or otherwise affect tissue proximate to 
the device. The relationship between temperature, time-at-temperature, and extent of 






surrounding the heat source [138, 139]. The intended location for implantation of the 
wirelessly powered recording device is either subcutaneous or intramuscular, so safe 
thresholds for thermal exposure of skin, muscle, and adipose are considered here. 
Empirical data for these thresholds exist but are difficult to generalize. However, the 
following heuristics might be used: tissue temperature should not exceed 43 °C for 
greater than 10 min. and a tissue temperature of less than 39 °C is considered safe for 
any length of time [140]. 
Evaluation of local temperature spikes due to heat diffusion from an active 
implantable device is performed by dispersing various quantities of energy in 16.4 mm3 
samples of bovine muscle. This is achieved by supplying a range of voltages across a 1 
kΩ resistor. Given Ohm’s Law and power dissipation through a resistive load being the 
product of current and differential voltage, the voltage drop across a resistance, R, 
necessary to consume a known power level, P, can be equated to √  . For example, a 
desired power dissipation of 10 mW is achieved by applying 3.16 V across the 1 kΩ 
resistor. The resistor is sealed within a medical epoxy package having dimensions of 
11.85 mm x 5.50 mm x 3.95 mm. These dimensions were selected such that they would 
resemble the form factors of previously developed implantable myoelectric sensors [141, 
142], which have been implanted into muscles at depths up to 1 cm. All muscle samples 
are maintained at body temperature (37 °C) throughout the experiment using an 
incubator. The device is continuously powered for approximately 15 min. until the 






three times (n = 3) at four different power levels: 10, 20, 30, and 40 mW. Tissue 
temperature adjacent to the device within the muscle is recorded in each trial using a 
thermocouple paired with LabVIEW for data acquisition. The increase in local tissue 
temperature due device heating can be seen in Figure 2.6. 
This experiment is intended to estimate the temperature change in tissue 
proximate to a device which is drawing current and expelling heat, but a moment should 
be taken to acknowledge the limitations of in vitro thermal measurements. Bioheat 
transfer is a complex phenomenon—the complete characterization of which includes 
irregular boundary conditions, varying thermal characteristics of tissues (density, 
specific heat, thermal conductivity, etc.), and complex geometries of the environment. 
Additional mechanisms that play a role in thermal regulation include blood perfusion 
and metabolic heat production: neither of which is present during in vitro analysis [143]. 
However, the local temperature measurements in bovine muscle samples give a first 
order approximation of temperature changes that may be expected as a result of 
thermal diffusion. The results of this experiment indicate that it would take a power 
consumption of 40 mW in order to elevate the local temperature in muscle by more 
than 1 °C. Since 40 mW far exceeds the amount of power than can be safely coupled 
through a far-field wireless link—regardless of the depth of implantation—these results 
suggest that unsafe temperature elevation in tissues from thermal diffusion would not 








Figure 2.6 Temperature increase in bovine muscle measured immediately adjacent to a 
device consuming between 10 and 40 mW of power. Three samples (n = 3) are tested at 
each power amplitude. Local temperature changes are measured with respect to a 
normal body temperature baseline (37 °C) using a thermocouple. © 2013 IEEE. 
 
2.6 Conclusion 
The relative potential for health and safety hazards suggested by the results of the 
RF exposure and thermal diffusion analyses suggest that the effects of RF exposure —
both thermal and non-thermal—is a greater concern than local temperature elevation 
from the thermal discharge of microelectronics. Prior to drawing any conclusion about 
the feasibility of far-field RF power transfer for implanted bioelectric sensors, it is crucial 
to note that the theoretical and numerical analyses contained in this chapter are all 
based on the presumption that MPE limits have been reached. This is a way of 
examining the best case scenario for the WPT link. In reality, a freely behaving animal 
will rarely be in the optimal location where MPE limits are reached, which only further 
diminishes the prospects of far-field RF power transfer for long-term monitoring of 






However, as noted in Section 2.4, a significant reduction in the duty cycle of a 
sensor’s on-phase could reduce the average power consumption to the point that the 
power link budget afforded by far-field RF power transfer might be sufficient—even 
when MPE limits are not reached. This solution would necessitate the design of a 
microelectronic system that achieves sufficiently low on-phase duty cycles of the 
transmitter while incorporating an effective power storage strategy. Without significant 
examination of the limitations of CMOS design, it is not certain that a system meeting 
these requirements is achievable. For this reason, alternative WPT strategies are sought 
for continuous power transfer to devices implanted in freely behaving animals. 
It is also evident that far-field RF power transfer is not a feasible WPT strategy for 
the clinical application of this work. While it is certainly possible that MPE limits could 
be consistently applied in the controlled environment of an upper-limb prosthesis, the 
extremely low power budgets that can be expected—even under the condition that 
MPE limits are reached—for devices embedded 1 cm and 2 cm into muscle are orders of 
magnitude less than the power requirements of existing myoelectric sensors. This leads 
to the conclusion that an alternative WPT strategy is also needed for the purpose of 







CHAPTER 3.  THE MYONODE: AN IMPLANTABLE SINGLE-CHANNEL RECORDING DEVICE 
3.1 Introduction 
The material presented in this Chapter incorporates content from the journal 
article “Enhancing the Versatility of Wireless Biopotential Acquisition for Myoelectric 
Prosthetic Control” by R. A. Bercich, Z. Wang, H. Mei, L. H. Smith, K. L. Seburn, L. J. 
Hargrove, and P.P. Irazoqui, which has been accepted for publication in the Journal of 
Neural Engineering pending revisions. All procedures involving live animals are reviewed 
and approved by the Purdue Animal Care and Use Committee. Mice are obtained from 
The Jackson Laboratory (Bar Harbor, ME). All experiments involving human subjects are 
approved by the Northwestern University Institutional Review Board. 
The practical limitations of near-field inductive coupling outlined in Section 1.3.2 
and the extremely low far-field power link budget derived in Chapter 2 seem to suggest 
that neither inductive nor radiative power coupling is sufficient for continuous WPT to 
devices implanted in freely behaving animals. However, recent advancements in the 
area of MRC [144, 145] have led to improved PTEs in inductive links that are poorly 
coupled (e.g. disparate in size, misaligned, or far from one another). This methodology 
utilizes bandpass filter theory to implement optimal impedance matching conditions, 






realized. This has been previously suggested as a viable option for power transfer in 
long-term animal monitoring with both stationary [146, 147] and non-stationary [148] 
external coils 
Implementation of the MRC methodology by Henry Mei, a graduate research 
assistant in the Center for Implantable Devices at Purdue University, led to the 
demonstrated ability of an MRC link to sufficiently couple tens of mW of power to a coil 
having a diameter of 1.2 cm using an external coil with a diameter of 13 cm outputting 1 
W of power. This corresponds to a PTE in the range of 1-5% rather than < 0.1%, which 
may be expected from far-field WPT per the link budget analysis performed in Section 
2.3. The implication here is that MRC can enable levels of power transfer between two 
coils—having greatly disparate diameters—that would be sufficient to run many of the 
wireless bioelectric sensors described in the literature (see Table 2.1). The sufficient PTE 
of this particular pairing of coils (13 cm external coil and 1.2 cm receive coil) is 
demonstrated in free space with coil-to-coil distances up to 5 cm. Concerns about 
power attenuation in tissue are abated by the fact that MRC achieves energy transfer 
through magnetic fields, the power flux densities of which are largely unaffected by 
biological tissue.  
The primary motivation for this work is to develop novel instrumentation for the 
study of neuromuscular disease mechanisms in freely behaving mice. Being only 13 cm 
in diameter and 5 cm in vertical range, the WPT environment made possible through the 
application of MRC methodology is not very large. However, it is sufficient for a mouse 






small for subcutaneous implantation in mice (1.2 cm), both of which enable a first pass 
at a fully wireless bioelectric sensor. The secondary motivation is to improve neural 
interfaces between muscle and upper-limb amputees. Since both of these aims entail 
some evaluation of muscle activity, the first microelectronics system is designed 
specifically for EMG acquisition and is given a simplified task set: to record and transmit 
one channel of data. This single-channel recording system specifically for fully wireless 
EMG acquisition is referred to as the Myonode  
Two implementation of the Myonode are presented here: one using CMOS 
technology and the other using only commercial off-the-shelf circuits on a custom 
printed circuit board (PCB). The construction, bench top analysis, and applied in vivo 
performance of both designs are summarized in this chapter. 
 
3.2 ASIC Implementation of the Myonode 
The first implementation of the Myonode uses CMOS technology to create an 
application-specific integrated circuit (ASIC). This method affords the most flexibility and 
customizability since the designer may judiciously strip away unnecessary sources of 
current consumption to create a system that meets only the necessary functional 
requirements. Reduction of average power consumption (a direct corollary of current 
consumption) serves as one of the primary objectives for this ASIC as this lessens the 








The necessary functional blocks for the Myonode’s ASIC include an amplifier, ADC, 
RF transmitter, voltage regulators, and digital logic. Figure 3.1 shows a block diagram of 
the ASIC within the conceptual design of the full EMG recording device. The design and 
simulated performance of the EMG amplifier is described in Section 3.2.1. The 
remaining functional blocks of the ASIC are designed by other students from the Center 
for Implantable Devices at Purdue University. Specifically, the ADC and clock are 
designed by Hansraj Bhamra; the transmitter is designed by Oren Gall; the voltage 
regulators are designed by Ashir Shah; and the digital logic is designed by Jithin Joseph. 
CMOS design is done on the X-FAB 180 nm process using Cadence software. Bench top 
performance of the full system ASIC is summarized in Section 3.2.2. An analysis of 








Figure 3.1 Conceptual block diagram of the full Myonode system including the EMG 
sensor and transmitter ASIC designed in CMOS (blue), power supply (green), and 
expected input signal (red). 
  
3.2.1 EMG Amplifier Design in CMOS 
The amplifier block of the EMG sensor ASIC is designed to be fully differential so 
that common mode noise sources are effectively rejected from the measured signal. 
Power line noise, for example, is a frequent artifact observed in bioelectric signals, so 
differential recording is common practice for both sEMG and imEMG [96, 149]. A folded 
cascode operational transconductance amplifier (OTA) topology [150] is selected owing 
to its relatively low power consumption and pervasive use in CMOS neural amplifiers 
within the literature [151-154]. The system is constructed such that it can run off of one 
supply voltage (1.8 V). In an effort to keep the first design simple and avoid integration 






ADC input voltage range between 0 and 1.8 V. This means that the ADC cannot read a 
negative voltage. Since differential EMG will exhibit both positive and negative 
amplitudes, both inputs need to be level-shifted to the mid-range voltage of the ADC 
(900 mV). This is implemented using common mode feedback within the differential 
amplifier circuit. 
The peak-to-peak amplitude of measured EMG is very much dependent on the 
size of the muscle, strength of contraction, and electrode configuration. While it is true 
that a larger inter-electrode space will lead to a higher measured amplitude, signal 
attenuation through tissue will increasingly affect signal amplitude as separation 
between the source and the electrodes increases [155]. When measuring EMG on the 
surface of the skin, it is easy to implement larger inter-electrode spacing, but this will 
impact signal specificity, amplitude, and frequency content. For this reason it is 
important to consider the signal source and characteristics of the desired signal when 
selecting an electrode, placing electrodes, and configuring the gain response of the 
amplifier. 
The maximum amplitude that may be expected from sEMG recorded with gel or 
metal dome electrodes is in the range of a few millivolts. Stimulus-evoked potentials, 
however, can reach tens of millivolts in peak-to-peak amplitude [149]. The Myonode is 
intended to collect both voluntary evoked potentials and stimulus-evoked potentials, so 
a low gain of 50 (34 dB) is the target for the bandpass region. It would be best under 
circumstances such as these—when different signals having amplitudes that differ by at 






in the ASIC in an attempt to keep the operating protocol simple on the first run. The 
intention being that, all other elements working properly, this ability may be integrated 
on subsequent systems. The resistive and capacitive elements which influence the gain 
of the amplifier also impact the bandpass cutoffs of the frequency response. A 
simulated gain of 34.7 dB, which is sufficiently close to the 34 dB specification, is 
achieved as a result of balancing desired gain and filtering specifications. 
The majority of power in sEMG signals is contained in the frequency band from 
10 to 500 Hz [149]. The high-pass cutoff used for sEMG ranges from 3 to 20 Hz as it’s 
been suggested that some useful information can be obtained about motor unit firing 
patterns at frequencies as low as 3 Hz [156]. A low-pass cutoff of 500 Hz is commonly 
used for sEMG signals. However, biological tissue behaves like a low-pass filter [157-
159], so the bandwidth of sEMG is lower in the frequency domain than EMG recorded 
from a group of fibers within a muscle or immediately adjacent to a single muscle fiber. 
For this reason the low-pass cutoff for imEMG is typically higher than that of sEMG: 
between 1 and 10 kHz [149]. Since the Myonode is intended for collection of both sEMG 
and imEMG, a bandpass region of 3 Hz to 1 kHz is the design specification.  
A two-pole low-pass filter is implemented in the CMOS amplifier through 
feedback on the differential amplifier (first stage) and by passive low-pass filters in the 
second stage. Figure 3.2 shows a schematic of the full amplifier circuit with stages 
delineated. In contrast to ideal operational amplifiers, which have a theoretical output 
impedance of 0 Ω, folded cascode OTAs have a large output impedance. As a result, the 






achieve the desired low-pass cutoff. Given process variation in fabrication and the 
relationship between resistor length and value, it is impractical and unwise to use very 
large resistors or create large resistances by placing many smaller resistors in series. 
Some circuit designers have used transistors biased in the sub-threshold region to 
create large pseudoresistances [160, 161]. However, this requires additional biasing 
circuitry so, instead, a MOS-bipolar device described in [125] is implemented here to 
create a large pseudoresistance in place of R1 and R2 (see Figure 3.2).  
 
Figure 3.2 Circuit schematic of fully differential amplifier implemented on X-FAB 180 nm 
CMOS process. First stage is designed using a folded cascade operational 
transconductance amplifier (OTA) topology. Amplifier is AC coupled using front-end 
capacitors. Two-pole low-pass filter is implemented through feedback in the first stage 
and passive filtering in the second stage. 
 
The second stage is buffered on both sides to isolate the passive filter and 
prevent shifting of the pole frequency due to influences of the first stage or loading 






kHz, which is sufficiently close to the 1 kHz specification. The amplifier is AC coupled 
with capacitors C1 and C2 in order to prevent DC offsets or very low frequency signals—
such as motion artifact—from reaching the amplifier inputs, which might cause 
saturation and railing at the outputs. 
 
3.2.2 Full System ASIC Evaluation 
The full system’s functional protocol is clocked at 250kHz and has a data rate of 
50 kbps. The ADC sampling rate is fixed at 5 kHz, which is selected based on the Nyquist 
frequency of the intended signal to avoid aliasing. The RF transmitter uses an on-off 
shift keying (OOK) protocol with a 4-bit start code and a 4-bit stop code to communicate 
each digitized 10-bit sample of EMG data. Figure 3.3(a) illustrates the full system ASIC 
layout in Cadence with the amplifier block highlighted in yellow. The final fabricated 
chip along with its physical dimensions is shown in Figure 3.3(b). Table 3.1 outlines the 
key performance specifications of the full system alongside the measured results for the 








Figure 3.3 Full system ASIC designed in 180 nm CMOS process for single-channel EMG 
recording and telemetry with the amplifier circuit highlighted in yellow. (a) ASIC layout 
in Cadence software and (b) image of the fabricated full system chip with a measured 







Table 3.1 Summary of simulated and measured parameters of the single-channel EMG 
recording and telemetry ASIC. 
Parameter Simulated Measured Units 
Peak gain 34.7 36.2 dB 
High-pass cutoff 2.32 32 Hz 
Low-pass cutoff 1.03 1.45 kHz 
ADC resolution 10 10 bits 
Max. input amplitude 33 28 mVpp 
Sampling rate 5 5 kHz 
Supply voltage 1.8 1.8 V 
Power consumption 0.67 1 mW 
Transmitter Frequency 2.4 2.46 GHz 
 
The measured results shown in Table 3.1, which represent the performance of a 
sample Myonode ASIC indicate that this chip is able to perform the assigned task set of 
amplifying, filtering, sampling, and transmitting EMG. It may be noted that some 
parameters such as filter cutoff frequency have drifted—possibly as a result of process 
variation. Two clear advantages of this ASIC should be highlighted: first, the low power 
consumption relative to other bioelectric sensors (see table 2.1) and, second, the small 
footprint, which is amenable to subcutaneous implantation in very small animals.  
This ASIC is used for in vivo EMG acquisition in an anesthetized mouse in parallel 
with a commercial preamplifier so that the measured signal of both instruments may be 
compared. The experimental procedure begins with blunt dissection to the sciatic nerve 
of a mouse. A two-contact platinum iridium cuff electrode is placed around the sciatic 






ipsilateral side such that the inter-electrode spacing is 5 mm. Then a stimulus current is 
applied to the sciatic nerve through the cuff electrode and the evoked CMAP is recorded 
from the muscle. The stimulus current amplitude is gradually increased—recruiting 
more axons and their innervated muscle fibers—until the amplitude of the CMAP 
response stops increasing. This yields a maximum CMAP which is congruous with 
published results [23]. The same maximum CMAP recorded from both a commercial 




Figure 3.4 Compound motor action potential (CMAP) recorded acutely in a wild-type 
mouse using needle electrodes with an inter-electrode spacing of 5 mm. The same 
CMAP is recorded from the biceps femoris muscle of a mouse using the Myoode ASIC 
(blue) and a neural preamplifier (P511, GRASS Technologies) with the gain adjusted to 







During this experiment the Myonode ASIC is powered using a DC voltage supply. 
The closely matched waveforms measured by the Myonode ASIC and a standard bench 
top apparatus shown in Figure 3.4 are a promising outcome for the ASIC-based system. 
This might encourage the next logical step to be taken: integrate the Myonode ASIC with 
a rectifier and coils designed for MRC power transfer so that the system may be 
wirelessly powered. However, there are significant functional and practical impediments 
to using this ASIC in chronic animal studies or for clinical neural interfaces for upper-
limb amputees. An evaluation of these obstacles as well as possible solutions is 
conferred in Section 3.2.3. 
 
3.2.3 Limitations of ASIC-Based System 
One of the most critical limitations of the ASIC-based Myonode is the extremely 
low yield of working ASICs (less than 5%) from the fabricated wafer. This is a significant 
practical concern given the time needed to test each system, which is done using a 
probe station owing to the very small size of the input and output pads. Additionally, the 
ASIC must be adjoined to a rectifier and some implement for wireless power coupling 
before the system can operate in a WPT environment. This has the advantage of 
modularity but increases complexity in an already delicate and miniature build process. 
Neither of these obstacles is necessarily a showstopper. However, the ultimate 
limitation is that the ASIC is one-trick pony without any flexibility in operation or 
performance. This makes the effort and expense of putting together even a small 






of the end-product. Specifically, the gain, bandwidth, sampling rate, and telemetry cycle 
of the ASIC—all of which are fixed—mean that a different system would need to be 
designed for each signal of interest.  
Alternatively, it is possible that some flexibility might be built into the ASIC 
through features like programmable gain, tunable filters, and flash memory for 
reprograming the device’s functional protocol. These are highly advanced elements, 
though; which means they require large amounts of time and expertise to implement. 
Not to mention the three- to four-month lead-times associated with fabrication of 
CMOS ICs. But perhaps the most compelling reason to avoid building such a complex 
system in CMOS is the fact that much of the effort is put into building circuit elements 
that may be thought of as “overhead”—that is, a replication of circuits that already exist 
and are available off-the-shelf. These commercial ICs are designed by experts for a 
variety of general and niche applications Moreover, the natural progression towards 
miniaturization in electronic technology means that most ICs come in very small form 
factors. Using only commercial ICs would allow a system to be built up from relatively 
small—in both function and size—components while leveraging the availability of 
sophisticated and reliable circuits. This has the added benefit of being replicable by 
other investigators interested in building and using the tool rather than negotiating the 
use of a proprietary circuit, which is better for the purposes of knowledge sharing in the 
scientific community. 
This is not to say that a final, polished design wouldn’t be best implemented in 






engineering design process is iterative in nature, it is wisest to work with modular and 
easily integrated parts for quick prototyping and testing. For this reason device design in 
CMOS is deferred and the remainder of this work is focused on the development of 
miniature microelectronics systems for fully wireless bioelectric data acquisition that is 
built using only commercially available, off-the-shelf components. 
 
3.3 Custom PCB Implementation of the Myonode 
The second implementation of the Myonode uses only commercially available ICs 
and passive components assembled on a custom designed PCB. This leverages the 
cutting edge in state of the art electronics while simultaneously increasing the reliability 
of the end device. This system offers a comprehensive and non-proprietary solution to 
many of the logistical challenges associated with device development as well as 
recording biopotentials chronically in both humans and small animals.  
All microelectronic elements are available off-the-shelf and include an established 
ARM Cortex-M0 processor. This sidesteps many of the practical impediments of working 
with ASIC-based systems by simplifying replication of the system and facilitating rapid 
changes to its functional protocol afforded by reprogrammable firmware. In fact, one of 
the most exciting prospects of this technology is the ease by which more advanced 
processing tasks could be outsourced to the onboard microcontroller. For example, 
some processing tasks for advanced pattern recognition prosthetic control algorithms 
[86] might be incorporated in firmware so that directives rather than raw data are 






making prior to data transmission, a prosthetic control algorithm’s performance might 
be augmented, accelerated, or in other ways enhanced. Flexible data processing and 
consolidation implemented in rewritable firmware may also prove to be a means of 
reducing total device power consumption by reducing the amount of data that is 
transmitted (and thereby reduce the RF transmitter’s “on” time). 
The circuit design, integration, prototype build process, packaging, and bench 
top evaluation of the custom PCB-based Myonode are covered in this section. 
Throughout the design phase, particular attention is given to the size constraints that 
come with working in mice. The maximum physical dimensions and permissible weight 
of the implant become even more restrictive when one considers that mouse models for 
neuromuscular diseases tend to be smaller than their wild-type counterparts owing to 
dysfunctional development or atrophy of skeletal muscle [162, 163]. Conceding that the 
device must be suitable for implantation both healthy and disease model mice results in 
a single-channel bioelectric sensor with a significantly smaller volume and mass than 
any comparable commercially available system. 
The task set for the custom PCB-based Myonode is the same as the task set for 
the ASIC-based Myonode: continuous acquisition and telemetry of EMG. Key duties 
performed by the microelectronics integrated on the custom PCB include filtering, 
sampling, digitizing, and transmitting recorded data in real-time. The analog front-end 
(AFE) circuit for amplifying and filtering EMG prior to digitization is described in Section 
3.3.1. The circuit structure for wireless power rectification and management is 






MCU that orchestrates the functional protocol of the device, and the MCU’s required 
peripherals is the subject of Section 3.3.3. Layout of the custom PCB and build 
procedure for the Myonode is also covered in Section 3.3.3. The bench top performance 
of the PCB-based Myonode is presented in Section 3.3.4. 
 
3.3.1 AFE Design Using Commercial ICs 
The AFE of the custom PCB-based Myonode is a differential recording channel 
comprised of a low-gain instrumentation amplifier (Texas Instruments, INA333) followed 
by a second gain stage that incorporates an active low-pass filter (see Figure 3.5 for a 
circuit schematic of the full AFE). The INA333 is selected for its high common-mode 
rejection ratio (CMRR) (100 dB), high input impedance (100GΩ), low power 
consumption (50μA), and appropriately small footprint (3 mm x 3 mm) [164]. One 
significant advantage to building the system from off-the-shelf components is the ability 
to adjust gain and bandpass filter cutoff frequencies as needed. Typically a majority of 
the gain is allocated to the second stage so that any DC offsets and low frequency 
signals from motion artifact or rectification of high-frequency noise is removed prior to 
significant amplification as these may otherwise cause the signal to rail.  
Gain on the first stage is typically 10 (20 dB)—the minimum necessary to achieve 
the peak CMRR from the INA333. This gain is set using a single resistor as directed in 
[164]. The second stage gain is usually 30 (29.5 dB) for sEMG, resulting in a total AFE 






total AFE gain of 1,000 (60 dB). Second stage bandpass gain may be calculated using the 
known gain equation for an inverting operational amplifier: 
 
      
    






Prior to the instrumentation amplifier, the signal passes through a first-order, 
low-pass filter. Both inputs are DC biased to a mid-supply common mode voltage 
(designated CM in Figure 3.5) using pull-up resistors (R1 and R2 in Figure 3.5), which is 
necessary when using the INA333 in single-supply mode. Following passage through a 
buffer, this mid-supply voltage (designated REF in Figure 3.5) also provides a reference 
voltage to which the INA333 level-shifts its output. This same buffered voltage reference 
is supplied to the non-inverting input of the second stage op amp to maintain the mid-
supply offset at the output of the AFE, which goes directly to the ADC. This DC offset is 
necessary since the SoC operates in single supply mode and its ADC can only read 
positive voltages. The buffer in Figure 3.5 prevents high frequency noise that may shunt 
to the common-mode supply voltage (CM in Figure 3.5) from coupling into the second 







Figure 3.5 Analog front-end (AFE) of the custom PCB-based Myonode. The AFE consists 
of a low-gain first stage instrumentation amplifier and a higher gain second stage 
inverting amplifier. A mid-supply reference voltage is generated by a low drop-out (LDO) 
regulator and buffered to create a low impedance source. A low-pass filter prior to the 
instrumentation amplifier serves to remove high frequency noise from induced by the 
incident electromagnetic field necessary for wireless power coupling. A high-pass filter 
between the first and second stages AC couples the signal and an active low pass filter in 
the second stage allows for selection of the low-pass cutoff frequency. 
 
The front end low-pass filter serves to shield alternating currents induced by the 
incident electromagnetic fields (which have frequencies in the single to tens of MHz) 
from the instrumentation amplifier inputs where they can be rectified into large 
amplitude, lower frequency noise that lies within the signal bandwidth. The bandwidth 
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where fhp is the high-pass cutoff frequency and flp is the low-pass cutoff 
frequency. 
More precise estimations of the AFE frequency response and small signal 
transient response are done using Simulation Program with Integrated Circuit Emphasis 
(SPICE)-based software. TINA-TI, a circuit simulator developed by Texas Instruments, is 
used here to take advantage of its library of component macros, which includes the 
INA33. Figure 3.6 shows the Bode magnitude and phase responses of the AFE 
configured for measurement of imEMG in a mouse. Figure 3.7 shows the simulated 
small signal response to a 100 Hz, 1 mVpp for the same AFE configuration. The TINA-TI 
circuit simulation is also used to select the appropriate passive component values to 








Figure 3.6 Bode gain and phase responses of the Myonode analog front-end (AFE) 
simulated in TINA-TI. AFE is configured for with a bandpass gain of 60 dB and a 
bandwidth of 10—1,000 Hz. 
 
 
Figure 3.7 Small signal transient response of Myonode analog front-end (AFE) to a 1 






3.3.2 Power Management Circuitry 
Conversion of applied magnetic fields into a usable voltage supply is achieved by 
the rectifier and power management circuit shown in Figure 3.8. Alternating currents 
induced in receiving coil are capacitive filtered through an impedance matching network 
(K-inverter) before being rectified to a DC voltage. The rectifier topology used in this 
device is a single stage bridge rectifier. A storage capacitor on the output of the rectifier 
serves to buffer the supply voltage during short bursts of elevated current consumption, 
such as those that occur when the transmitter is turned on to send data. The rectified 
voltage is regulated to 1.8 V by a low-dropout (LDO) linear voltage regulator. This 
regulated voltage supply is used to power all active circuit components. Subsequently, 
this voltage is down-regulated to 0.9 V to provide a stable common-mode reference 
voltage to the AFE (see Figure 3.5). Stabilizing capacitors are used at the outputs of both 
regulated voltages and decoupling capacitors are placed proximate to IC power supply 










Figure 3.8 Power rectification and management circuitry on the custom PCB-based 
Myonode. Incoming alternating currents are capacitive filtered in the k-inverter (C1 and 
C2) and rectified to a DC voltage in a single stage bridge rectifier. A stabilizing capacitor 
(C5) serves to buffer the supply voltage from spikes in current consumption and is 
placed in parallel with a 5.6 V Zener diode, which protects the regulator from rectified 
voltages above its maximum input voltage. 
 
 All power necessary to run the Myonode’s microelectronics is wirelessly coupled 
to the system using the MRC strategy implemented by Henry Mei. This design method 
enables the realization of maximum attainable PTE. This method works by implementing 
analytically derived optimal impedance matching conditions suggested by the bandpass 
filter model of inductive links. This allows the WPT link to be precisely tuned for optimal 
PTE to single or multiple receive devices [165, 166]. 
The WPT link is designed for operation at 13.56 MHz. This is selected by a 
combination of factors including desired dimensions of the testing environment (which 
influences the geometry of the external coil) as well as considerations for the 
designated ISM radio bands. The source for the electromagnetic field is supplied by an 
RF signal generator (Agilent, N5182A) and amplified by a class E amplifier (Mini-Circuits, 






by the external coil is kept below maximum output power requirements as designated 
by the FCC regulations for intentional radiators [106]. 
 
3.3.3 Full System Integration and PCB Design 
Device logic is mediated by a central MCU. The MCU employed in this device is a 
32-bit ARM® Cortex™ M0 within a low-power system-on-chip (SoC) package (Nordic 
Semiconductors, nRF51822). This SoC has a built-in 8/9/10-bit ADC which receives data 
in the range of 0-1.8V from the AFE. It also has an embedded 2.4GHz transceiver which 
outputs modulated data packets through a balun and finally to a ceramic 2.4GHz chip 
antenna (Johanson Technologies, 2450AT07A0100). System logic and operations are 
clocked at 16 MHz by means of an off-chip crystal oscillator. Figure 3.9 shows a 
schematic of the microcontroller and its peripherals. 
The Myonode is enabled with wireless data telemetry through an embedded 
transceiver on the low power SoC. The sampling rate of the system is typically set to 5 
kHz, which requires the MCU to wake up from sleep mode every 200 μs, record a data 
point, then go back to sleep. Utilizing sleep mode is one of multiple strategies employed 
to reduce total power consumption. In addition to running all active components on the 
lowest possible voltage supply (1.8 V), the device is able to save power by putting 
samples into packets for transmission rather than sending each sample independently. 
This minimizes overhead power consumption from transmitter startup and reduces the 
total amount of time in which the transmitter is active; a state in which it draws a 






of data corruption during wireless transmission becomes higher. To balance between 
efficiency and data integrity, a payload length of 32 bytes is chose. Once 31 bytes of 
data is collected, the microcontroller triggers the transmit task and the transmitter uses 
direct memory access to retrieve the 31 samples stored in memory and puts them in the 
payload. Each packet of data consists of a 5-bit preamble and 5 bytes of address 
information followed by the payload (1-byte packet ID + 31 bytes of data) and, finally, a 
2-byte cyclic redundancy check. The firmware for the Myonode is written in C 
programming language by Grant Wang, a member in the Center for Implantable Devices 
at Purdue University. 
The device communicates with a base station using the telemetry protocol 
developed by Nordic Semiconductor. The base station’s functional tasks are regulated 
by the same Nordic Semiconductor SoC as the Myonode. It receives data packets 
through the integrated receiver which has a sensitivity of -85 dBm for a 0.1% bit error 
rate (BER) at 2 Mbps. The data is sent via a serial-peripheral interface (SPI) to a 
computer where is can be plotted in real-time and saved. In the case where multiple 
devices are operating in an array, the base station can receive data from up to eight 
channels simultaneously by the sharing the SPI bus. Additionally, each device is assigned 
a unique 2 MHz-wide channel within the 2.4 GHz ISM band to avoid interference and 
synchronization issues. In all cases the wireless signal is modulated using Gaussian 







Figure 3.9 Circuit schematic of the system-on-chip (SoC) and its essential peripheral 
components for timing and data transmission, which are used in the custom PCB-based 
Myonode. The nRF51822 SoC has an integrated analog-to-digital converter (ADC), 2.4 
GHz transceiver, and 32-bit ARM® Cortex™ M0. 
 
The AFE, power rectification and management circuitry, MCU, and necessary 
MCU peripherals are integrated on a custom 4-layer PCB fabricated by Sierra Circuits. 
Efforts to miniaturize the finished device implored that the following custom PCB 
specifications be used: 0.004” minimum trace width/spacing, 0.006” minimum via 
diameter, 0.03” finished board thickness and one blind via set on an FR-4 dielectric 
substrate. A low temperature solder paste (Chip Quik, SMDLTFP) is used to assemble 
microelectronic components on the board. Following assembly the firmware is 
programmed into the MCU’s flash memory through a peripheral 10-pin M50 vertical 
male header that is not part of the final device. This header is detached and the extra 
board material is removed to minimize the size of the finished device, which has 






The recording electrode pair is connected to the microelectronics through two 
0.3 mm vias and set with a two-part silver conductive epoxy (8331S-15G, MG Chemicals). 
Devices built for chronic implantation use 304 series stainless steel wire (0.051 mm 
diameter) insulated with nylon to connect the board to two gold pad electrodes 
deposited on a parylene substrate similar to a patch or epimysial electrode. The 
geometry of the electrode pads used for the in vivo experiments is square with a side 
length of 0.5 mm and an inter-electrode spacing (center to center) of 3 mm. 
The receiving coil for chronic implantation in mice is assembled using 22 AWG 
magnet wire (Belden, 8051) and is formed by making three turns around a rod with a 
diameter of 12 mm. The coil is connected to the PCB by soldering to pads connected to 
the inputs of the K-inverter. The receiving coil adjoined to the PCB can be seen in Figure. 
3.10. The final step in assembly is the process of sealing the device, which is done using 
parylene C deposition. Parylene C is a conformal dielectric with demonstrated biological 








Figure 3.10 Myonode device constructed from commercial microelectronics integrated 
on a custom PCB which measure 5 mm x 8 mm x 2.7 mm once assembled. The PCB is 
affixed to a rigid receive coil having a diameter of 1.2 cm and a thickness of 3 mm, which 
is tuned for MRC power transfer with an external transmitting coil having a diameter of 
13 cm. 
 
Alternatively, coils printed on a thin, flexible substrate are designed to reduce 
the effective footprint of the receive coil and better sustain dynamic loading and flexural 
stress, which are expected in both applications of the Myonode. These coils are 15 mm x 
15 mm and are printed on a polyimide substrate fabricated by FlexPCB (see Figure 3.11). 
They have a total thickness of 0.13 mm and a minimum bend radius of 0.91 mm, which 
allows them to conform to the shape of a body. This may improve biocompatibility for 
subcutaneous implantations in mice and simplify integration with fabric body liners for 







Figure 3.11 (a) Rendering of receive coil fabricated on a flexible polyimide substrate with 
2 oz. copper deposition and insulating polyimide coverlay. Coil footprint is 15 mm x 15 
mm and has a finished thickness of 0.13 mm. (b) Picture of the fabricated flexible coil. 
 
3.3.4 Bench Top Performance of the Myonode PCB 
The assembled Myonode PCB is put through a series of engineering confidence 
tests prior to being used for bioelectric data acquisition. These include a fidelity check, a 
wireless powering check, and a soak test. The data fidelity check is performed by 
applying a sinusoidal waveform across the differential inputs and comparing the known 
input waveform to the reconstructed signal following digitization, transmission, and 
reconstruction. An example of this is given in Figure 3.12 for a device configured to 
collect sEMG. The wireless powering check entails placing the finished device in the WPT 
environment and observing successful device power up and data transmission. The soak 
test is carried out through submersion of the packaged device in 0.9% phosphate buffer 







Figure 3.12 Data fidelity test for a device configured for sEMG collection. Analog front-
end (AFE) gain is set to 300 (49.5 dB) 
 
The frequency response of the AFE circuit is measured using a dynamic signal 
analyzer (Agilent, 35670A) and is shown in Figure 3.13. The measured result is a close 
match with the Bode plot generated by the TINA-TI circuit simulation given in Figure 3.6. 
The input-referred noise of the system is quantified by measuring the power spectral 
density (PSD) at the AFE output when the differential inputs are shorted together and 
subsequently factoring out the gain response. Integrating the measured PSD, which is 
shown in Figure 3.14, over the recording channel bandwidth yields the peak-to-peak 








Figure 3.13 Measured frequency response of the custom PCB-based Myonode analog 
front-end (AFE) configured for intramuscular EMG (imEMG) recording. Bandpass gain is 
60 dB, high-pass -3 dB cutoff is 10 Hz, and -3dB cutoff is 1 kHz. 
 
 
Figure 3.14 Measured input-referred noise power spectral density (PSD) of the analog 
front-end (AFE) on the custom PCB-based Myonode. Integration of the PSD over the 























































The common-mode gain of the recording channel is measured on the dynamic 
signal analyzer by shorting the differential inputs together and applying a sinusoidal 
input waveform with an amplitude of 700 mVpp while sweeping the frequency across 
the bandwidth. The input waveform amplitude is selected so that it is large enough to 
be detected at the highest common-mode attenuation without railing the AFE at the 
frequency of lowest common-mode attenuation. Using both the differential and 
common-mode gain measurements allows the CMRR of the AFE to be calculated: 
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where Ad(f) is the frequency dependent differential voltage gain and Acm(f) is the 
frequency dependent common-mode voltage gain. Figure 3.15 plots the calculated 
CMRR from 1 Hz to 5 kHz and reveals that the CMRR is greater than 80 dB from 1 to 100 
Hz. This is important because the largest expected common-mode noise source is power 
lines, which create electromagnetic fields oscillating at 60 Hz. It is of interest to note 
that the reported CMRR of the INA333 instrumentation amplifier is >100 dB . The reason 
for this discrepancy is the addition of passive elements (resistors and capacitors) prior to 
the instrumentation amplifier input (see Figure 3.5). These circuit elements are 
necessary for single supply function within the WPT environment, but cause CMRR 
depletion due to mismatch in their values (surface mount chip components of this size 






meets the minimum recommended specification for EMG [168].Table 3.2 serves to 




Figure 3.15 Measured common-mode rejection ratio (CMRR) of the analog front-end 
(AFE) on the custom PCB-based Myonode. Input waveform was common to both AFE 

























Table 3.2 Summary of custom PCB-based functional parameters. Minimum and 
maximum values given for adjustable parameters and reflect ranges used in this work. 
Typical values represent default settings or measured characteristics. 
Parameter Conditions Min Typ. Max Unit 
Bandpass gain 40 60 66 dB 
High-Pass filter cutoff 0.1 10 -- Hz 
Low-Pass filter cutoff -- 1 5 kHz 
ADC digital resolution 8 8 10 bits 
ADC analog resolution -- 4.7 0.6 µV 
Input-referred voltage noise f = 10Hz to 1kHz -- 2.3 -- µVpp 
Common-mode rejection ratio f = DC to 60Hz -- >80 -- dB 
Sampling rate -- 5 20 kHz 
Transmission (data packet send) rate -- 161 -- Hz 
Transmitter output power -20 4 4 dBm 
Transmission center frequency -- 2.4 -- GHz 
Transmission channel bandwidth -- 2 -- MHz 
Average current consumption Sampling Rate = 5kS/s -- 1.6 -- mA 
Average power consumption Sampling Rate = 5kS/s -- 2.9 -- mW 
 
3.4 In Vivo EMG Acquisition in Mice 
The in vivo validation of the Myonode involves implantation of the device in both 
wild-type and disease model mice. The purpose of these experiments is threefold: first, 
to confirm that the packaging strategy is viable for device implantation; second, to 
determine whether or not the device is suitably small for subcutaneous placement in 
mice; and third, to observe the fidelity of power transfer within the WPT environment. 
An explanation of the surgical methods and experimental procedures used to 
successfully measure voluntary and spontaneously evoked EMG in both wild-type mice 






3.4.1 Experimental Design and Methods 
The first in vivo test for the fully wireless Myonode is to measure a known 
stimulus-evoked response with animal under anesthesia. This serves as a final check to 
be sure that the electrode design and configurable circuit parameters have been chosen 
and implemented correctly. The device’s recording electrodes are placed on the surface 
of the lateralis gastrocnemius (LG) muscle and 100 μs-long stimuli are applied to the 
sciatic nerve using a bench top stimulator. Stimulus frequency is kept low (0.5 Hz) to 
avoid time-dependent changes in the measured response as a result of nerve 
desensitization or muscle fatigue, and the evoked responses are recorded at a sampling 
rate of 5 kHz. The stimulus current amplitude is gradually increased until an evoked 
response is observed. Figure 3.16 illustrates a series of five stimulus-evoked CMAPs 
measured by the Myonode in response to a stimulus pulse with a current amplitude of 
72μA (charge of 7.2 nC per cycle). 
 
 
Figure 3.16 Five superimposed compound muscle action potentials (CMAPs) measured 
from the lateral gastrocnemius (LG) muscle by the fully wireless Myonode in response to 







Following demonstration that the device—as well as its supporting hardware 
and software—can collect and reconfigure a CMAP response, the device is implanted in 
a mouse to record chronic, voluntary evoked EMG. The surgical procedure includes a 1 
cm incision transverse to the animal’s midline while in the prone position. Blunt 
dissection technique is used in the midsection of the back to create a pocket for the 
device to be inserted subcutaneously. The electrode pads are placed on and sutured to 
the surface of the biceps femoris. Electrode sutures are placed at the junction between 
the electrode leads and pads and the device is secured to the fascia by two suture loops 
around the receive coil. The biceps femoris muscle is the selected target for the first 
implantation since it is close to the animal’s midsection, where the bulky device will fit 
under the loose skin without inhibiting motion of the limbs. This allows the surgeon to 
avoid making a larger single incision or second incision in order to reach a target that is 
more remote relative to the device. Following recovery the animal is placed inside the 
WPT environment for data collection. 
 The WPT testing environment constructed for untethered mouse work consists 
of a two-turn transmitting coil made from 10 AWG copper wire made to fit around the 
base of a tub with a 13 cm diameter as shown in Figure 3.17. The dimensions of this 
environment are selected such that there would be sufficient coupling between the 
transmitting and receiving coil at any point within the enclosed space and sufficient 
room for the mouse to comfortably move. Both of these aims are achieved within while 
maintaining an output (transmitting) power below 1 W using the testing environment 







Figure 3.17 Experimental setup for chronic implantation of custom PCB-based Myonode 
in freely behaving, untethered mice. The wireless power transfer (WPT) environment 
consists of a power transmitting coil encircling a tub with a 13 cm diameter (green). The 
RF signal is sourced from a waveform generator (blue) and amplified through a class E 
amplifier (orange). Data is telemetered from the implanted Myonode to a base station 
(yellow), which relays the data to a software interface (red) through a USB interface. 
 
3.4.2 Collection of Voluntary Evoked EMG in Wild-Type Mice 
All wild-type mice are from the C57BL6/J (Black 6) strain. The in vivo EMG 
collected from a freely behaving wild-type mouse is shown in Figure 3.18 along with 
baseline data collected while the mouse is under anesthesia. These data are recorded 
from epimysial (pad) electrodes on the biceps femoris. The data collected on day 1 show 
the characteristic, periodic interference patterns as the mouse moves around the WPT 
environment. This is an exciting outcome as it demonstrates that the device and 
integrated WPT strategy can enable collected of voluntary evoked EMG from an 






EMG signal is visibly deteriorated and eventually lost within the noise floor. It is 
suspected and subsequently confirmed that this is due to a mechanical failure of the 
electrode leads, which caused one of the differential inputs to float. 
The wild-type mouse experiment is terminated at day 16 so the device can be 
explanted and inspected. Importantly, though, the device continued to work in the WPT 








Figure 3.18 EMG recorded from biceps femoris muscle of a mouse over the course of 16 
days. Baseline data is collected from anesthetized animal immediately following device 
implantation. Signal deterioration over time is due to a mechanical failure at the 
junction between the electrode pad and lead. Device operation and telemetry is 
successful for 16 days at which point the experiment is ended so that the device may be 
explanted and examined. All data has been digitally bandpass filtered (5Hz-1kHz 
passband) and notch filtered at 160Hz and all 160Hz harmonics to remove periodic noise 
associated with data transmission. 
 
3.4.3 Collection of Aberrant Muscle Activity in Neuromuscular Disease Model 
A Myonode device is implanted in a mouse model for familial MD to collect 
disease-related aberrant muscle activity. The surgical procedures and device placement 
are identical to those used for chronic implantation in wild-type mice. In this case the 






gene (strain C57BL/6J-Lama2dy7J/J). Mutations of the LAMA2 gene cause congenital MD 
type 1A in humans [169]. This model is characterized by hypomyelination, muscular 
degeneration, and eventual loss of hind limb function. As peripheral nerves and muscle 
become affected, large, transient muscle fasciculation can be seen. This overt 
phenotype is the reason that this particular disease model is selected for early 
applications of the Myonode. EMG associated with these fasciculation can be recorded 
from the mouse during stationary periods in which spontaneous contractions of the 
hind limb are observed. 
Figure 3.19 illustrates aberrant muscle fasciculation collected from a familial MD 
model mouse using the fully wireless Myonode in the WPT testing environment. This 
electrophysiological phenotype is recorded during a stationary period (no ambulation) 
which spontaneous contractions of the hind limb are observed. This is one example of a 
disease signature that can be tracked with relative ease using a fully wireless and 
implantable biosensor. This signature can be used to better understand disease 
progression or evaluate novel therapies without the potential confounds introduced by 









Figure 3.19 Aberrant muscle fasciculation measured from the biceps femoris muscle of a 
mouse model for familial muscular dystrophy (MD). The animal is stationary during the 
recording period during which time spontaneous contractions of the hind limb are 
observed. 
 
3.5 Human EMG Measurement for Prosthetic Arm Control 
In this section the custom PCB-based Myonode is used to collect human imEMG 
and sEMG, which is subsequently integrated with established myoelectric control 
schemes to direct both virtual and electric-powered upper-limb prostheses. One of the 
goals for the wireless, single-channel Myonode is to embed multiple devices in an array 
within muscles to create reliable neural interfaces for upper-limb prosthesis control. The 
current shape and size of the device does not permit intramuscular implantation, so 
further refinement of the device and an institutional review board (IRB) approval is 
needed before this can happen. In the interim, however, two of the most critical 
capabilities of the device may be tested: first, its ability to measure the desired signal 
and, second, its ability function when placed in an array with other devices.  
Human-subject imEMG is collected to demonstrate that the device can retrieve 
useable EMG from a differential electrode pair embedded in muscle. Human-subject 







the usability of the measured EMG is demonstrated by interfacing it with established 
myoelectric prosthetic control systems.  
 
3.5.1 Collection of imEMG from an Able-Bodied Human Subject 
An imEMG signal from the extensor carpi radialis longus (ECRL) muscle in an 
able-bodied human subject is collected with the fully wireless device and used to control 
a powered prosthetic arm in development at the Rehabilitation Institute of Chicago 
[170]. The imEMG is collected using bipolar fine wire EMG electrodes (Natus Medical, 
Inc.) that are connected to the Myonode through an interposer board. Fine wires are 
introduced into the ECRL muscle using a hypodermic needle. The insertion location is 
guided by reference texts [171] and confirmed with corresponding test contractions. 
The EMG is sampled at 5 kHz. The mean absolute value (MAV) of the EMG signal is 
calculated from a 250 ms sliding window with a 50 ms frame increment. The MAV is 
used as the input to a three-state configuration of single-site myoelectric control [77]. 
The magnitude of the MAV signal is mapped to one of three possible states in 
this myoelectric control system: no motion, hand close, or hand open. The mappings is 
determined by two thresholds on the MAC signal, which delineated three ranges 
corresponding to the three states. The no motion state resulted from MAV activity less 
than the lower threshold; the hand close state resulted from MAV activity between the 
two thresholds, and the hand open state resulted from MAV activity greater than the 
higher threshold. Threshold values are set empirically by the experimenters—similar to 







states without fatigue. When in either of the two active states, the prosthesis is moved 
at a constant velocity. 
Figure 3.20 depicts imEMG collected by the Myonode from the ECRL muscle of 
an able-bodied patient. While configuring the three motion classes of the myoelectric 
control system, the patient is directed to produce three isolated contractions at a self-
selected “high-intensity” followed by two isolated self-selected “low-intensity” 
contractions, which can be seen distinctly in Figure 3.20. These data are streamed in 
real-time and used to differentiate between three states of a single degree of freedom, 
resulting in real-time myoelectric control of a prosthetic hand. Figure 3.21 portrays the 
setup for this experiment.  
 
 
Figure 3.20 Intramuscular EMG (imEMG) collected by a fully wireless Myonode from the 
extensor carpi radialis longus (ECRL) muscle of an able-bodied human subject (gain = 54 
dB). Subject is directed in this instance to produce three self-selected “high-intensity” 









Figure 3.21 Experimental setup to collect imEMG from extensor carpi radialis longus 
(ECRL) muscle to direct hand open and hand close in both a virtual and robotic 
prosthetic arm. Fine wire needle electrodes are fed through an interposer board to 
connect to the Myonode device on the bench top. 
 
3.5.2 Myonode Cuff Array for Multi-Channel sEMG Recording 
In addition to wirelessly powering a single device, the MRC optimization 
methodology can be expanded to incorporate multiple receivers by strategically 
controlling the power distribution [172]. Power coupling to eight devices is achieved by 
application of an anti-Helmholtz transmitting coil designed by Henry Mei. This coil is 
intended to be worn around the forearm as shown in Figure 3.22(a) in a manner similar 
to current inductive power links for transradial amputees [50]. The transmitting coil is 
made using 8 AWG copper wire and consists of two coils strategically wound in opposite 
directions then connected in parallel from the feed point indicated in Figure 3.22(b) to 







characterized by magnetic fields which point outward and perpendicular to the surface 
of the forearm as shown in Figure 3.22(c). This allows for adequate and equivalent 
coupling between the transmitting and receiving resonators sufficient to power eight 
devices positioned circumferentially around the forearm.  
 
 
Figure 3.22 Simulation of the transmitting anti-Helmholtz coil for power transfer to an 
array of Myonode’s placed circumferentially around the forearm. (a) Intended 
placement of the transmitting coil around a human body model in HFSS®. (b) 
Transmitting coil dimensions when viewed from the side and top. (c) Illustration of the 








The flexible receive coils described in Section 3.3.3 are used here as they will 
conform the surface the forearm and put less stress on the junction with the PCB. The 
intended arrangement of eight printed spiral coils within the anti-Helmholtz coil is 
depicted in Figure 3.23. Figure 3.24(a) shows the assembled fabric forearm cuff with 
eight Myonode devices connected to dry metal dome electrodes (Motion Control, Inc.) 
embedded in the fabric cuff. This arrangement allows for eight channels of differential 
sEMG to be measured around the circumference of the forearm. Minimal adaptations 
were required of the Myonode PCB in order to make it compatible with the forearm cuff. 
A stainless steel extension spring is connected to the each differential input via on the 
PCB by way of a copper post potted in the via at one end and inserted into the extension 
spring at the other end. The copper post is soldered at both junctions for stability and 
electrical continuity. Metal snap connectors are soldered to the free ends of the 
extension springs so that they could be easily connect and disconnected from the dry 
metal dome electrodes. Figure 3.24(b) shows one of these modified Bionodes adapted 










Figure 3.23 Transmitting anti-Helmholtz coil modeled in HFSS® with eight flexible 
receive coils positioned equidistant from one another around the inside coil the 




Figure 3.24 Adaptation of the Myonode for integration of multiple devices on an 
adjustable forearm cuff for multi-channel surface EMG (sEMG) recording. (a) Fabric 
forearm cuff with eight pairs of embedded dry metal dome electrodes. Electrodes 
interface with the differential recording inputs of the Myonode through metal snaps. (b) 
Single Myonode adapted for the forearm cuff. Metal snaps are soldered to an extension 
spring which is connected to the Myonode through copper post potted in a via. The rigid 








During testing the fabric cuff is secured snugly around the proximal third of the 
subject’s forearm—near the center of the brachioradialis muscle. An elastic bandage is 
wrapped around the cuff and forearm to protect the microelectronics. The anti-
Helmholtz coil is then slipped over the top of the cuff and the elastic bandage.  A 
pattern recognition system is used to correlate the streaming sEMG data from the array 
of devices to the intended motion of the user. In order to train the system, the user 
provides four repetitions of training contractions, which are comprised of 3-second 
contractions for each of the following seven motion classes: no motion, pronation, 
supination, wrist flexion, wrist extension, hand open, and hand close. A set of time 
domain features—the Hudgins set—is used, which includes MAV waveform length, 
number of slope sign changes, and zero crossing rate [173]. Additionally sixth order 
autoregressive features are calculated for each channel from 250 ms sliding windows 
with a 50 ms frame increment. Finally, a linear discriminant analysis (LDA) classifier is 
trained using features extracted from the training contractions. The user is then able to 
use the classifier to direct three degrees of freedom in a virtual prosthetic arm. During 
real-time control the LDA classifier successfully predicted which motion class the user 
wished to generate from newly produced sEMG features and the corresponding velocity 
output to the virtual arm is made proportional to the mean sEMG amplitudes produced 
and normalized by motion class [174]. 
This experiment demonstrates that eight Myonode devices can be wirelessly 
powered simultaneously using an anti-Helmholtz transmitting coil with a power output 







categorization of seven different motion classes using established myoelectric 
prosthetic control algorithms. Figure 3.25 shows an image of the experimental setup for 
multi-channel sEMG acquisition and control of a virtual arm.  
 
 
Figure 3.25 Experimental setup for multi-channel sEMG collection from an able-bodied 
subject. Data are collected from eight Myonode devices integrated on a fabric forearm 
cuff and powered through a wireless power transfer (WPT) link utilizing magnetic 
resonance coupling (MRC). Data are classified in real-time using a pattern recognition 
control system which is subsequently used to direct three degrees of freedom in a 
virtual arm. 
 
This experiment offers the following key result: that multiple Myonode devices 
can be successfully powered in an eight-channel array while retrieving usable EMG. The 
eventual goal of this project is to collect motor control information from within the 
muscle, which will require further reduction in the dimensions and an alternative 







some benefit to sEMG-modulated prostheses that are presently issued to patients. 
Specifically, multiple Myonode devices might be embedded in prosthetic sockets or 
elastomeric liners in order to wirelessly collect sEMG. This might simplify the patient-
prosthesis interface by removing all rigid electrical connections between the prosthesis 
and the electrodes. The Myonode would serve as a wireless preamplifier connected 
directly to the electrodes and close to the signal source and it would telemeter the 
sEMG data to the processor rather than sending it through a rigid adapter. This would 
lessen restrictions on how the prosthesis is designed and mounted. Moreover, it would 
eliminate the chance of an electrical failure or interruption due mechanical stresses and 
failures. Lastly, it would significantly streamline the use of elastomeric liners, which can 
improve suspension of the prosthesis and the electrode-skin contact [175]. 
The potential uses for the Myonode in prosthetic control are not limited to upper-
limb amputees. Lower-limb amputees are an important patient population to consider 
as they significantly outnumber upper-limb amputees [174] and EMG collection has 
been shown to improve control of powered prosthetic legs [176, 177]. Lower-limb 
amputees could benefit from chronic, wireless imEMG recording for many of the same 
reasons as upper-limb amputees (higher signal selectivity, signal permanence, etc.), but 
also because sEMG recorded in lower-limb prosthetic sockets contain substantial 
motion artifact caused by heel-strike [178]. This issue could be negated by permanent 








The Myonode represents the first pass at a fully wireless and implantable 
bioelectric sensor for freely behaving mice. One implementation of the Myonode 
attempts to build the functional circuit blocks in CMOS in hopes of benefiting from the 
smaller size and power consumption that come with ASIC-based systems. This resulted 
in a circuit that is capable of recording and transmitting bioelectric data on a power 
budget of 1 mW, but suffered from an overwhelmingly low production yield, difficulties 
interfacing with the ASIC chip, and functional rigidity. A second, more successful, 
implementation of the Myonode is designed and built using commercial off-the-shelf ICs 
and passive components integrated on a custom-designed PCB. This results in a finished 
device which is larger and demands more power than the ASIC. However, the additional 
size and power draw are counterbalanced by significant benefits such as configurability, 
customizable firmware, quick prototyping, and—most importantly—use of cutting edge 
microelectronics. This takes advantage of the state of the art in circuit design as well as 
quality control procedures already in place for commercial ICs, assuring greater 
reliability of the end-product. 
 The Myonode is designed specifically for EMG collection and is used to observe 
voluntary evoked muscle activity from a wild-type mouse and spontaneous aberrant 
muscle activity in a mouse model for familial MD. These are exciting outcomes as they 
demonstrate that the device is capable of collecting useful metrics for tracking 
neuromuscular diseases over time (see Section 1.1.1). It also affirms the viability of MRC 







known and repeatable CMAP waveform is measured to validate the in vivo data 
digitized and transmitted by the Myonode. This stimulus evoked response is collected 
mid-surgery while the animal is under anesthesia. However, CMAP responses are 
needed to normalize voluntary muscle activity in each animal over time in a longitudinal 
study. The amplitude of the CMAP response itself can also be an indicator for muscle 
atrophy [23]. A single channel of EMG is sufficient for a proof of principle, but a more 
advanced instrument is needed to accurately interpret changes in muscle behavior over 
time. For this reason the fully implantable device will need an integrated stimulator to 
evoke the CMAP and be tuned appropriately to measure the CMAP. 
Chronic electrophysiology in freely behaving animals faces many of the same 
obstacles as chronic electrophysiology in humans for prosthetic control. For this reason 
the work that went into developing an implantable system for mouse work also offered 
an opportunity to contribute to amputee rehabilitation. The human clinical work 
reported in this chapter includes three important results: 1) The Myonode is able to 
record usable imEMG, making it functionally suitable for intramuscular electrodes; 2) 
multiple Myonodes can be simultaneously powered to generate eight usable channels 
of sEMG; and 3) the Myonode in its current form could improve the interface between 
current socket liners and prosthetic sockets by using it as a permanently integrated 
preamplifier. The immediate utility of the Myonode for elastomeric liners as well as the 
Myonode’s compatibility with a more flexible and efficient WPT strategy (MRC) 








The next phase of this work will expand the capabilities of the Myonode and 
tackle its critical limitations. These limitations include single-tasking, weak mechanical 
properties of the electrode interface, and the small WPT testing environment. These 
fixes and new features result in a more sophisticated and versatile device termed the 








CHAPTER 4. THE BIONODE: A FULLY IMPLANTABLE RECORDING AND STIMULATING 
DEVICE FOR LONG-TERM SMALL ANIMAL MONITORING 
4.1 Introduction 
The material presented in this Chapter incorporates content from the journal 
article “Bionode for Fully Wireless Recording and Stimulating of Bioelectric Events in 
Rodents within a Large Volume Cavity Resonator” by R. A. Bercich*, S. T. Lee*, D. J. 
Pederson, Z. Wang, M. A. Arafat, H. Mei, C. Quinkert, G. Albors, J. P. Somann, J. G. R. 
Jefferys, and P.P. Irazoqui, which has been submitted for publication to IEEE Transaction 
on Biomedical Engineering. This chapter also incorporates content from the journal 
article “Cavity Resonator Wireless Power Transfer System for Freely Moving Animal 
Experiments” by H. Mei, K. A. Thackston, R. A. Bercich, G. R. Jefferys, and P. P. Irazoqui, 
which has been submitted for publication to IEEE Transactions on Biomedical 
Engineering. All procedures involving live animals are reviewed and approved by the 
Purdue Animal Care and Use Committee. 
The development and application of the Myonode device—a fully wireless and 
implantable single-channel bioelectric sensor—is detailed in Chapter 3. This chapter is 
dedicated to the development and application of the Bionode, which evolved from the 
Myonode. Functionally and practically the Bionode greatly improves upon the Myonode, 







of electrophysiological studies and truly state-of-the-art for fully wireless animal 
monitoring. First, it has an integrated biphasic, current-controlled stimulator for precise 
evocation of biopotentials. Second, it offers two independently configurable recording 
channels. Third, the electrode interfaces are fully redesigned for reusability as well as 
improved mechanical and electrical stability. Fourth, it is enabled with bidirectional 
telemetry for open communication between the implanted device and an external base 
station, which allows for immediate changes to functional protocol and stimulus 
directives. Lastly, the Bionode is compatible with a large, resonant cavity WPT 
environment which affords more space and flexibility for freely behaving animal 
experiments. These advancements along with some minor improvements to the system 
are described in Sections 4.2 through 4.4. 
The Bionode device described in this chapter reflects the end result of three 
design iterations. The first iteration used single supply mode on all microelectronics and 
a high side stimulator (meaning that both output electrodes are driven to high voltages 
that are disparate in amplitude by the product of current and electrode impedance 
during stimulation). The second iteration addressed stimulus artifacts that occur on 
startup due to improper default switch configurations within the stimulator circuit as 
well as high amplitude, transient current spikes that would occur at the onset of each 
stimulus pulse as a result of switching noise. The third iteration moves segments of the 
AFE and stimulator into dual supply mode and implements a low side stimulator to 
address current shunting to the AFE inputs, which causes sustained saturation of the 







Recent progress in cavity resonator-based WPT system lead by Henry Mei has 
produced large volume animal testing environment that itself serve as a magnetic field 
source and container The cavity resonator is designed to maximize PTE through optimal 
impedance matching in a manner similar to the MRC power transfer method employed 
for the Myonode [70, 71]. The electrical and physical characteristics of the cavity dictate 
its resonant frequency and thereby the operation frequency of the WPT link. The 
resonant cavity used in this work is 60 cm x 60 cm x 30 cm and is made out of sheet 
aluminum (thickness = 1.6 mm), which results in a resonant frequency between 340 and 
350 MHz. This is an important point because the higher operation frequency (relative to 
that of the coil pairing used for WPT to the Myonode) allows the size of the receive coils 
to be reduced while maintaining similar PTE performance. This is a wonderful piece of 
enabling technology as it improves two conditions of the Myonode system: the 
restrictive size of the animal monitoring environment and the coil size, which is 
cumbersome at 1.2 cm. 
The Bionode consists of a power module board and a core module, which has all 
of the microelectronics needed for biopotential acquisition, neuromodulation 
(stimulation), and bidirectional telemetry. Temperature sensing is also enabled through 
the incorporation of a thermal sensor. The power module board and the core module 
are separate PCBs which are assembled individually and then stacked to minimize the 
footprint of the Bionode at the expense of increased thickness. The Bionode is designed 
strategically so that it can take advantage of WPT using the novel cavity resonator 







oriented in transverse planes) on the power module to minimize sensitivity to 
misalignment between the receiving device and magnetic field direction. The profile of 
the magnetic field ( ⃗ ) within the cavity is characterized by its TM110 resonant mode and 
circulates about the feed point in its center [71]. The use of this cavity and its adaptation 
for longitudinal collection of neuromuscular information in mice is detailed within the 
experimental design and methods for chronic mouse work in Section 4.7.1. 
Sections 4.6 and 4.7 detail the use of the Bionode within a series of acute and 
chronic experiments in both rats and mice. These experiments serve importantly to 
demonstrate device in vivo viability and data validity. More excitingly, though, they 
include the application of the Bionode to the study of neuromuscular and motoneuron 
disease mechanisms. The ability to use the Bionode to expose new information about 
clinically relevant disease models is an exciting end result to this engineering design 
challenge. 
 
4.2 Power Module Development 
The power module acts as a power supply by coupling RF energy sourced from a 
large cavity resonator and rectifying the induced voltage to DC. Orientation mismatch of 
the transmitter and receiver is a notorious problem for freely behaving animal 
experiments. While the resonant cavity solution has improved performance compared 
to conventional WPT systems, it is not immune. To lessen the effect of device 







connected to the power module: each with a separate optimally designed impedance 
matching circuit. The methodology of the optimal impedance matching for the cavity is 
described in [71].  
 
4.2.1 Circuit Design for Power Management 
Figure 4.1 shows a circuit diagram of the full power module board. The inputs to 
this circuit are two AC voltages induced in the receive coils. These each pass through 
their own J-inverter impedance matching network before both are rectified and 
summed by a voltage doubler. This constitutes a biaxial RF-to-DC conversion circuit. This 
rectified voltage is fed to a bank capacitor (68 μF capacitance) which stores excess 
charge in a kind of reservoir. This storage capacitor serves to buffer the power supply 









Figure 4.1 Circuit schematic of the Bionode’s power module board. AC voltages induced 
in two receive coils by incident RF fields are passed through impedance matching 
networks (J-inverters), rectified, then regulated to the four voltage supplies needed for 
dual supply operation of the Bionode’s analog front-end (AFE) and stimulator. 
 
The unregulated, rectified voltage is also surge protected by a 5.1 V Zener diode. 
The rectified voltage is then applied to a network of voltage regulators and inverters 
which output all the necessary power supplies for the main PCB. This network includes a 
low-dropout (LDO) linear regulator to produce a 1.8 V supply (VDD) used by the AFE, 
stimulator, and MCU. This supply is subsequently inverted by a switched capacitor 
voltage inverter (MAX1720, ON Semiconductor) to create a -1.8 V supply (VSS) for the 
AFE and stimulator. The rectified voltage is also doubled using another switched 







headroom for the stimulator. The 5.1 V Zener diode on the rectified voltage limits the 
output of the voltage doubler to 10.2 V in theory and 10.5 V in practice. A second 
TL7660 is placed in series with the first and configured as a voltage inverter rather than 
multiplier to generate the -10.5 V supply for the stimulator. 
The power module has a footprint of 8mm x 13.5 mm and a thickness of 0.56 
mm (unpopulated). The four-layer PCB is designed in Altium and fabricated by Advanced 
Circuits using on FR-4 substrate. Once the microelectronics have been assembled on the 
power module, it is stacked and electrically connected by wires to the core module 
using five connection points (VDD, VSS, 10.5 V, -10.5 V, and ground). A picture of the 
assembled power module is shown in Figure 4.2. 
 
 
Figure 4.2 (a) Front view and (b) back view of assembled power module PCB board with 
5 mm diameter biaxial receive coils. Footprint dimensions are 8 mm x 13.5 mm. 
 
4.2.2 Flexible Substrates for Power Module Boards 
An alternative to the rigid power module is designed using copper deposited on 







fabrication discussed in Section 3.3.3 and is shown in Figure 4.3. This has three key 
advantages: 1) It reduces the power module board thickness by over 400%, which 
decreases the total thickness of the device; 2) the flexible coil is able to conform to the 
shape of the body once implanted, which makes it less of an obstruction than rigid coils; 
and 3) the receive coil is continuous with the circuit board, reducing the chances of a 
mechanical failure from a soldered joint at the coil terminals. The flexible power module 
is used for one iteration of the Bionode as shown in Figure 4.4. It is not used in the final 
Bionode design owing to changes in the power module circuit to accommodate a dual 
supply mode as well as difficulties incorporating a second printed coil for the biaxial 
receive coil system.  
 
 
Figure 4.3 Flexible power module fabricated from a flexible polyimide substrate with a 
thickness of 013 mm with an integrated. (a) Rendering of power module in Altium with a 










Figure 4.4 Bionode core module stacked on top of a flexible power module board. 
 
4.3 Bionode Core Module Development 
The purpose of the Bionode’s core module is to integrate the microelectronics for 
biopotenial acquisition, neuromodulation, thermal sensing, and telemetry. The power 
supplies for all core module microelectronics are provided by the power module board 
(see Section 4.2). The same Nordic Semiconductor SoC that is used in the Myonode is 
used on the Bionode’s core module to run and coordinate its various tasks. The SoC has 
256 kB of flash memory which, once again, allows for rapid changes to the device’s 
protocol through reprogrammable firmware. 
Wireless communication between the Bionode’s core module and a user interface 
for saving data and changing the device’s functional parameters is facilitated by a base 
station. The communication protocol, firmware development, and base station design 
are the results of incredible work done by Dan Pederson and Zhi Wang: two members of 







recorded data points, stimulation circuit status, and thermal measurements to the base 
station. During the normal data collection phase, the Bionode digitizes data from each 
recording channel using the SoC’s integrated ADC. The ADC can be set to collect data 
using either 8- or 10-bit precision. Once 40 bytes of data have been acquired, the 
Bionode sends a wireless data packet to the base station. 
Multiple settings and instructions can be communicated in the opposite 
direction—to the Bionode—through update packets sent by the base station to the 
transceiver embedded in the SoC on the Bionode’s core module. Configurable settings 
include recording parameters (sampling rate, ADC digital resolution, and selection of 
ADC input channels) and stimulation parameters (amplitude, pulse width, frequency, 
duration, and calibration settings). Instructions to begin or end a stimulation session as 
well as update the temperature measurement are also permitted. 
 
4.3.1 AFE for Biopotential Recording 
  Topologically the AFE on the Bionode is very similar to the AFE on the Myonode 
(see Section 3.3.1) and consists of an instrumentation amplifier (first stage) followed by 
a higher gain second stage and bandpass filter. Figure 4.5 displays the circuit diagram for 
the Bionode’s AFE, which has undergone three changes since the Myonode: first, the 
instrumentation amplifier is run in dual supply mode; second, the reference voltage is 
generated by a resistor divider rather than a regulator; and third, an alternate second 







The transition from single supply to dual supply eliminates the need for pull-up 
resistors to maintain a common mode, mid-supply, DC bias on the inputs to the 
instrumentation amplifier (first stage). This greatly increases the input impedance of the 
recording channels, which equates to twice the pull-up resistance in the Myonode since 
both input are tied to the same reference voltage for DC biasing. Alternatively, this 
topology takes advantage of the high differential impedance (100 GΩ) of the INA333. 
The input voltage range for the ADC on the Myonode is 0 to 1.8 V: a setup made 
possible by prescaling the analog input to the MCU. Prescaling puts limitations on the 
sampling rate and is not used in the Bionode where the ADC still operates in single 
supply mode but uses the default input voltage range of 0 to 1.2 V. Therefore the AFE 
output must still be offset to the middle of the ADC input voltage range. Here the AFE 
takes advantage of a 1.2 V reference voltage readily available from the digital-to-analog 
convert (DAC) that is introduced to the system as part of the stimulator circuit. This 1.2 
V reference is voltage divided in half using equal valued resistors (R3 and R4 in Figure 
4.5) and buffered to create a low impedance source. 
The second stage op amp is the OPA313 (Texas Instruments), which has a higher 
gain-bandwidth product (1 MHz) than its predecessor. This lessens the limitations on the 
low-pass filter cutoff and allows it to be raised to 10k while maintaining that a majority 
of signal gain occurs in the second stage (typically 40 dB). This makes the recording 
channel more suitable for general neural recording since single unit potentials from 
individual nerves, muscle fibers, and neurons have frequency content in the range of 








Figure 4.5 Bionode analog front-end (AFE) circuit diagram. Instrumentation amplifier 
(first stage) is followed by a higher gain second stage with an integrated bandpass filter. 
A reference of 0.6 V is needed to bias the AFE output to the middle of the ADC input 
range. This reference comes from the digital-to-analog converter(DAC) following voltage 
reduction through a resistor divider. 
 
The Bionode contains two independent recording channels. The gain and 
bandwidth of each channel’s AFE can be reconfigured through passive component 
selection. The gain of the first stage is set by a single resistor, Rf, based on the 
relationship given in [164] while the gain of the second stage may be approximated by 
the known gain equation of an inverting operational amplifier (see equation 3.1). 
Meanwhile, the bandwidth cutoffs may continue to be approximated by equations (3.2) 
and (3.3) and verified using SPICE software for circuit simulation. The passive 
component values selected in order to achieve the appropriate gain and bandwidth for 








Table 4.1 Passive component values used in Bionode analog front-end (AFE) for 
neuromuscular target signals in mice. 
Target Signal Total AFE Gain Rf C1 R1 C2 R2 
CMAP 60 dB 11 kΩ 1 μF 10kΩ 20 pF 1 MΩ 
Spontaneous EMG and NAP 34 dB 25 kΩ 1 μF 10 kΩ 330 pF 100 kΩ 
 
The frequency response for each of the two anticipated AFE configurations is 
simulated in TINA-TI and shown in Figure 4.6. The gain of each channel must be selected 
carefully since the Bionode does not have the ability to adjust gain after implantation. 
Gain is selected for each channel based on results from in vivo experiments outlined in 
Section 3.4 as well as within the literature [23]. Given the demonstrated capability of 
maximum CMAP responses to exceed peak-to-peak amplitude of spontaneous EMG 
activity by at least an order of magnitude, it is not judicious to use the same channel to 
target both signals until adjustable gain is integrated. Rather, one channel should be 
used specifically for CMAP responses and another for spontaneous EMG or NAP. The 
Bionode’s AFE has a CMRR of at least 80 dB from DC to 60 Hz and an input referred 









Figure 4.6 Simulated frequency response of the analog front-end (AFE) configured for 
spontaneous EMG and NAP (solid line) and CMAP (dotted line). 
 
4.3.2 Current-Controlled, Biphasic Stimulator 
The first step to integrating a stimulator on the Bionode is selecting the 
mechanism by which charge will be precisely injected into the excitable tissue. Voltage-
controlled (potentiostatic) stimulation is certainly easier to implement and, as 
demonstrated by Simpson and Ghovanloo, more power efficient than current-controlled 
(galvanostatic) or charge-controlled (switched-capacitor) stimulators [180]. However, a 
voltage-controlled stimulator presents a critical limitation which is that it offers no 
command over the level of current applied to the system. This is an issue because the 
electrical model of the tissue-electrode interface includes a capacitive element on 
account of the Helmholtz double layer which is forms between electrodes and 


























capacitive current and then approach a more stable Faradaic current. This means that 
the current amplitude at any time during a stimulus pulse will be dependent on the 
properties of the electrode and impedance between the working and counter electrode 
(which is likely to change over time as scar tissue forms in and around a cuff electrode 
placed on a nerve). Since the level of depolarization—and thus the electrophysiological 
response—of an electrically excitable tissue membrane is directly related to the 
amplitude of the current, an absence of this information makes it extremely difficult to 
reproduce and compare results from different animals [181]. For this crucial reason, a 
current-controlled rather than voltage-controlled stimulator is selected for the Bionode. 
The recommended parameters for electrical stimulation are well characterized 
and include biphasic pulse generation for charge balancing. This allows for the reversal 
of electrochemical processes that occur during a stimulating pulse, which helps to 
prevent electrode degradation and resulting deposition of chemical species into tissue 
[181]. Other stimulation parameter such as frequency, pulse width, and pulse pattern 
distribution are not as well studied and are of interest for biological efficacy and 
decreased power consumption in the recently burgeoning field of electroceuticals [182, 
183]. While outside the scope of this work, it is exciting to note that the Bionode and its 
supporting hardware and software constitute a streamlined and comprehensive 
platform for testing these additional parameters for functional electrical stimulation and 
other therapeutic devices. 
Figure 4.7 shows a circuit diagram of the biphasic, current-controlled stimulator 







Center for Implantable Devices at Purdue University, who helped to develop the 
stimulator topology in its current (dual supply) form. The output current to a stimulating 
(working) electrode (designated STIM in Figure 4.7) is achieved using an op amp 
constant current sink with parallel N-channel and P-channel MOSFETs for generating 
either positive or negative current. The time-dependent features of the stimulus output 
(pulse width and pulse period) are regulated by a single pole triple throw (SP3T) switch 
that selects between an off-state (output connected to ground) and two possible on-
states: one for a negative (cathodic) pulse and another for positive (anodic) pulse 
relative to a counter electrode that is connected to circuit ground. All stimulation 









Figure 4.7 Circuit schematic of the Bionode’s biphasic, current-controlled stimulator. 
Both positive and negative stimulus pulses may be applied to the STIM node, which is 
connected to a working electrode. Stimulus current is collected by a counter electrode 
shorted to circuit ground. 
 
The current amplitude during each stimulation phase is determined by a 
programmable control voltage generated by a 12-bit DAC (MAX5535, Maxim Integrated) 
either directly (for anodic pulses) or following a unity gain voltage inverter (for cathodic 
pulses). The inverting op amp, which operates in dual supply mode, is needed since the 
DAC (operated in single supply) cannot output negative voltages. The control voltage is 
applied to the non-inverting terminal of an op amp during a stimulus pulse, which will 
drive the inverting input to the same voltage. The voltage on the non-inverting input is 
applied across a known resistor—R4 in Figure 4.7—to create a constant current sink 







divided by R4). The resistor R4 is set to 200 Ω by default and for all applications in this 
work. 
The current through R4 is replicated by current mirrors using matching P-channel 
MOSFETs (UM6K34N, Rohm Semiconductor) or N-channel MOSFETs (NX3008PBKS, NXP 
Semiconductors), depending on the direction of the current. This allows for isolation 
between the portion of the circuit that sets the desired current and the portion of the 
circuit that applies the desired current to the tissue. The matched current is directed to 
the working electrode (STIM) and collected by a counter electrode referenced to circuit 
ground. One disadvantage of this topology is that it requires a very close match in 
MOSFET characteristics within each current mirror in order for the applied current to 
match the set current through R4. Even though the MOSFETs selected for the current 
mirrors are identical parts that even come in the same package, the relationship 
between desired and applied current is non-linear and varies from build to build. 
The same non-linearity is observed —to a lesser extent--in stimulus pulse width. 
Lower stimulus currents necessitate a more dramatic positive calibration in the pulse 
width. Figure 4.8 compiles stimulator calibration curves for four different stimulator 
builds at a desired pulse width of 100 μs. Blue traces represent positive pulse calibration 
and red traces represent negative pulse calibration. Pulse amplitude correction, which is 
indicated by solid traces can range from -50 to +146 μA for positive pulses and from -80 
to +6 μA for negative pulses. Pulse width correction for both negative and positive 
pulses becomes less dramatic at higher current amplitudes; however, they are 







as high as +50 μs (half the pulse width setting). The implication of Figure 4.8 is that the 
stimulator topology implemented on the Bionode can supply predictable and reliable 
stimulus waveforms provided that each stimulator build has been characterized and is 
accompanied by its respective calibration data. This is an inconvenience but not an 
obstruction to the application of this device to animal work. 
 
 
Figure 4.8 Stimulus pulse width (dotted lines) and amplitude (solid lines) calibration 
curves for correcting nonlinearity between requested and actual parameters of positive 
(blue) and negative (red) stimulus pulses. Requested pulse width is 100 μs. 
 
The functional performance of the stimulator is evaluated on the bench top by 
connecting its output to a known load impedance (10 kΩ), sweeping the stimulator’s 













































































cycle), and calibrating the pulse width and current amplitude at each set of stimulation 
parameters. Figure 4.9 illustrates a sampling of the biphasic stimulator outputs for a 
range of stimulus current amplitude settings at a 50% duty cycle. When optimally 
calibrated, the measured charge balance error is less than 1% at a pulse width of 100 μs. 
This is calculated by integrating the current through a 10 kΩ resistor during 200 
successive stimulus pulses (alternating between anodic and cathodic) Dividing this 
integral by the number of pulses gives the average net charge imbalance per pulse pair. 
 
 
Figure 4.9 Current-controlled, biphasic stimulator output measured on the bench top 
using a 10 kΩ load between the working electrode and counter electrode (ground). 
Pulse width, current amplitude, and duty cycle are all selectable in real-time telemetry 
from the base station to the Bionode. A pulse width of 100 μs and a 50% duty cycle are 
used here to illustrate the measured output current for a range of amplitude settings. 
 
A significant challenge that appears repeatedly across iterations of the Bionode 







delay between initial generation of the electromagnetic field and control of digital logic 
lines to the switch that controls the phase (on or off) of the stimulator. This means that 
the logic lines that designate switch position (see Figure 4.7 for an example) float to 
unknown and likely high voltages on account of high line impedance before the MCU is 
able to startup and carry out its programmed protocols, which include regulating the 
voltages on these digital I/O lines. This issue is exacerbated by the relatively long 
(compared to the other ICs on the core module) MCU startup time, which is over 100 ms 
when powered from an ideal DC voltage supply. However, the delay between initial 
voltage rise on the power supply line and MCU startup can increase dramatically as a 
result of variable rise rates and possible fluctuations on the main voltage supply line; 
both of which can occur unpredictably with WPT to a freely behaving animal.  
Consider the following likely scenario: an electromagnetic field source is turned 
on and couples energy to a receiving device within the cavity resonator. The induced AC 
current is continuously rectified, which causes an increase in the rectified voltage as its 
storage capacitor is charged. Once the rectified voltage reaches approximately 1.2 V, the 
1.8 V LDO regulator will turn on and follow the input (rectified voltage) as it increases up 
to 1.8 V. Once the LDO regulator turns on (at a rectified voltage as low as 1.2 V) current 
will travel to and diffuse throughout the Bionode, partially turning on some ICs and 
possibly inducing transient elevations in electrical potential in extremely close, short, 
and high impedance traces. Simultaneously, as the DAC boots up (which will happen 
faster than MCU boot up), its output will float until it receives directives from the MCU. 







unregulated and may float to a logic high condition that connects the control voltage 
from the DAC to the constant current sink. This results in erroneous and undesirable 
stimuli within tissue and has been observed both on the bench top and in vivo. 
Furthermore, this activity is erratic in nature, and so presents a challenge to the circuit 
design, which is often done under the easier but limiting assumptions of constant DC 
powering and steady state conditions. 
This artifact is potentially catastrophic in situations where coupling between the 
resonant cavity and receive coils on the power module may not offer a sufficient PTE to 
run the device in all possible locations and positions of the animal. One can imagine a 
scenario in which the animal moves into a position such that the device is beginning to 
turn on when suddenly a large, unwanted stimulus is applied. This would likely cause 
the animal to move abruptly, causing a quick shift in voltage supply amplitude. This 
would, in the best case scenario, increase the supply voltage so the system continues to 
turn on and, in the worst case scenario, decrease the supply voltage and return to 
conditions in which the system is poised to deliver another unwanted stimulus. The 
likelihood of frequent, unwanted stimulation to the peripheral nerve in this case would 
likely lead to experimental confounds and unnecessary stress imparted on the animal. 
Even more disastrous to study outcomes is the possible behavioral conditioning that 
would result from a large and likely painful stimulus delivered every time the device 
turns on. This might cause the animal to avoid areas of its environment where WPT is 








One solution that is implemented in the course of iterating the Bionode’s core 
module is the use of pull-down and pull-up resistors on the switch logic lines in order to 
hold these to either high or low logic levels during startup at the expense of added 
current consumption during normal operation. The stimulator topology shown in Figure 
4.7 is no exception to this matter as the SP3T switch has two digital logic lines directing 
the switch position. This switch is outfitted with a pull-up resistor to the positive voltage 
supply (1.8 V) on one digital pin for a forced logic high and a pull-down resistor to 
ground on the other digital pin for a forced logic low. This logic configuration ensures 
that the output of the switch is toggled to ground by default even when the device is 
starting up. 
However, even when logic lines can be configured intelligently for startup as 
they have been here, there is still the possibility that another critical node in the 
stimulus circuit path will float to a non-zero voltage relative to circuit ground up until 
the point when all active components in the system are turned on and operating in 
steady state. This turns out to be the case for the assembled stimulator on the Bionode. 
Despite control over the digital lines of the phase switch, high amplitude currents can be 
measured on the stimulator output during startup. This reemerging problem is 
addressed by observing that the only way for current to flow through the single N-
channel or P-channel MOSFETs on the output of the op amp is if the gate voltage is 
biased. The likely explanation here is that the output of the op amp, which operates in 
dual supply mode, runs positive for the short period of time between activation of the 







happens, recall that the-1.8 V supply voltage (VSS) is generated on the power module by 
a voltage inverter preceded and supplied by the 1.8 V LDO regulator than generates 
VDD. For this reason, the Bionode’s core module will always see changes in VDD before 
changes in VSS during startup. 
A pull-down resistor to ground on the gates of these MOSFETs is a simple and 
elegant way to stifle this unwanted bias voltage as it cuts the problem off at its source. 
The pull-down resistor (R3 in Figure 4.7) needs to be sufficiently small so that any 
voltage applied to the gates will readily discharge to ground. The size of this resistor is 
determined empirically by incrementally decreasing the resistance until the startup 
artifact disappears. The value of R3 is 1 kΩ for the extent of this work. This solution 
comes at very little expense since the op amp output is almost always 0 V under normal 
operation (no stimulation) and only increases total device consumption during the brief 
periods of stimulation. This does not noticeably affect the behavior of the stimulator 
itself because once the op amp is fully turned on it can source enough current to 
effectively bias the gate voltages as needed. 
 
4.3.3 Thermal Sensing 
The Bionode is equipped with a temperature sensor IC (TMP112, Texas 
Instruments) on the core module in order to monitor thermal changes within the device. 
Due to the position of the sensor on the surface of the core module PCB and the 
packaging strategy, which placed a barrier between the internal microelectronics and 







tissue interface. Rather, it sits adjacent to the heat source. This makes it difficult to 
compare temperature changes in the tissue to the appropriate safety thresholds and 
recommendations outlined in Section 2.5. However the temperature change measured 
by the sensor is more exacting than that experienced by the tissue because the 
temperature at the source will always be greater than the temperature experienced by 
the tissue. Resultantly, a limit may be imposed on the temperature rise at the source 
which automatically shuts down the device once an established threshold has been 
crossed. If this threshold is equated to maximum safe temperature changes in tissue, 
this would prevent tissue damage from thermal toxicity. 
The fidelity of the temperature monitoring protocol is demonstrated in a 
controlled water bath. A packaged Bionode is submerged in the bath adjacent to a 
commercial thermocouple (Fluke 80BK-A Type-K). The Bionode’s power supply terminals 
are wired out of the device and connected to DC power supply. Wireless powering is not 
desired in this experiment as it will likely cause local heating within the device as a result 
of electromagnetic field induction and voltage rectification. This would unnecessarily 
complicate the temperature gradient profile when the experimental objective is to 
confirm that the thermal sensor—as it is implemented and packaged—will accurately 
track known temperatures changes in its environment. 
The temperature of the water bath is raised to 40 °C and then allowed to cool. 
During cooling the temperatures measured by the thermocouple and IC thermal sensor 
are recorded at a rate of one sample per minute. The results of this experiment are 







sensor and the thermocouple over time is 0.525 ± 0.057 °C. These data suggest that 
there is a consistent DC offset in the thermal sensor measurements across the range of 
temperatures likely to occur near a subcutaneous implant in a rodent. This means that 
accounting for this offset in each device can be done using a simple, single-point 
calibration at a known reference temperature. 
 
Figure 4.10 Comparison of temperature measurements from a thermal sensor IC 
(TMP112 mounted on the Bionode’s core module PCB) and a commercial thermocouple 
tracking change in water bath temperature over time. 
 
4.3.4 Custom PCB Design for Integration of Core Microelectronics 
The microelectronics for the Bionode’s core module are integrated on a six-layer 
PCB made from FR-4 substrate with thickness of 1 mm. This PCB is fabricated by 
Advanced Circuits and has a footprint of 8mm x 13.5 mm (the same as the power 
module). Given the unavoidable close proximity of the mixed-signal electronics, care is 































Bionode. Figure 4.11 shows front and back views of a core module PCB designed and 3D 
rendered in Altium as well as pictures of an assembled prototype. 
 
 
Figure 4.11 Front and back view of the Bionode core module rendered in Altium and 
fabricated on a custom PCB. 
 
A monopole strip antenna for bidirectional telemetry at 2.4 GHz is printed on the 
bottom layer of the PCB and replaces the chip antenna that is used for the same 
purpose on the Myonode. Because of the RF communication frequency and the limited 
real estate, this antenna is inevitably electrically small. Electrically small monopole 
antennas exhibit better performance (measured in antenna gain) when the length of the 
antenna increases to approach a quarter wavelength at the frequency of operation. 







maximize its length, which is 11.5 mm. The input to the antenna is impedance matched 
to maximize the power transferred to the antenna, which increases signal power and 
fidelity. 
 
4.4 Bionode Full System Bench Top Characterization 
The power and core modules together constitute the implantable system, which 
communicates wirelessly with an external base station. Figure 4.12 shows a block 
diagram of the complete hardware system that highlights the key functional blocks. In 
addition to two recording channels, one stimulating channel, and a thermal sensor, the 
device also offers two optional input channels which connect directly to ADC input pins 
on the SoC. These are included so that the Bionode device can be paired with other 
types of sensors. The external base station serves to route incoming data from the 
implant to a graphical user interface (GUI) for real-time viewing and data storage. The 
GUI also enables communication of directives such as sampling rate, ADC resolution, 








Figure 4.12 Block diagram illustrating key sub-elements of the fully Bionode system. The 
implantable Bionode device includes the power module board stacked on top of the 
core module board. The power module board provides the supply voltages necessary to 
run the microelectronics on the core module. The device is enabled with two-way 
telemetry with an external base station, which relays data to a computer. The graphical 
user interface (GUI) is written in Python3 and can be used to plot and save data. The GUI 
is also able to control functional parameters of the remote device such as sampling rate, 
ADC resolution, and stimulus waveform settings. 
 
It is necessary to understand the cumulative power consumption profile of the 
Bionode in order to make inferences about the PTE of the WPT link once the device is 
operating in an animal. This information is also needed to select an appropriately sized 







phases of the device’s functional protocol (like sampling and transmitting) draw 
additional current for short periods of time. It is important that during these phases of 
elevated current consumption the supply voltages do not droop and initiate shutdown 
of any onboard ICs. The power consumption profile over time is compiled using a small-
value (5 Ω) resistor in series with the each of device’s voltage supplies and measuring 
the differential voltage across the series resistor over time. The current drawn from 
each supply is calculated using Ohm’s Law and then all the individual currents are 
summed. Figure 4.13 illustrates the cumulative, temporal power consumption of the 
device when it is sampling at a total rate of 5 kHz. The average power consumption 
under these conditions is 5.03 mW. Figure 4.14 illustrates the total temporal power 
consumption of the device when it is sampling at a total rate of 25 kHz. The average 
power consumption under this condition is 6.72 mW.  
The smaller spikes observed in Figures 4.13 and 4.14 are associated with ADC 
operation during data sampling. Also clear in these figures are much larger, sustained 
spikes that occur less frequently and are attributed to transmitter use. In both scenarios 
the ADC resolution is maintained at 8-bit, which means that after every 40 samples 
(small spikes) a larger spike should occur as the transmitter is turned on to send a 
packet of data as established by the telemetry protocol. This is confirmed by the 









Figure 4.13 Power consumption profile of the Bionode over time when sampling rate is 
set to 5kHz and stimulator is off. 
 
 
Figure 4.14 Power consumption profile of the Bionode over time when sampling rate is 
set to 25 kHz and stimulator is off. 
 
The average power consumption is a useful metric for comparing this system to 



























































conditions that must be considered when designing an effective power management 
strategy. It is established in Section 4.2.1 that the rectified voltage is limited to 
approximately 5.25 V in practice as a result of a 5.1 V Zener diode and that this rectified 
voltage is applied across a large storage capacitor that serves as a charge bank. Since the 
amount of charge stored in a capacitor is directly proportional its capacitance, it is 
desirable to make this capacitor as large as possible so that it can buffer periods of large 
current draw. This is especially important when the system has recently turned on and 
the rectified voltage may be just barely above the 1.8 V needed for stable operation of 
the most ICs—including the MCU. In this vulnerable state, rapid fluctuations on the 
power supply might cause the device to turn off and on repeatedly: prohibiting the 
collection of continuous data. A worst case scenario approximation for the amount of 
charge that may need to be available at any time is calculated by integrating the large 
power spike corresponding to data transmission at 25 kHz. This results in a total charge 
budget of 6.44 μC. A 47 μF capacitor is able to source this quantity of charge while 
experiencing a voltage drop of only 0.14 V. This means that a rectified voltage as low as 
1.94 V is all that needs to be reached between the time when the MCU turns on and the 
first transmission occurs in order to prevent untimely shutdown in the middle of startup. 
In practice, this makes it much easier for the system to start up and immediately reduce 
power supply ripple. 
Each device undergoes the same series of engineering confidence tests prior to 
implantation as outlined in Section 3.3.4. Figure 4.15 shows an example of an 







During this test a known input waveform (sine wave) is applied to both input channels, 
and the telemetered signals are reconfigured and plotted. The amplitude of the test 
signal is set to 2mVpp—the lowest amplitude sine wave that can be generated cleanly 
by available equipment. A frequency outside of the AFE bandwidth (10 Hz in this case) is 
used to prevent the signal from railing in the high gain (60dB) channel. 
 
 
Figure 4.15 Full system response to a known input sine wave with an amplitude of 2 
mVpp and a frequency of 10 Hz. Channel 1 is the output from the high gain (60 dB in 
bandpass) analog front-end (AFE) intended for spontaneous muscle and nerve activity 
while channel 2 is the output from the low gain (34 dB) in bandpass) AFE intended for 
larger CMAP responses. 
 
The peak-to-peak amplitude of the signal into the ADC (after the effects of AFE 
gain and filtration) is predicted in circuit simulation to be 1.07 V for the high gain 







outputted from the second, low gain (34 dB) channel is 52.7 mV and measured to be 
42.7 mV. The slight discrepancies between simulated and measured results at this out-
of-band frequency are likely due to the tolerances (1-5%) of the passive components 
used to set the bandwidth. However, deviations in the AFE frequency response on this 
minor scale will not perceivably alter the quality of measured bioelectric signals. 
The performance characteristics of the full system Bionode as well as those 
specific to the AFE and stimulator are summarized in Table 4.2. Typical values represent 
either measured system parameters or default parameters, although some of these may 
be altered during assembly or within the firmware. When given, minimum and/or 
maximum values designate the permitted ranges of parameters that can be adjusted at 
any time using the GUI and wireless communication to the device. The Bionode’s high 
level of functionality and flexibility is reflected in Table 4.2, which specs out the most 







Table 4.2 Bionode performance characteristics. Typical values represent measured 
characteristics for the default configuration. Minimum and maximum values represent 
ranges for adjustable parameters. 













Gain 1  -- 60 -- dB 
High-pass cutoff 1  -- 0.01 -- kHz 
Low-pass cutoff 1  -- 1 -- kHz 
CMRR DC to 60 Hz 80 -- -- dB 
Input Impedance 2  -- 100 -- GΩ 
Input-referred noise f =0.01-3 kHz -- 50 -- nV/√Hz 
Ch.1  Ch.2 crosstalk  -- -99 -- dB 
Ch. 2  Ch.1 crosstalk f =100Hz -- -98 -- dB 
ADC resolution  8 -- 10 bits 
ADC input voltage range  -- 1.2 -- V 







Voltage headroom 3  ±4 ±10.5 ±10.5 V 
Current amplitude Load = 10 kΩ 50 -- 1,050 µA 
Current amplitude resolution  -- 1.5 -- µA 
Pulse width (PW)  50 -- -- µs 
Pulse width resolution  -- 1 -- µs 
Pulse rate  -- -- 20 kHz 





Mass 4  -- 2.2 -- g 
Average power consumption 
SR = 5 kHz 





Peak power consumption Transmitter on -- 20.5 -- mW 
Temperature resolution 0-65 °C -- 0.07 -- °C 
1These parameters may be modified during the build phase based on signal of interest. 
2Input impedance reported by INA333 datasheet released by Texas Instruments [25] 
3Voltage headroom depends on power transfer efficiency (PTE) and is limited to 10.5V to 
prevent damage to the voltage regulator IC. 
4Mass measured after medical epoxy encapsulation. 
 
 
4.5 Implant Assembly for Mice 
The Bionode’s power and core modules are placed inside a cylindrical capsule 
when implanted in rats. This packaging strategy allows the contents of the capsule to be 







implant. At over 3 cm long and 1 cm wide this implant is unsuitable for a mouse of any 
size. An alternative packaging strategy is needed that maximally reduces the dimensions 
of the device. The strategy must also support a modular electrode interface whereby 
different types of electrodes may be easily connected for different experimental goals 
and disconnected for reuse.  
This second objective does not necessarily preclude the use of parylene-C 
deposition, which is used to seal the Myonode (see Section 3.3.3). Sealing the device 
with a 15 to 20 μm-thick layer of parylene-C layer is certainly the least bulky packaging 
strategy and would lead to the smallest total volume and mass. However, such a thin 
barrier between the biaxial receive coils and the tissue means that the coil properties 
are likely to be affected and thereby detuned by the tissue. This would make it difficult 
to achieve optimal impedance matching conditions as the tuning process would have to 
somehow anticipate the variable conditions of the device’s environment once implanted. 
More importantly, though, the conformal dielectric does not offer structural support to 
mechanically stabilize the now complex assembly of modules and coils. These present 
multiple points of weakness for the flexural and torsional loading likely to occur once 
implanted. For this reason an alternative coating process is used, which results in a 
more rigid and permanent fixture of the device modules. 
The process of packaging the Bionode for implantation in mice is described in 
Section 4.5.1. This process simultaneously addresses the requirements for 
miniaturization, reusability, robustness, and post-packaging coil tuning. The ability to 







after the device has been sealed is a crucial capability since the process of sealing the 
coils has been shown to detrimentally alter their tuning. A method of protecting and 
isolating this circuitry so that it is always accessible is integrated into the build process 
that produces a packaged, readily implantable device. Sections 4.5.2 and 4.5.3 describe 
the build and electrical performance of the two types of electrodes used in this work: 
cuff electrodes and anchored intramuscular electrodes. 
 
4.5.1 Packaging of Bionode Modules 
Figure 4.16 illustrates the step-by-step packaging process for a Bionode intended 
for implantation in mice. It begins with a fully assembled core module, which includes a 
temporary 10-pin header for ease of programming and debugging. The first step is to 
remove this header and solder 0.51 mm-diameter male pins (Mill-Max, 3320-0-00-15-00-
00-03-0) to the now exposed pads of the recording and stimulating channels’ inputs and 
outputs. These pins will be used to modularly connect to different types of electrodes 
and are manufactured at a length of 6.35 mm. However, they are trimmed to two thirds 
this length prior to mounting to avoid lengthening the device more than is necessary 
why still ensuring electrical continuity to the companion female header (Mill-Max, 3061-
0-19-15-21-27-10-0). At this stage a small piece of clear tape is placed above the 
microelectronics on the core module to isolate them electrically from components and 
traces on the bottom side of the power module, which is stacked on top of the core 







and electrically affixed to one another through five parallel wires. Each wire connects a 
supply voltage or, in one case, ground between the two modules.  
 
 
Figure 4.16 Bionode packaging process for implantation in mice. 
 
Next, a two-part mold putty is mixed and press-fit into the space around the coils’ 
impedance matching circuitry to protect it from direct contact with the epoxy which will 
permanently secure the modules and electrode pins in place. The putty is again used to 
create a cylindrical mold for the device that will allow it to be inserted lengthwise while 







M-31CL) and the device is slowly inserted into the mold. Additional epoxy is added from 
the top to fill open space around the device. Care is taken to make sure the level of the 
epoxy does not surpass the top edge of the board where it can begin to detrimentally 
coat the electrode pins, which should be left exposed.  
Once the epoxy has set, the device is removed from the mold and excess epoxy 
is removed using a rotary contour sander (Dremel, 100-N/6). During the sanding process 
the epoxy above the putty insert protecting the impedance matching circuitry is etched 
away and the insert is removed. At this point the coils undergo their final tuning to 
account for any changes in performance on account of the epoxy shell. After tuning a 
second putty insert is placed above the impedance matching network to prevent 
detuning from epoxy adjacent to the capacitors and to allow for future access to the 
matching network as needed. 
A second, shorter, cylindrical mold is made in order to seal the open part of the 
device around the putty insert. Half of the device is placed inside the mold and a second 
round of medical epoxy is injected and allowed to set. The device is then removed from 
the mold and excess epoxy is once again removed by the rotary contour sander to 
minimize the volume of the finished device. The average mass of the Bionode in this 
form (without electrodes) is 2.24 g (n = 4). The maximum dimensions are 8 mm x 8 mm x 
15 mm, resulting in an estimated volume of 0.96 cm3. A comparison to other fully 
implantable devices that have been used in mice (see Table 1.1) demonstrates that the 








The pin terminals between the Bionode and the selectable electrodes present a 
challenge in that they, too, must be isolated from the tissue environment. However, 
since it is desirable that the devices be reusable, these interfaces must be sealed with 
something that is less permanent than medical epoxy but still biologically inert. After 
the desired electrodes have been attached to the electrode pins, a two-part silicone 
adhesive (Nusil, MED2-4213) is mixed and applied between and around the pin 
terminals and heat set at 100 °C. This adhesive serves to isolate the input and output 
channels from the surrounding tissue while also easing flexural stresses on the leads 
wires where they are crimped into the female headers. The transition from flexible wire 
to rigid header is the most likely point of mechanical failure due to repeated or 
excessive bending, so extra silicone is built up around this junction to add springiness 
to—and prevent very small radii of curvature from occurring at—the joint. 
 
4.5.2 Recording Electrodes for Chronic imEMG 
The epimysial recording electrodes that are used for EMG collection with the 
Myonode are phased out in the Bionode on account of the lack of success with 
anchoring them to the muscle while simultaneously avoiding catastrophic failure of the 
joint between the lead and electrode surface. They are replaced by anchored imEMG 
electrodes, the build process of which is described in [184]. Briefly, two 7-stranded 
stainless steel (type 316) wires coated in perfluoroalkoxy alkane (PFA) (A-M Systems, 
793200) are placed in parallel and crimped together inside the barrel of a 27 gauge 







and a 1 mm-long exposures is cut with a scalpel on each wire between the knot and the 
needle. On one wire this exposure begins 2 mm from the knot and on the other wires 
this exposure begins 4 mm from the knot, resulting in an inter-electrode spacing of 2 
mm. The free ends of the wires that are not crimped together into the needle are 
crimped individually to female header pins that connect to the male electrode pins on 
the Bionode. Figure 4.17 illustrates two sets of these imEMG electrodes (as well as a 
stimulating cuff electrode, which is the subject of Section 4.5.3) affixed to the Bionode. 
 
 
Figure 4.17 Bionode implant equipped with two pairs of intramuscular EMG (imEMG) 
recording electrodes and a stimulating cuff electrode. 
 
The implantation procedure is fairly simple and involves threading the needle 
and its wires through the target muscle until the knot stops further advancement of the 
wire. When this is done care must be taken to ensure that the distance from the 
insertion point (where the knot is now flush with the muscle) to the exit point is at least 







is tied with both wires at the exit point such that the tightened knot sits flush with the 
surface of the muscle. Finally, the needle and excess wire are removed by making a cut 
close to the second knot. 
 
4.5.3 Cuff Electrodes for Peripheral Nerves 
A cuff electrode is designed specifically for either recording or stimulating of 
peripheral nerves in mice. This cuff electrode is an adaptation of the build process 
described in [23]. The base of each cuff electrode is a 3 mm length of silicone tubing (A-
M Systems, 806700), which has an inner diameter of 0.635 mm and an outer diameter 
of 1.2 mm. A 30 gauge needle is inserted into the tube interior and then out of the tube 
approximately 1 mm circumferentially from the insertion point. A 6 cm length of 7-
stranded stainless steel wire—the same wire used for the imEMG electrodes (see 
Section 4.5.2)—is cut and a 5 mm length of the wire is bared at one end by stripping off 
the PFA coating with a scalpel. The stripped end of the wire is threaded through the 
needle and then the needle is extracted, leaving behind the wire interwoven in the tube 
wall. The portion of the bare wire inside the tube is then shaped to the interior wall of 
the tube, forming a semicircular electrode contact that occupies at least 75% of the 
tube’s interior circumference. This process is repeated 1 mm down the length of the 
tube to create a second electrode contact and an inter-electrode spacing of 1 mm. 
The bare ends of both wires protruding from the tubing are trimmed to 
approximately 1 mm from the surface of the tube and then fixed in place with the same 







the bare wire ends from slipping back through the tubing wall. The other end of the 
wires which are still coated with PFA and form the electrode leads are also fixed to the 
tubing with silicone adhesive. Finally, a lengthwise cut is made in the wall of the tubing 
between where the lead wires enter and the extra wire exits so that the cuff can be 
slipped around the nerve. Each lead wire is then crimped into a female header pin 
compatible with the male electrode pins on the Bionode. Figure 4.17 illustrates one of 
these cuff electrode as well as two recording imEMG electrodes connected to the 
Bionode. 
The electrical performance of these cuff electrodes needs to be characterized 
since it can affect the performance of the stimulator circuit. For simplicity the stimulator 
is evaluated on the bench top using a 10 kΩ resistor to represent the electrode and 
tissue impedance load at the stimulator output. In reality, this is not a good model for 
an electrode surrounded by an electrolyte. As pointed out in Section 4.3.2, the 
electrode-tissue interface can be modeled by a resistor in parallel with a capacitor, so 
the electrode impedance will have some dependence on the frequency content of an 
applied voltage. It is possible that by a combination of electrode material and small 
surface area the impedance of the electrode might be high enough that the voltage 
headroom (±10.5 V) might be reached before the desired current amplitude is reached. 
For this reason the frequency-dependent impedance profile of each cuff electrode is 
measured using a Gamry Reference 600+ potentiostat. During the electrochemical 
impedance spectroscopy (EIS) test the cuff electrode is submerged in a phosphate 







of a series of fabricated cuff electrodes. As a point of comparison to other cuff 
electrodes, the average total impedance of these cuff electrodes is reported at 1 kHz 
and is 13.8 ± 6.8 kΩ (n = 16). The high standard deviation of the measured impedance is 
likely due to the fact that the cuff electrodes are made by hand and the surface area of 
the wire exposed inside the silicone tube can change on account of process variation. 
 
 
Figure 4.18 Impedance profiles of 16 mouse nerve cuff electrodes. Average impedance 
at 1 kHz is 13.8 kΩ. 
 
The rectangular waveform of the current pulse applied during stimulation (see 
Figure 4.9) will result in a complex frequency composition of the corresponding voltage 
waveform. What’s more, the voltage needed to source the desired current will depend 
on the amplitude and pulse width of the stimulus. This makes it difficult to predict 























output current based on the data of Figure 4.18 alone. Instead, the current through the 
cuff electrode is measured directly to confirm that currents up to 1 mA may be applied 
through the cuff electrode without reaching the voltage headroom. During this test the 
cuff electrode is submerged in 0.9% PBS and the voltage across a low-value (5 Ω) 
resistor in series with the cuff electrode is measured over time. Figure 4.19 compiles the 
measured current through the cuff electrode for the same series of stimulus waveforms 
given in Figure 4.9 (where a 10 kΩ load is used in place of the cuff electrode in PBS). 
 
 
Figure 4.19 Stimulus current measured in series with a nerve cuff electrode submerged 
in 0.9% phosphate buffer solution (PBS) for five different current amplitude settings. 
Pulse width is set to 100 μs. 
 
 
The added noise observed in Figure 4.19 compared to Figure 4.9 is due to the 
fact that very small voltages are being measured across a 5 Ω series resistor instead of 











































current pulse is still seen clearly and closely matches the current amplitude setting. This 
affirms that the current amplitude is not being clipped as a result of high electrode 
impedance. A moment is taken here to point out a slight discrepancy in the measured 
current amplitudes of Figures 4.19 and 4.9. Particularly at higher pulse amplitudes there 
is an overshoot of achieved current as compared to desired current. This can be 
attributed to the fact that the stimulus amplitude calibration (see Section 4.3.2) is 
performed when the stimulator’s load is a 10 kΩ resistor. This issue might be addressed 
to some extent by performing the stimulator calibration using a cuff electrode in PBS as 
the stimulator’s output load. However, this still does not guarantee a perfect replication 
of in vivo load conditions, and there will always be some mismatch between optimal 
calibrations on the bench top and in vivo.  
The sensitivity of the stimulator’s amplitude calibration to changes in the load 
impedance, part-to-part variation in current mirror MOSFETs, desired pulse width, and 
supply voltages is a weakness of this stimulator topology. However, these shortcomings 
can be handled by anticipating the stimulus pulse configurations that will be used in a 
chronic animal study and determining the optimal calibration for each of these potential 
configurations on the bench top under stimulator load conditions proximate to those 
that will exist in vivo. This strategy is employed for each Bionode used in this work. 
The data of Figure 4.19 confirms that these cuff electrodes are suitable for the 
environment and stimulus pulse parameters anticipated for this work. However, it 
would also be useful to know how close the stimulator is to reaching its voltage 







a higher voltage to achieve the same current. For this reason the voltage at the output 
of the stimulator connected to a cuff electrode in 0.9% PBS is measured during a 100 μs, 
maximal (1 mA) stimulus pulse, which can be seen in Figure 4.20. Figure 4.20 shows that 
the voltage under these stimulus conditions will not exceed 3.25 V, which means that 
the cuff electrode impedance would have to more than triple before the voltage 
headroom (10.5 V) is reached. This is unlikely to occur given that the current necessary 
to generate a maximum CMAP from a peripheral nerve cuff in a mouse remained 
unchanged over the course of 60 days in a previous study [23]. 
 
Figure 4.20 Stimulator output voltage corresponding to a 100 μs rectangular current 
pulse of 1 mA. Dotted red lines delineate stimulus pulse duration. 
 
4.6 Acute In Vivo Performance in Rodents 
The Bionode is intended for use in both rats and mice. The first in vivo evaluation 













































channels to measure stimulus evoked potentials in an anesthetized rat. The procedures 
and outcomes of this experiment are covered in this section. This experiment is 
followed by a similar procedure in a mouse in order to verify the efficacy of the 
recording and stimulating electrode strategies designed specifically for mouse work as 
described in Sections 4.5.2 and 4.5.3. This second experiment also serves to illustrate 
the expected amplitude of evoked CMAP signals, which will validate the gain selected 
for the recording channel. For the sake of CMAP amplitude resolution the maximum 
CMAP should occupy most of the ADC input voltage range, but it is important that the 
gain not be so high that the signal rails before the maximum CMAP is achieved. This 
experiment allows the gain on the channel intended for CMAP collection to be chosen 
intelligently. 
 
4.6.1 Experimental Design and Methods 
Simultaneous nerve stimulation using the Bionode’s biphasic, current-controlled 
stimulator and measurement of CMAP response with the Bionode’s AFE is performed 
first in a female Long Evans rat weighing 330 grams obtained from Envigo (Indianapolis, 
IN). This is done by first connecting a two-contact cuff electrode between the stimulator 
output and circuit ground then placing the cuff around the sciatic nerve of the rat. 
Stimulus pulses are then applied to the nerve and the CMAP response those stimuli are 
recorded from the biceps femoris muscle using the imEMG electrode described in 
Section 4.5.2. The current amplitude is gradually increased until the peak-to-peak 







during this experiment and a stimulation frequency of 2 Hz is used to avoid time-
dependent changes in the measured response. Since CMAP responses in rats can be ten 
of mV in magnitude, the Bionode’s AFE is configured for a gain of 25 (28 dB) to prevent 
saturation. The Bionode is powered from a DC supply during these experiments and the 
AFE output recorded on an oscilloscope for ease of data collection. These procedures 
are subsequently repeated in an anesthetized mouse. 
 
4.6.2 Graded CMAP Response to Applied Stimuli 
Figure 4.21 illustrates the peak-to peak amplitude of the CMAP measured in the 
biceps femoris muscle resulting from increasing stimulus current amplitude applied to 
the sciatic nerve of a rat. The threshold current needed to elicit a measurable CMAP 
response is 300 μA and the maximum CMAP amplitude is 30 mVpp. Figure 4.22 shows a 
series of CMAPs recorded for stimulus current amplitudes ranging from 300 μA to 400 
μA. During this experiment the stimulus artifact precedes the CMAP response by 








Figure 4.21 Peak-to-peak compound motor action potential (CMAP) response measured 
in the biceps femoris muscle by the Bionode’s analog front-end (AFE) in response to 
increasing stimulus current amplitude from Bionode’s stimulator applied to the sciatic 
nerve. Pulse width and stimulus frequency are fixed at 100 μs and 2 Hz, respectively. 
 
 
Figure 4.22 Samples of measured compound motor action potentials (CMAP) responses 
to stimulus amplitudes ranging from 300 μA to 400 μA applied to sciatic nerve of a rat. 
CMAP responses are measured using an intramuscular EMG (imEMG) electrode in the 







































This series of measurements is repeated in a wild-type (Black 6) mouse with the 
recording channel gain adjusted to 50 (34 dB) in anticipation that the maximum CMAP 
response will be smaller in the mouse than in the rat. Figure 4.23 shows the stimulus 
evoked muscle response to stimulus pulses ranging from 50 μA to 1 mA (the full range 
of the stimulator). Each waveform represents the average of three consecutive CMAP 
responses. The CMAP responses are recorded at a higher resolution in the range where 
it is expected that most axons will be recruited and rapid changes in CMAP amplitude 
will occur (200 μA to 400 μA). The waveforms compiled in Figure 4.23 are synchronized 
by the stimulus artifact, which precedes the CMAP response by approximately 1 ms and 
is not shown. It makes sense that the delay between stimulus artifact and evocation of 
the muscle response would be shorter in the mouse than in the rat owing to the shorter 








Figure 4.23 Measured compound motor action potential (CMAP) response to increasing 
stimulus amplitude applied to the sciatic nerve in a mouse. Each waveform represents 
the average of three consecutive responses measured from the biceps femoris muscle. 
Pulse width and stimulus frequency are fixed at 100 μs and 2 Hz, respectively. 
 
The data shown in Figure 4.23 suggest that a maximum CMAP amplitude of 
approximately 20 mVpp can be expected from this electrode configuration. The 
conclusion being that the low gain channel (34 dB) would be appropriate to measure 
this signal in a chronic experiment without exceeding the input voltage limitations of the 
ADC. One exciting thing to note about Figure 4.23 is a second, delayed waveform that 
can be observed starting around 2.5 ms at current amplitudes as low as 360 μA. Based 
on the characteristic delay and size, it is possible that this is an F-wave resulting from 







small percentage of them to fire. This leads to a second, smaller CMAP, the delay of 
which can be used to measure NCV [185]. Since NCV is a common metric used for 
tracking neuromuscular and motoneuron diseases, the measured F-wave could be 
valuable in quantifying pathological changes in the nerve in future animal disease model 
studies [186, 187]. 
 
4.7 Chronic Recording and Stimulating of Bioelectric Activity in Rodents 
The broad motivation for this project is to enable untethered collection of 
bioelectric activity in rodents. The more specific goal is to utilize this novel 
instrumentation in the study of neuromuscular and motoneuron disease mechanisms in 
mice. The acute, in vivo experiments of Section 4.6 indicate that the Bionode meets the 
desired performance criteria for study of normal and pathological activity of the 
neuromuscular system. The first chronic implantation of the Bionode is described in 
Section 4.7.2 and entails long-term EKG monitoring in a rat. Being both periodic and 
easily recognized, the EKG waveform is a good target for a first attempt at chronic data 
collection. This experiment serves three purposes: first, to evaluate the powering 
fidelity that might be expected from a freely behaving animal within the cavity 
resonator; second, to quantify the loss of data (BER) from the wireless data link 
operating within the cavity; and third, to demonstrate long-term, in vivo viability of the 
fully wireless and implantable system. 
The chronic performance of the Bionode in mice is demonstrated here in three 







a single implant. The second is an experiment comparing NAP activity in a CMT type 2D 
disease model to a wild-type control. The third is an experiment comparing CMAP 
responses to pulse trains in an ALS disease model compared to a wild-type control. The 
procedures for each of these experiments are covered in Section 4.7.1. Results of the 
validation experiment are discussed in Sections 4.7.3 and 4.7.4 while preliminary data 
from the disease models and their controls are presented in Section 4.7.5. These 
experiments represent only a small subset of possible chronic applications for the 
Bionode in mice, but serve to highlight a couple of experimental paradigms which are 
either enabled or improved by an untethered, batteryless implant. 
 
4.7.1 Experimental Design and Methods 
The first longitudinal experiment—a Bionode configured to measure two 
channels of EKG (Leads I and II configurations [188])—is performed in a female Long 
Evans rat obtained from Harlan Laboratories (Indianapolis, IN). The Bionode used in this 
experiment is not the final design iteration described in this chapter (see Section 4.1 for 
a description of the three Bionode iterations). The only important different to note for 
this experiment, though, is that the AFE operates in single supply mode and is identical 
to the AFE used in the Myonode (see Figure 3.5). This AFE is configured for a bandwidth 
of 1 Hz to 1 kHz and a gain of 60 dB.  
The surgical procedures begin with the rat in the prone position. A 3 cm rostral-
caudal incision is made on the side of the rat 0.5 cm left of midline. A subcutaneous 







implant, which is packaged in a 3D-printed capsule and coated with medical epoxy as 
shown in Figure 4.24. The implant is inserted into the pocket and oriented lengthwise 
such that the front coil lies fully in the transverse plane and the top coil lies fully in the 
sagittal plane, which are optimal for PTE in the magnetic field while the animal is 
walking normally on all fours and while rearing up on its hind limbs. Suture points on the 




Figure 4.24 Bionode packaging for chronic implantation in rats. (a) Stacked power and 
core modules prior to encapsulation. (b) Closed capsule coated in medical epoxy and 
ready for implantation. Two pairs of electrodes are connected for lead I and lead II 
measurement of EKG. 
 
The EKG is recorded by differential electrode pairs, which are routed to their 
target locations through subcutaneous tunneling to a second, lateral 0.5 cm incision 
close to the desired recording site. Once each lead reaches its target location it is 
sutured into place on the surface of proximate muscle. After each electrode has been 
anchored in place, both incision sites (the one over the device and the one over the 







surgery, should be acknowledged as well as those of Dan Pederson and Henry Mei, who 
periodically collected EKG data from the animal. 
The Bionode is used in three different chronic mouse experiments. In all cases 
the configuration of the AFE channels is the same: one low gain (34 dB) channel for 
larger signals such as stimulus evoked CMAP and one high gain (60 dB) channel for 
smaller signals such as spontaneous imEMG or NAP. The goal of the first experiment is 
to stimulate and measure CMAP as well as record voluntary evoked EMG from the same 
mouse. This comprehensive test is performed in a 25 g, wild-type (Black 6) mouse and is 
intended to confirm that all of the device’s functional blocks work correctly and 
concurrently once implanted. The surgical procedure for this and all subsequent chronic 
mouse experiments begins the same way: the animal is placed in the prone position and 
a 10 to 15 mm rostral-caudal incision is made beginning near the division of the vastus 
lateralis and the biceps femoris muscles and approximately 5 mm to the right of midline. 
Each implantation requires subcutaneous blunt dissection in the rostral direction until a 
pocket large enough to house the device is made. The device is inserted under the skin 
and anchored in place by a suture stitches through connective tissue on either side of 
the silicone adhesive-coated electrode pins. This stitch prevents the device from slipping 
backward towards the hind limb, which it is has a tendency to do without any anchoring. 
At this point the surgical technique will diverge depending on the number of electrodes 
and their respective targets. 
For the purposes of the comprehensive validation test, the device is equipped 







electrode pair on each recording channel. This configuration is shown in Figure 4.17. The 
cuff electrode is slipped around the sciatic nerve and closed with a loose suture loop 
around the cuff circumference. Both imEMG electrodes are threaded through the biceps 
femoris muscle parallel to the muscle fibers. A second anchoring knot is made and the 
needle along with the excess wire is cleft from the electrode as described in Section 
4.5.2. The incision is then sutured closed and the animal is placed in the cavity for initial 
data collection. The mouse is returned periodically to the cavity following implantation 
for data collection. Recording sessions in the cavity need not be very long in this study 
as the objective is successful collection of spontaneous EMG, which will occur any time 
the animal moves. The other objective of this study—successful provocation of CMAP 
responses from a fully implanted system—is done under anesthesia to reduce stress on 
the animal and improve data quality. A small coil (diameter = 7 mm) that is tuned to 
resonate at the same frequency as the cavity is used to wirelessly power the device at 
close proximities, which is possible when the animal is under anesthesia. This small coil 
is also used mid-surgery to confirm that the device is working properly prior to suturing 
the animal closed. 
The second mouse experiment—and the first to integrate disease models—seeks 
to illustrate motor evoked potentials in the sciatic nerve of a healthy mouse as well as 
those present in a mouse carrying a genetic mutation of the GARS gene, which encodes 
for glycyl-tRNA synthetase. Mutations of the GARS gene are associated with phenotypes 
of CMT type 2D and are known to affect the properties of the peripheral nerves [189, 







disease. The target signals in this study are voluntary peripheral NAPs and possible 
aberrant nerve activity associated with visible tremors in the disease model. The 
Bionode’s electrode configuration for this study is comprised of a single recording cuff 
electrode connected to the high gain channel. The surgical procedures are identical to 
the wild-type validation experiment except that no electrodes are inserted into the 
muscle and the high gain recording channel terminates in a cuff electrode that is 
attached to the sciatic nerve. 
The purpose of the third experiment is to record stimulus evoked CMAP in the 
Tg.SODG93A, which is a disease model for ALS. These CMAP responses will be evoked in 
two ways: first, with low frequency (1-2 Hz) supramaximal stimuli to observe changes in 
maximum CMAP, which should decrease over time based on prior evidence [23]. Second, 
with sequences of faster (3-50 Hz) repetitive nerve stimulation (RNS) to observe the 
percentage difference in peak-to-peak CMAP response from the first to the last pulse in 
a stimulus train (typically ten pulses) [18]. This change should be more significant in the 
disease model than a healthy control, especially as both get older. Both of these 
changes in stimulus evoked CMAP behavior have been previously observed in the 
Tg.SODG93A model, so this experiment will serve to corroborate these findings while 
leveraging significant gains in efficiency and data resolution on account of the Bionode 
substituting for instrumentation of established protocols. For example, the procedure 
used to collect CMAP responses to RNS involves anesthetizing the animal, inserting 







surface of the hind limb. This setup is complex and repetitively invasive, which means 
that the measurements are typically taken only once every few weeks in a single animal. 
This experiment is intended to show how the Bionode can patently simplify the 
procedure for measuring stimulus evoked CMAP responses over time, which would have 
at least the immediate benefit of allowing changes in CMAP behavior to be observed at 
much higher temporal resolution. The surgical procedure for this experiment is nearly 
identical to that of the first validation experiment except that the high gain channel 
which is used previously for collection of spontaneous EMG is not used. A peripheral 
nerve cuff connected to the Bionode’s stimulator is fastened to the sciatic nerve and an 
imEMG electrode from the low gain AFE is anchored inside the biceps femoris muscle as 
described in Section 4.5.2. For simplicity CMAP responses will be measured while the 
animal is awake and freely behaving within the resonant cavity. If for any reason this 
presents a significant issue, the mouse can, alternatively, be anesthetized briefly while 
the stimulus protocol and CMAP collection are carried out. Under these circumstances 
the device can be powered wireless using the same small, precisely tuned coil used for 
CMAP collection in the first chronic mouse experiment.   
Data collection for each chronic mouse experiment is performed inside the 
resonant cavity. This testing environment is adapted for mouse work by introducing a 
motorized wheel, which is built with the assistance of Curtis Slaughbaugh, a student in 
the Center for Implantable Devices at Purdue University. In this way data can be 
collected either from the animal freely behaving in the open space within the cavity or 







the cavity such that it resides within the strongest part of the magnetic field [71]. This 
considerably de-risks the WPT link by ensuring that the animal can always be placed and 
made to behave in an optimal position for power transfer. The wheel itself should incite 
cyclic behavior in the peripheral nerves and muscles of the hind limb, which can be 
useful in verifying and comparing measured data. The cavity’s resonant mode and 
performance are highly sensitive to electrically conductive materials, so care is taken to 
ensure that all parts of the motorized wheel that reside within the cavity are made from 
plastic. Figure 4.25 shows the motorized wheel within the cavity; its drive shaft passes 
into the WPT environment through a 9.5 mm hole. The shaft is driven by a DC motor 
(McMaster-Carr, 6409K17) that allows up to 25 rpm and 20 in·lbs of torque at 12 V. The 
supply voltage is regulated by a DC power supply on the bench top. 
 
 
Figure 4.25 Resonant cavity WPT environment equipped with mouse wheel for 
controlled, cyclic behavior located where peak power transfer efficiency (PTE) is 








During each recording session the animal is placed in the desired space—either 
the wheel or the open field—and then a lid is secured to the top of the cavity. In 
addition to routing data packets and instructions, the base station provides up to 4 W of 
power at the appropriate frequency (340 to 350 MHz) to the resonant cavity. The base 
station is placed outside of the cavity and communicates via Wi-Fi with a nearby 
computer running the GUI. Figure 4.26 captures the full testing setup and demarcates 




Figure 4.26 Comprehensive testing environment for fully wireless data collection from 
freely behaving animals including the resonant cavity (red), base station (yellow), power 









4.7.2 Longitudinal EKG Measurement 
Data collection from the Bionode implanted in the rat and configured for EKG 
measurement is performed in the resonant cavity as described in [71]. Following 
implantation and animal recovery, the rat is placed in the cavity for initial (day 0) data 
collection. Data is collected periodically over the course of 79 days in order to confirm 
continued device operation and to tack the quality of the EKG over time. Figure 4.27 
shows a sampling of EKG measured over time from post-surgical days 0, 7, 43, and 79. In 
each instance the data is sampled at 2.5 kHz. The signal strength is quantified by the 
peak-to-peak amplitude of the EKG signal average over 30 heartbeats during each 
recording session. On day 0 the measured signal strength is 0.95 ± 0.045 mV. A decrease 
in the signal strength is observed on day 7 from a measured peak-to-peak EKG 
amplitude of 0.72 ± 0.041 mV. However, signal strength remains steady through day 43 
(0.69 ± 0.069 mV) and day 79 (0.73 ± 0.089 mV). This signal degradation is likely due to 
formation of scar tissue around the electrodes contacts in combination with the 
relatively small (10 MΩ) input impedance of the now obsolete AFE used in this 
experiment. The unwanted voltage division of the recorded signal will likely improve 
greatly in subsequent chronic implantations where the final AFE (see Figure 4.5), which 







Figure 4.27 EKG collected longitudinally by a Bionode implanted in a rat. 
 
The data collected in this experiment allows for an applied quantification of BER 
which offers a more realistic estimation of the Bionode’s wireless performance as 
compared to bench top measurements where the transmitting and receiving antennas 
may be stationary and very close to one another. The BER is calculated by the 







A recording session is defined here as any period of data collection from a freely 
behaving animal within the resonant cavity lasting longer than 30 minutes. This 
measurement is performed over the course of nine recording sessions ranging from day 
– to day 64 post-implantation. The minimum and maximum BERs observed across the 
nine recording sessions were, respectively, 0.07% (measured on day 5) and 1.07% 
(measured on day 23). The combined recording time of these nine sessions is 39 hours, 
over which the total BER is 0.38%. 
This experiment also allows powering fidelity to be quantified from a freely 
behaving animal within the WPT environment. If the monitoring period is long enough 
(a few hours), the ratio between the total time the device is on and total monitoring 
session time will represent the applied powering fidelity, which accounts for normal 
animal behaviors such as walking, resting, eating, drinking, and grooming. This offers a 
more practical and objective metric than peak PTE, which is how the quality of WPT links 
are often reported. The applied powering fidelity measured from the rat in the cavity 
over eight recording sessions—each last at least half an hour—for a total monitoring 
time of 35.5 hours is over 93% [71].  
The outcomes of the chronic rat experiment are useful for understanding and 
setting expectations for the long-term performance of the full system. In this way they 
help to guide the experimental setup for the chronic mouse studies. For example, the 
calculated powering fidelity of 93% is likely sufficient for metrics like RMS or peak-to-
peak amplitude of voluntary evoked EMG from normal ambulation. However, more 







a more consistent WPT link if only because this will greatly simplify data parsing. This 
observation led to the development of the mouse wheel (see Figure 4.25). This structure 
keeps the animal in a portion of the cavity where the magnetic field strength is 
strongest and the implanted device has the best chance for continuous, uninterrupted 
data acquisition. 
 
4.7.3 Stimulus Evoked CMAP  
The ability to generate chronic, stimulus evoked CMAP is demonstrated in a wild-
type mouse during the first chronic mouse experiment with the Bionode. All stimulus 
pulse widths are 100 μs in duration and are evoked at a rate of 1 Hz. By convention, 
data from the cathodic stimulating phases are used when reporting CMAP responses 
[181]. To minimize the amount of time the animal is anesthetized, the stimulus 
amplitude is increased until an incipient CMAP response is observed. In this experiment 
to first observable CMAP occurs at 300 μA. The presumed maximum CMAP is then 
evoked immediately thereafter by setting the current amplitude to the upper limit of 1 
mA. Figures 4.28(a) and 4.28(b) show superimposed threshold CMAPs and maximum 
CMAPs, respectively, measured in a wild-type mouse seven days post-surgery. Each 
CMAP is detected and synchronized by the stimulus artifact, which can be observed 
preceding the beginning of the CMAP by approximately 1 ms. The data shown in Figure 
4.28 represent the first reported CMAPs evoked and measured in mice by a fully 








Figure 4.28 Series of (a) incipient and (b) maximum CMAP measured from Bionode 
implanted in wild-type mouse on Day 7 post-surgery. 
 
4.7.4 Voluntary Evoked EMG  
In the course of the validation experiment, voluntary evoked EMG is measured 
periodically from the wild-type mouse while it is freely behaving in the open field of the 
resonant cavity (see Figure 4.25). Figure 4.29 plots representative data from days 0, 2, 
and 5 post-surgery. This is already a marked improvement over the longevity of the 
electrode interface used on the Myonode, which failed within 48 hours of implantation. 
While the timespan is relatively short, this series of data is a promising indication for the 









Figure 4.29 Samples of voluntary evoked EMG collected from a freely behaving wild-
type mouse using the fully wireless Bionode system. 
 
The intended course of the validation study is to collect voluntary evoked EMG 
as well as threshold and maximum CMAPs (like those shown in Figure 4.28) for as long 
as possible. However, beginning on day 9 the device becomes ostensibly detuned and 
ceases to operate in the cavity. Performance while powered with the small coil for 
stationary experiments is also considerably degraded to the point that only faint 
contractions are observed in response to purportedly large stimuli. This seems to 
suggest that the microelectronics are intact but some change has occurred in either the 
coils or the matching network to significantly drop the PTE to the point that the 
stimulator’s voltage headroom is far below where it should be. Nevertheless the device 







and complete healing of the incision wound can occur. This allows for some inferences 
to be made about how well the animal fares with the device as it is positioned and 
whether or not chronic implantation of the Bionode in such a small specimen is realistic.  
It seems that the device is generally tolerated; the mouse is observed eating and 
grooming shortly after surgery and its gait is only marginally affected by the cuff around 
the sciatic nerve: an effect which becomes less noticeable over time. Figure 4.30(a) 
depicts the Bionode next to the animal subject prior to implantation. Figures 4.30(b) and 
4.29(c) depict the animal subject from the top and the side after the device has been 
implanted for two weeks. Full wound closure and healing is achieved and the device is 
still positioned above the hip. These are both promising results since two potentially 
catastrophic events that can occur are that the mouse chews its stitches and they fall 
out prior to wound closure and that the device slips backwards until it rests on top of 
the hind limb flexor muscles. The latter scenario causes impairment of hind limb motion 
and puts hazardous stresses on the electrode leads as they undergo sharp bending 
between the electrode interface on the Bionode and their target nerve or muscle. One 
caveat should be noted here and that is that this implantation is performed in a fairly 









Figure 4.30 (a) Bionode device next to mouse immediately prior to implantation (day 0). 
(b) Top view of mouse 2 weeks after device implantation (day 14). (c) Side view of 
mouse two weeks after implantation. 
 
The device is explanted after two weeks so that the point of failure can be 
determined. Careful dissection results in confirmed integrity and continuity of the 
electrode leads. The crimped terminals of the recording and stimulating electrodes as 
well as the entire electrode interface on the Bionode are inspected for displacement, 
breaches, or breakage. The electrode interface is still fully intact following explantation, 
which is yet another promising outcome of the experiment. The source of the failure is 
discovered to be the epoxy around the putty insert which encases the impedance 
matching circuit. This particular segment of epoxy is applied during the second 
deposition phase as described in Section 4.5.1, and is spongy to the touch following 
removal from the animal. When set properly the epoxy should be firm, so the likely 
explanation is that it did not set properly and allowed fluid to leak into the cleft that 
houses the impedance matching circuitry. This conclusion is reinforced by the detection 







future assemblies to be sure that the second epoxy deposition phase which forms the 
barrier around the putty insert is properly set. 
 
4.7.5 Ongoing Study in CMT and ALS Disease Models 
The experiments for evaluating voluntary evoked nerve activity in the CMT type 
2D disease model and stimulus evoked CMAP from the hereditary ALS disease model are 
ongoing. However, some preliminary findings and data are discussed here. Figure 4.31 
illustrates recurrent bursts of sciatic nerve activity resulting from forced walking inside 
the wheel shown in Figure 4.25. These data are collected from a GARSC201R mouse: a 
model for CMT Type 2D. There is no clear precedent within the literature for collecting 
and quantifying voluntary peripheral nerve activity in awake and behaving mice. These 




Figure 4.31 Voluntary nerve action potentials (NAPs) collected from an awake and 
behaving mouse while performing forced walking within a wheel. 
 
This new instrumentation and methodology may be used to track changes in 







Additionally, they can be used to test the effects of pharmacological agents on nerve 
activity. For example, sodium channel blockers introduced into the extracellular 
environment around the nerve might disparately impact nerve behavior in the CMT 
Type 2D disease model compared to its control, which might implicate sodium channel 
deficiencies as playing a role in the disease mechanism. This is just one of many 
potential experimental protocols which would be easy to carry out once the Bionode is 
implanted and stabilized in its environment. 
Another early result of the GARSC201R mouse study is the observation of 
intermittent, low-amplitude potentials which occur while the animal is at rest. Three 
examples of such activity as well as the baseline signal measured while the animal is 
under anesthesia are compiled in Figure 4.32. The sampling rate and ADC resolution 
used while collecting these data are 2.5 kHz and 8-bit, respectively. It may be that this 
activity is the result of nerve injury or irritation by the cuff electrode. However, one of 
the established phenotypes of this model is a visible tremor in the hind limb and tail. 
Another explanation for the observed spontaneous nerve activity might be that it 
correlates with this tremor. If this is the case, then these data are the first of their kind 
measured from this model. However, more instances of this activity will need to be 
recorded in the disease model and an absence of comparable activity in the wild-type 










Figure 4.32 Sciatic nerve activity recorded from a disease model for CMT type 2D during 
stationary periods within the open field of the resonant cavity. Baseline data represents 
nerve activity while the animal is anesthetized. Examples 1, 2, and 3 represent 
intermittent, low-level potentials measured while the animal is at rest. 
 
The ability to both elicit stimuli and record the response allows the Bionode to 
collected stimulus evoked CMAP from awake and freely behaving animals. The change 
in amplitude of the CMAP response to a fixed stimuli over time can indicate changes in 
muscle mass (resulting from growth or atrophy) or impairments of somatic signal 
transduction. Figure 4.33(a) illustrates a series of CMAPs recorded from an awake and 
freely behaving Tg.SODG93A mouse the day after implantation of the Bionode using a 







and the CMAP amplitude plateaus near 700 μA. This gives the minimum and 
supramaximal conditions for this pulse width, which can be tracked over time.  
In order to confirm that the observed response is a CMAP and not an artifact, the 
pulse width is doubled to 200 μs and the current amplitude is gradually increased once 
again. Figure 4.33(b) plots the result of this second sweep. In this instance the threshold 
current needed to elicit a CMAP is 400 μA and the CMAP amplitude plateaus near 650 
μA. The consistent and appropriate duration of the muscle response in both cases 
(approximately 2 ms) as well as the observation that the stimulus intensity needed to 
trigger a measurable response is smaller when the stimulus duration is longer (which is 
consistent with the known behavior of strength-duration curves for excitable tissues) 
suggest that the implanted instrumentation is effectively collecting the signal of interest.  
 
 
Figure 4.33 Evoked compound muscle action potential (CMAP) measured from the 
biceps femoris of a Tg.SODG93A mouse in response to a stimulus pulse with a duration of 
(a) 100 μs and (b) 200 μs. All waveforms shown are averages of ten successive CMAPs 








Another measurement of interest in the Tg.SODG93A mouse is the trend in 
stimulus evoked CMAP amplitude in response to higher frequency (3 to 50 Hz) stimulus 
pulse trains. Figure 4.34 plots the average amplitude of successive CMAPs resulting from 
RNS at 20 Hz. These data are collected the day after surgery using a pulse width of 100 
μs and a resting period of at least 10 seconds between subsequent pulse trains. This 
creates an RNS response signature which can be used to detect deficits of the 
neuromuscular junction or the muscles themselves over time [18, 191]. 
 
 
Figure 4.34 Peak-to-peak compound muscle action potential (CMAP) response to 
repetitive nerve stimulation (RNS) measured as a percentage of the amplitude of the 
first pulse in a 20 Hz pulse train. The stimulus pulse train uses supramaximal conditions 
Error bars at each pulse number reflect standard deviation (n = 7). 
 
4.8 Conclusion 
The Bionode represents the state-of-the-art in fully wireless and implantable 



































furthermore, allow anesthesia and tethering to be removed entirely from experimental 
protocols for long-term bioelectric data collection. This offers significant gains in 
efficiency as well as data resolution and consistency compared to many established, 
long-term electrophysiology protocols for mice. The fully implantable recording device 
developed in this work is able to collect two crucial target signals useful in studying 
neuromuscular disease progression–CMAP and voluntary nerve activity—that have 
never before been measured in a mouse by a fully wireless system.  
The Bionode follows the same design principle as the Myonode—that is, all the 
microelectronic elements integrated on the Bionode’s power and core modules are 
commercially available. This offers flexibility and consistency in the finished product (not 
to mention faster turnaround on design iterations) which would have been 
impracticable had the systems been designed all or partially in CMOS technology. 
Despite the added volume and power consumption that come with compiling 
individually packaged and standalone ICs, the Bionode maintains a form factor that is 
tolerable for subcutaneous implantation in mice and effectively powered by the 
resonant cavity WPT environment.  
The demonstrated performance of each of the Bionode’s functionalities while 
implanted in freely behaving mice supports its capacity to serve as an implement for 
finding new electrophysiological information about neuromuscular disease mechanisms. 
Two possible applications for this novel instrumentation are presently underway, which 
examine bioelectric markers of CMT and ALS. However, this system can be feasibly 







the collection of CMAP waveforms as well as voluntary muscle and nerve activity from 
devices implanted chronically in mice, but other useful metrics such as NCV, single fiber 
EMG, and CNAPs could certainly be targeted as well through appropriate AFE 
configuration paired with clever electrode design and placement. 
An added benefit of having two recording channels is the capability to measure 
both the input to and output from muscles, which can degenerate for a variety of 
reasons in different neuromuscular disease models. This pairing of measurements might 
paint a more complete picture of disease progression by, as an example, allowing the 
user to identify which part of the neuromuscular system is affected first (nerve, 
neuromuscular junction, or muscle) and then monitor the temporal changes in each 
location relative to one another. This is yet another nod to the appreciable adaptability 
of the device, which implies that this work only scratches the surface of possible 








CHAPTER 5. CONCLUSION 
This work describes the development of a fully wireless and implantable device 
capable of recording both spontaneous and stimulus evoked bioelectric activity in mice. 
These efforts are driven by a need for improved instrumentation to study the 
electrophysiological mechanism by which neuromuscular and motoneuron diseases 
manifest and progress in mouse models. The finished device, which is termed the 
Bionode, improves on current technologies outlined in Table 1.1 by offering more 
capabilities and better performance in a comparably small volume (less than 1 cm3). 
Moreover, the Bionode is designed for compatibility with a resonant cavity, which is the 
largest (by volume) reported WPT environment for rodents. 
One of the early efforts of this work explores the feasibility of far field RF power 
transfer to bioelectric sensors embedded in tissue. The theoretical and numerical 
analyses of the power link budget between an electromagnetic field source and a 
receiving antenna inside mammalian tissue show conclusively that this WPT strategy is 
unsuitable for continuous operation of bioelectric sensors. This type of WPT link is more 
suitable for passive systems or those with much lower average power consumption that 







The Myonode—the precursor to the Bionode—serves to establish and debug build 
procedures, optimize the implant’s functional protocol, and fine-tune the AFE topology 
and configuration. The Myonode is limited by only a single channel of recording, but is 
able to collect voluntary evoked EMG from mice, including some interesting disease-
related aberrant muscle activity. The Myonode is also replicated and powered in an 
array for the purpose of relaying EMG for myoelectric-controlled prostheses. This offers 
some improvements to the versatility of wireless neural interfaces for upper-limb 
amputees. 
The design procedures for both the Myonode and Bionode are predicated on the 
assumption that CMOS design and fabrication are not suitable for the development 
phase of new instrumentation. This is especially true considering the evolution of the 
WPT strategy in parallel with the evolution of the implantable device, which brings with 
it a handful of unanticipated issues. The dozen PCB design iterations used in this work is 
the best evidence in support of the decision to avoid an ASIC implementation until the 
system’s topology is solidified. The use of only commercially available ICs and passives 
to build the Bionode did greatly improve yield and reliability compared to the CMOS 
tape-out described in Chapter 3. The end result is a batteryless implant which is capable 
of one channel of stimulating, two channels of recording, thermal sensing, and 
bidirectional telemetry. It is possible at this point to consider the benefits of condensing 
large blocks of this system on CMOS in order to further miniaturize and improve the 







A few limitations of the Bionode should be noted. First, owing to its volume and 
mass, there is a limitation on the size of the mouse in which the device can be implanted. 
An estimate of this limitation can be inferred from the reported device volume to 
minimum mouse size reported in Table 1.1.Being approximately 1 cm3, the Bionode may 
be theoretically placed in animals as small as about 16 g. This does preclude the study of 
some neuromuscular diseases with prominent musclular atrophy or reduced body mass, 
but it should be suitable for most adult mice without such severe degenerative 
phenotypes. Second, the rate of data lost from fully wireless powering and 
communication will never be better than what one can expected from a tethered setup. 
The combination of powering and data fidelity—both of which are less than 100%—
means that some data will invariably be lost when using the Bionode in an animal within 
the WPT environment. This should not pose a serious problem unless extremely rare, 
transient behaviors are the target. This particular scenario has been anticipated and 
partially addressed by the construction of a smaller testing environment (mouse wheel) 
placed in the optimal position within the cavity and close to the base station antenna.  
One of the things that makes this device such a powerful tool is the fact that it 
addresses with very little compromise the limitations of tethered headstages, wireless 
headstages, and battery powered implants all at the same time. The Bionode has been 
used to collect both voluntary and stimulus evoked bioelectric signals in freely behaving 
animals. It is the first fully implantable system to collect voluntary nerve activity and 
CMAP in mice and the first one capable of recording its own evoked potentials. Also, on 







that can record both the input and the output of muscles, which might allow it to 
pinpoint important pathological information like disease origin and clocked, directional 
progression. 
This project’s criteria for success should be revisited at this point. Recall that the 
main objective is to create novel instrumentation for chronic electrophysiology that is 1) 
small enough to be fully implanted in a mouse, 2) given sufficient functionality to be 
used in a variety of electrophysiological experiments, 3) able to function in the living 
environment once implanted, and 4) compatible with a WPT environment that enables 
the continuous collection of bioelectric activity from freely behaving mice. The chronic 
animal experiments described in Chapter 4 serve as the final indication that each of 
these criteria has been fulfilled. Furthermore, the applications of this novel 
instrumentation to the study of neuromuscular and motoneuron diseases underscores 
its immediate utility within the scientific community and newly supported capabilities 
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 Integrated implantable device sub-elements from an interdisciplinary team; carried 
out meticulous testing, debugging, and assessment of implant performance. 
 Tailored device and electrode design for longitudinal study of neurodegenerative 
disorders. 
 Created a mammalian tissue model to investigate far-field wireless power transfer in 
the body. 
 Wrote and carried out experimental protocols for acute and chronic animal work to 







Charles C. Chappelle Research Fellow in the Center for Implantable Devices (CID) 
Purdue University, West Lafayette, IN (May. 2010—May 2011) 
 Documented the problem domain of prosthetic limb rejection and global availability. 
 Built an electric-powered, four degree-of-freedom upper-limb prosthetic prototype. 
 Completed extensive training with electrical lab equipment, machine shop tools, and 
medical/surgical instrumentation. 
Senior Design Student Collaborator with Abbott Point-of-Care 
Purdue University, West Lafayette, IN (Aug. 2009—Dec. 2009) 
 Coordinated with a team to develop a companion device for Abbott’s iSTAT® blood 
analyzer that isolates plasma from whole blood, resulting in a publication and 
preliminary patent. 
 Maintained meticulous records of experimental procedures, results, and reference 
literature. 
 Reported progress regularly to corporate partners through monthly conference calls. 
Summer Undergraduate Research Fellow in the Brain-Computer Interfaces (BCI) Lab 
Purdue University, West Lafayette, IN (May 2009—Aug. 2009) 
 Made a model cardiovascular system to calibrate stent-mounted sensors. 
 Explored a novel method for chronic measurement of blood oxygen saturation 




Graduate Teaching Assistant in BME 301: Bioelectricity 
Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 
(Fall 2011, Fall 2012, and Fall 2015) 
 Introductory course to neural anatomy, bioelectric signals, and modeling of 
bioelectric events that integrated hands-on circuit building and algorithm design 
in Python and numerical methods in MATLAB. Taught by Prof. Pedro Irazoqui and 
Prof. Eugenio Culurciello. Responsibilities included producing homework 
assignments and solutions, writing tutorials for working with Python and 
Raspberry Pi single-board computer (SBC), delivering select lectures, grading, 
and conducting office hours to aid individuals with assignments or exam 
preparation. 
Graduate Teaching Assistant in BME 489: Senior Design Projects Lab 
Weldon School of BME, Purdue University, West Lafayette, IN (Fall 2013 and Fall 2014) 
 Capstone course for seniors in BME in which students on small teams 
quantitatively defined and solved a semester-long design project. Course 
emphasized practical and hands-on learning, experimental design, and design 
documentation. Taught by Prof. Pedro Irazoqui. Responsibilities included 
technical mentorship of individuals and teams, collaborative brainstorming with 








Graduate Teaching Assistant in BME/ECE 528: Measurement and Stimulation of the 
Nervous System 
Weldon School of BME, Purdue University, West Lafayette, IN (Spring 2015) 
 Graduate-level course that covered the engineering challenges of recording and 
triggering bioelectric events while taking a close look at the interface between 
excitable tissue and electrodes or other hardware in the body. Enrollment was 
offered for both on-campus and distance learning students. Taught by Prof. 
Eugenio Culurciello. Responsibilities included regular correspondence with 
distance learning students, presentation of select lectures, and moderation of 
class forum for discussion and questions. 
Teaching Assistant for nanoHUB-U online offering of Bioelectricity  
Weldon School of BME, Purdue Univ., West Lafayette, IN (Spring 2014) 
 Online course introducing neural anatomy, bioelectric signals, and modeling of 
bioelectric events. Taught by Prof. Pedro Irazoqui. Responsibilities included 
course beta-testing, production of all homework assignments, and delivering 
filmed recitation sessions detailing homework solutions. 
Graduate Teaching Assistant in BME 295: Frontiers in Biomedical Engineering  
Weldon School of BME, Purdue Univ., West Lafayette, IN (Fall 2011) 
 Seminar course for new BME students aimed at improving written and oral 
communication skills, awareness of ethical issues, and professional dynamics in 
the scientific community while introducing cutting-edge areas of research within 
various branches of biomedical engineering. Responsibilities included course 
structure, lecture planning and delivery, grading, résumé review, and one-on-
one soft skill mentoring to equip students with tools for networking, developing 
their career paths, and navigating the job search. 
Director/Coach of the Purdue University Color Guard and Winter Guard  
Purdue University Bands and Orchestras, West Lafayette, IN (Apr. 2010—Present) 
 Team comprising 34 undergraduate students that performs with the Purdue 
Marching Band during the fall semester and competes as an indoor ensemble 
during the spring semester. Responsibilities include providing daily instruction on 
elements of technique and performance, along with constructive feedback; 
preparing written materials for public distribution; production design and 
choreography; organizing travel logistics; personally mentoring students; and 
developing team’s core philosophy and artistic direction. 
Tutor for Student Athletes  
Purdue Intercollegiate Athletics, West Lafayette, IN (Jan. 2007—Jan. 2009) 
 One-on-one scheduled tutoring sessions to help student athletes with homework 
or test preparation in engineering, science, and math courses. Responsibilities 










AWARDS, FELLOWSHIPS, AND HONORS 
 
 Estus H. and Vashti L. Magoon Award for Excellence in Teaching in 2015 
 Purdue Teaching Academy Graduate Teaching Award in 2015 
 Member of nanoHUB-U course development team that received 2014 Excellence in 
Distance Learning Award 
 Third place in 2011 NCIIA BMEStart competition for biomedical innovations 
 Charles C. Chappelle Graduate Fellowship in 2010-11 
 Received B.S. degree with Academic Distinction (top 10% of graduating class) 
 Best Poster Award at the 2009 Summer Undergraduate Research Fellowship (SURF) 
Symposium 
 Member of Tau Beta Pi Engineering Honor Society 
 Jenny Helms Award for leadership and academic excellence awarded by Purdue 
University Bands in 2008 
 
PATENTS AND PUBLICATIONS 
 
 R. A. Bercich*, S. T. Lee*, D. J. Pederson, Z. Wang, M. Arafat, H. Mei, C. Quinkert, G. 
Albors, J. Somann, J. Jefferys, P. P. Irazoqui, “Bionode for Fully Wireless Recording 
and Stimulating of Bioelectric Events in Rodents within a Large Volume Cavity 
Resonator,” IEEE Transactions on Biomedical Engineering. In review. 
 R. A. Bercich, Z. Wang, H. Mei, L. H. Smith,  K. L. Seburn, L. H. Hargrove, and P. P. 
Irazoqui, “Enhancing the Versatility of Wireless Biopotential Acquisition for 
Myoelectric Prosthetic Control,” Journal of Neural Engineering. In review. 
 H. Mei, K. A. Thackston, R. A. Bercich, J. G. R.  Jefferys, and P. P. Irazoqui, “Cavity 
Resonator Wireless Power Transfer System for Freely-Moving Animal Experiments,” 
IEEE Transactions on Biomedical Engineering. In review. 
 P. Irazoqui, R. Bercich, H. S. Bhamra, J. Maeng, C. Meng, O. Gall, Y. Kim, J. Joseph, and 
W. Chappell. Wirelessly-Powered Implantable EMG Recording System. US Patent 
Number 13/955,808 filed on July 31, 2013. 
 R. Bercich, D. Duffy, and P.P. Irazoqui, “Far Field RF Powering of Implantable Devices: 
Safety Considerations,” IEEE Transactions on Biomedical Engineering 2013 doi: 
10.1109/TBME.2013.2246787. IEEE Transactions on Biomedical Engineering: 60.8. 
 R. Bercich, J. Bernhard, K. Larson,  and J. Lindsey, “Hand-Held Plasma Isolation Device 
for Point-of-Care Testing” IEEE Transactions on Biomedical Engineering 2010 doi: 




 R. A. Bercich, “Improving the Mechanistic Study of Neuromuscular Diseases through 
the Development of a Fully Wireless and Implantable Recording Device,” Ph.D. thesis, 







 R. A. Bercich, “Robotic Arm for Testing and Demonstration of Targeted Muscle 
Reinnervation with Implications for Low-Cost Upper-Limb Prostheses,” M. S. thesis, 
Department of Biomedical Engineering., Purdue University, West Lafayette, IN, 2011. 
 
PRESENTATIONS AND ABSTRACTS 
 
 D. J. Pederson, R. A. Bercich, and P. P. Irazoqui, “Emphasizing Application in 
Bioelectricity Course.” 25th Annual Meeting of the Biomedical Engineering Society, 
Tampa, FL (October 7—10, 2015).  
 K. L. Seburn, R. A. Bercich, Z. Wang, D. Pederson, H. Mei, and P. P. Irazoqui,  
“Miniature Wireless and Batteryless Device for Longitudinal Recording and 
Stimulating of Bioelectric Events in Small Animals.” 45th Annual Meeting of the 
Society for Neuroscience, Chicago, IL (October 17—21, 2015).  
 R. A. Bercich, “Improving the Mechanistic Study of Inherited Peripheral Neuropathies 
through Development of a Wireless Neuromuscular Recording Device.” Biomedical 
Engineering Graduate Student Association Invited Presentation. University of 
Minnesota, St. Paul, MN. 7 Nov 2014. 
 K. L. Seburn, R. A. Bercich, and P. P. Irazoqui, “Development of Miniaturized, 
Wirelessly Powered Neuromuscular Recording Devices for Use in Mice.” 9th 
International Motoneuron Meeting, Halifax, Nova Scotia, Canada (June 15—19, 
2014). 
 R. Bercich, Z. Wang, K.L. Seburn, and P.P. Irazoqui, “Implantable Sensor for 
Longitudinal Recording of Spontaneous and Voluntary-Evoked EMG and NAP in 
Untethered Animals.” 6th International IEEE/EMBS Conference on Neural 
Engineering (NER), San Diego, CA (Nov 6—8, 2013).  
 R. A. Bercich, J. Joseph, O.Z. Gall, J. Maeng, Y.J. Kim, and P.P. Irazoqui, “Implantable 
Device for Intramuscular Myoelectric Signal Recording.” 34th Annual International 
Conference of the IEEE Engineering in Medicine and Biology Society, San Diego, CA 
(Aug. 28 –Sep. 1, 2012).  
 P. P. Irazoqui, and R. A. Bercich, “Myonode: Improving Robustness of Prosthetic Arm 
Control with an Innovative RF-Based Implantable EMG Recording System.” 
International Workshop on Clinical Brain-Neural Machine Interface Systems. Houston 




Guest Speaker for Seniors Exploring Engineering (SEE) 
Purdue University, West Lafayette, IN (Oct. 2012) 
 Event hosted by the Women in Engineering Program (WIEP) geared toward 
women in their senior year of high school who were interested in engineering. 








Lab Staff Volunteer for Exciting Discoveries for Girls in Engineering (EDGE) Camp 
Purdue University, West Lafayette, IN (Aug. 2011) 
 Volunteered at a camp hosted by the Women in Engineering Program (WIEP) 
that is offered to freshmen and sophomores in high school. Event included 
hands-on lab sessions where students developed and tested their own 
hypotheses related to cell culture growth in various mediums. Responsibilities 
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